ICD-O code	Text	File_Name
8000/6	afectación de médula ósea	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/6	infiltración ósea	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
9500/6	neuroblastoma estadio IV (afectación de médula ósea	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/6	RC medular	dev-set1-to-publish/cantemist-norm/cc_onco861.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8720/3	Melanoma	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco716.ann
9120/0	Angioma	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8980/3	Carcinosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8033/3	carcinoma sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8980/3	carcinosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
9050/3	mesotelioma	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8033/3	sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1/H	tumor heterogéneo	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8084/3	carcinoma escamoso de células claras	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	Infiltración pleural por neoformación maligna	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8980/6	Carcinosarcoma pulmonar estadio IV (pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/34	tumor indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	enfermedad a nivel de sistema nervioso central	dev-set1-to-publish/cantemist-norm/cc_onco11.ann
8000/6	T2N2M0	dev-set1-to-publish/cantemist-norm/cc_onco106.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco106.ann
8000/6	recidiva pleuropulmonar	dev-set1-to-publish/cantemist-norm/cc_onco106.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8140/32	adenocarcinoma de colon moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco563.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3	carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/1	tumoraciones	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/32	carcinoma urotelial pTa GII	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	carcinoma mixto urotelial	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/31	carcinoma urotelial con diferenciación glandular T1 de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/31	carcinoma urotelial, de bajo grado de la OMS	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/1/H	tumoración papilar	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	variante tipo nested de carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/1/H	tumoración papilar	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	carcinoma urotelial tipo nested	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	carcinoma urotelial infiltrante de vejiga tipo nested	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/34/H	carcinoma urotelial infiltrante de alto grado tipo nested	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	carcinoma urotelial infiltrante de variante tipo nested	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8120/3/H	variante histológica tipo nested del carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco43.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8310/6	metástasis de carcinoma renal de células claras	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8310/32	carcinoma renal de células claras de 6 cm de diámetro máximo, grado 2 de Fhurman	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8310/6	metástasis de adenocarcinoma de células claras	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8000/6	lesión osteolítica	dev-set1-to-publish/cantemist-norm/cc_onco224.ann
8046/3	CPNM	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8070/3	Carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8070/3	carcinoma escamoso	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/3	maligno	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8070/6	metástasis de carcinoma escamoso	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8070/6	metástasis de un carcinoma escamoso	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	infiltración pleural	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	lesión tumoral en el músculo	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	infiltración tumoral de la pleura	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8000/6	enfermedad a nivel pulmonar y hepático	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8046/3	cáncer pulmonar de células no pequeñas	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8046/6	cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico	dev-set1-to-publish/cantemist-norm/cc_onco740.ann
8586/3	Carcinoma tímico	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
8586/3	carcinoma tímico	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
8586/3	carcinoma tímico	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
8586/3	carcinoma tímico	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
9440/3	glioblastoma multiforme	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco608.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	masa pélvica	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8000/6	implante en cúpula vaginal	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8140/6	Adenocarcinoma de colon derecho pT4bN2aM1	dev-set1-to-publish/cantemist-norm/cc_onco500.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	cáncer de mama metastásico	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8010/6	metástasis por carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8000/6	cutánides	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8500/6	Metástasis cerebelosa de carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco695.ann
8310/3	carcinoma renal de células claras	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8310/33	carcinoma renal de células claras grado 3 de Fuhrman	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco246.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8140/6	adenocarcinoma de pulmón (T2BN0M1b	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	lesión frontal	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	enfermedad cerebral	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	lesión frontal	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	masa retroperitoneal	dev-set1-to-publish/cantemist-norm/cc_onco708.ann
8000/6	Lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8140/33	adenocarcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8520/3	carcinoma lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8520/3	carcinoma lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8520/3	carcinoma lobulillar infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/6	implante tumoral	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8520/6	Carcinoma lobulillar de mama IV con afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8000/6	infiltración colónica	dev-set1-to-publish/cantemist-norm/cc_onco533.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8272/0	macroadenoma hipofisario	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	nódulo en región supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8010/64	metástasis de carcinoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	tumor mamario oculto luminal (TxN2M1)	dev-set1-to-publish/cantemist-norm/cc_onco450.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8720/6	melanoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8000/6	pT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8720/6	melanoma diseminado	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8000/6	lesión resecada del músculo	dev-set1-to-publish/cantemist-norm/cc_onco404.ann
8000/6	Masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8041/3	cáncer microcítico	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9590/3	linfoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	masa prevertebral	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/3	neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8821/1	tumor desmoide	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/6	metastásis ósea de neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	Afectación metastásica de la médula ósea de las vértebras sacras	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/6	metástasis ósea de neuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
9500/6	recaída de neuroblastoma, a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco66.ann
8000/6	Lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	Masa suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8041/3	carcinoma de célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	enfermedad a nivel cerebral	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	enfermedad sistémica	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	implantes pleurales	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/3	linfangitis carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	progresión pleural	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	progresión pleuropulmonar	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8041/6	carcinoma microcítico de pulmón enfermedad extendida	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8041/33	carcinoma pobremente diferenciado tipo oat-cell	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	adenopatías patológicas mediastínicas, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	nódulos hiperecogénicos hepáticos	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8041/6	Carcinoma microcítico de pulmón enfermedad extendida	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	T4N3M1c	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	lesión de 6 mm a nivel mesencefálico	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8002/1	tumor microcítico	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
8000/6	RP ósea	dev-set1-to-publish/cantemist-norm/cc_onco681.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
9120/6	angiosarcoma cardiaco (11,3 x 10,8 cm) estadio IV (metástasis	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8000/6	nodulares pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco127.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8140/6	metástasis por adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesión de cavidad oral	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesión en cavidad oral	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesión en trígono retromolar	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	enfermedad ósea	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesión en hemisacro	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8000/6	lesión en cavidad oral	dev-set1-to-publish/cantemist-norm/cc_onco674.ann
8140/31	adenocarcinoma bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/6	lesiones ocupantes de espacio en parénquima hepático	dev-set1-to-publish/cantemist-norm/cc_onco402.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	lesión ocupante de espacio a nivel cerebeloso	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8140/6	Adenocarcinoma colorrectal estadio IV (SNC	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8140/32	adenocarcinoma de sigma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	lesiones ocupantes de espacio en hemicerebelo	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8000/6	recaída cerebelosa	dev-set1-to-publish/cantemist-norm/cc_onco631.ann
8140/33	Adenocarcinoma gástrico pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8000/6	implante peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8000/6	T4N3M1	dev-set1-to-publish/cantemist-norm/cc_onco428.ann
8380/3	adenocarcinoma endometrioide	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8380/3	adenocarcinoma endometrioide	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8020/3	carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8000/3	tumor maligno	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8044/34	carcinoma indiferenciado de células pequeñas-intermedias	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8263/3	adenocarcinoma endometrioide de patrón villoglandular	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8930/3	estromal maligno	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8930/34	sarcoma del estroma endometrial indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8000/34	tumoral indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco322.ann
8815/0	Tumor fibroso solitario	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
9040/3	sarcoma sinovial	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
8815/0	tumor fibroso solitario	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
8815/0	tumor fibroso solitario	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco499.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
9560/0	neurinoma	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8815/0	tumor fibroso solitario	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8815/3	tumor fibroso solitario maligno	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/6	recaída pleural múltiple	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8815/3	tumor fibroso solitario maligno	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/6	progresión pleural	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/6	progresión tumoral a nivel pleural	dev-set1-to-publish/cantemist-norm/cc_onco452.ann
8000/6	Cáncer de mama metastásico	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión a nivel cerebral	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8000/6	progresión a SNC	dev-set1-to-publish/cantemist-norm/cc_onco929.ann
8140/33	Adenocarcinoma poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8140/33	Adenocarcinoma poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/6	Nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8000/6	Nódulo hipermetabólico a nivel de vértice de pulmón	dev-set1-to-publish/cantemist-norm/cc_onco309.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco261.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	malignidad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8171/3	hepatocarcinoma fibrolamelar	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8171/34	hepatocarcinoma fibrolamelar poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8171/3	Hepatocarcinoma fibrolamelar	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	T3aN1M0	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8171/3	CHC fibrolamelar	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	recidiva hepática, peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	implantes perihepático	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	progresión hepática, intercostal	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	lesión intercostal	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8000/6	PE pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco717.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8500/3	carcinoma ductal	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8500/32	adenocarcinoma ductal moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	nodulares presentes en el pulmón	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	cáncer de páncreas intervenido con extensión abdominal	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8140/6	Infiltración del peritoneo parietal por adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	Metástasis pulmonares de cáncer	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8000/6	extensión abdominal	dev-set1-to-publish/cantemist-norm/cc_onco101.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8041/6	metástasis de carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco2.ann
8140/34/H	adenocarcinoma invasor de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco821.ann
8000/6	Masa retroperitoneal	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9473/3	Tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/6	masa retroperitoneal	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/6	masa retroperitoneal	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9061/3	seminoma	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9071/3	tumor del seno endodérmico	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9071/3/H	tumor del seno endodérmico de patrón microquístico	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9065/3	tumor germinal no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9473/3	tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9065/3	tumor no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9065/3	tumor de células germinales no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9501/3	meduloepitelioma	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9071/3/H	tumor del seno endodérmico de patrón microquístico y variedad hepatoide	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9071/3	variedad hepatoide	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
9501/3	meduloepitelioma	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8000/6	afectación retroperitoneal	dev-set1-to-publish/cantemist-norm/cc_onco137.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco135.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco135.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco135.ann
8000/1	neoformativo	dev-set1-to-publish/cantemist-norm/cc_onco135.ann
8000/6	lesiones nodulares pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco135.ann
8000/6	afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/6	afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8020/3	carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8020/3	carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8160/3	carcinomas de la vía biliar	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/9	tumores de origen desconocido	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8000/9	tumores de origen desconocido	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8160/3	tumores de vías biliares	dev-set1-to-publish/cantemist-norm/cc_onco807.ann
8020/3	Carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/6	Implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8020/3	carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8010/33	carcinoma poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8441/34	carcinoma seroso de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/6	lesión sospechosa en hígado	dev-set1-to-publish/cantemist-norm/cc_onco746.ann
8000/1	Neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8000/6	cT1cN0M0	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8500/3	carcinoma ductal	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8000/1	neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8000/6	metástasis de una neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8520/62	carcinoma lobulillar infiltrante G2 cT2N1M1	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8520/6	metástasis orbitaria por carcinoma lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8500/32	Carcinoma ductal infiltrante G2	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8522/3	Carcinoma infiltrante ducto-lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco243.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8380/32	adenocarcinoma de endometrio de tipo endometrioide moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco114.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
9989/3	síndrome mielodisplásico	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8070/3/H	carcinoma escamoso infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8071/3/H	carcinoma escamoso infiltrante queratinizante	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8000/6	lesiones líticas en acromion	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8070/6	carcinoma escamoso de pulmón, T4N2M1b	dev-set1-to-publish/cantemist-norm/cc_onco992.ann
8000/6	cM0	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8720/3	melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8720/3	melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	nódulos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8720/6	metastásico de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	nodulares subcutáneas	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8000/6	nodulillos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8001/1	satelitosis	dev-set1-to-publish/cantemist-norm/cc_onco963.ann
8480/3	Carcinoma coloide	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/6	cT2N0M0	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/6	cT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8480/3	carcinoma coloide	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8480/3	tumoración epitelial infiltrante constituida por muy abundante material coloide	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8000/6	pT3aN1(1/16)M0	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8310/32	carcinoma renal de células claras, grado 1-2 de Fürhman	dev-set1-to-publish/cantemist-norm/cc_onco161.ann
8461/3	carcinoma seroso papilar	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	lesiones blásticas a nivel de L1	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	Afectación de apófisis	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	focos nodulares en D11	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	afectación del cuerpo vertebral	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	expansión ósea	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8500/32	Carcinoma Ductal Infiltrante Grado II de Nottingham	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/6	lesiones de predominio lítico en unión condro-esternal	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8500/6	Carcinoma Ductal Infiltrante de Mama cT4NxM1	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8000/3	Ca	dev-set1-to-publish/cantemist-norm/cc_onco341.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
9064/3	tumor germinal	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8170/3/H	hepatocarcinoma multifocal	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
9071/3/H	tumor de yolk salk de tipo endometroide	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
9071/3	tumor de células germinales del seno endodérmico	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
9071/3	yolk sac tumor	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8000/3/H	neoplasia que adopta un patrón de crecimiento papilar y tubular infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco93.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8500/3	carcinoma ductal infiltrante (CDI) grado 3	dev-set1-to-publish/cantemist-norm/cc_onco972.ann
8020/3	Carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8000/6	Nódulo pulmonar contralateral	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8020/6	Carcinoma indiferenciado de pulmón, Estadio IV (T2bN2M1a)	dev-set1-to-publish/cantemist-norm/cc_onco8.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8170/32	HCC moderadamenteo diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco392.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	infiltración medular	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
9801/3	leucemia aguda	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	masa anexial	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8145/3	adenocarcinoma gástrico de tipo difuso	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8490/3	adenocarcinoma gástrico de tipo difuso antral, con células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8490/3	adenocarcinoma gástrico de tipo difuso con células en anillo sello	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8145/3	adenocarcinoma gástrico de tipo difuso	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	ypT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	ypT4N0M0	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8140/6	recidiva ovárica bilateral de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8490/6	infiltración masiva de médula ósea por adenocarcinoma gástrico con células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8000/6	progresión ganglionar y ósea	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8490/6	infiltración masiva difusa de médula ósea por adenocarcinoma con células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8490/6	infiltración masiva de médula ósea por adenocarcinoma con células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco911.ann
8441/3	carcinoma seroso	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8441/34	carcinoma seroso de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8001/1	células neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8441/34	carcinoma seroso de ovario de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco570.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/6	Metástasis	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8140/32	adenocarcinoma bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco856.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	progresión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8500/33	carcinoma ductal infiltrante grado III	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8500/33	Carcinoma ductal infiltrante grado III	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	pT4N2M0	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	lesiones milimétricas supratentoriales	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8000/6	enfermedad a nivel sistémico	dev-set1-to-publish/cantemist-norm/cc_onco620.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8310/32	carcinoma de células claras de riñón derecho grado 2 (Fuhrman)	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8310/32	carcinoma de células claras grado 2 (Fuhrman)	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	nódulos en el LSI	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8000/6	nódulo de 8 mm en el LSI	dev-set1-to-publish/cantemist-norm/cc_onco166.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8800/3	tumoración de origen mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8800/3	tumoración mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8936/3	tumor estromal gastrointestinal (GIST) maligno	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8000/6	metastatizado	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8000/6	nódulo hipodenso de 12 mm en región iliaca	dev-set1-to-publish/cantemist-norm/cc_onco952.ann
8170/3	CHC	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8170/3	CHC	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8000/3	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8170/3/H	CHC multicéntrico	dev-set1-to-publish/cantemist-norm/cc_onco438.ann
8510/3	Carcinoma Medular de tiroides	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8510/3	Carcinoma medular de tiroides	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8510/3	Carcinoma medular de tiroides	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
9863/3	Leucemia mieloide crónica	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8000/3	MEN 2	dev-set1-to-publish/cantemist-norm/cc_onco256.ann
8046/3	CNMP	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	lesión hepática	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	progresión a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	progresión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	adenopatías mediastínicas y supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	lesiones blásticas en columna cervical	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8140/6	adenocarcinoma de pulmón ALK positivo avanzado (estadio cT4cN3M1b	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	progresión a nivel del SNC	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
8000/6	lesiones subcentimétricas supra e infratentoriales	dev-set1-to-publish/cantemist-norm/cc_onco865.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
9120/3	angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	progresión hepática	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	lesión hipodensa en el lóbulo hepático	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8000/6	lesiones ocupantes de espacio hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco73.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8140/6	metástasis por adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/3	masa pulmonar maligna	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/6	LOE de 14 x 17 mm en región parietal	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8000/6	LOE cerebral	dev-set1-to-publish/cantemist-norm/cc_onco879.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	enfermedad a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	lesiones cerebrales	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	lesiones cerebrales	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	lesiones ocupantes de espacio en hemisferio cerebral	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8070/6	carcinoma epidermoide de pulmón estadio IV, cT4 cN0 M1c	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8000/6	lesiones pulmonares y hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco917.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/3	síndrome de Lynch	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8163/3	tumor de origen pancreatobiliar	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/3	síndrome de Lynch	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8000/6	masas peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco875.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8002/34	"tumor neuroendocrino (TNE) indiferenciado tipo ""oat cell"""	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/34/H	tumor neuroendocrino (TNE) indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/34/H	TNE de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/34/H	Tumor Neuroendocrino pulmonar de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco391.ann
8000/6	T3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8770/0	lesión spitzoide	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8720/0	lesión hiperpigmentada	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	M1d(1)	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8720/6	metástasis por melanoma	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	enfermedad a nivel del sistema nervioso central	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	lesión paracardiaca	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8000/6	captación nodular peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco649.ann
8120/3	Carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	Nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	micronódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	micronódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/3	neoformación maligna	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8452/1	tumoración papilar sólida	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8120/33	carcinoma sólido urotelial de alto grado (G3)	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	micronódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	lesión intrapélvica renal	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	lesión en la pelvis renal	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	lesión renal	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	Lesión renal	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	masa en cara anterior de iris	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	masa a nivel del iris	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	Lesión en iris	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8000/6	lesión intraocular	dev-set1-to-publish/cantemist-norm/cc_onco747.ann
8500/3	Carcinoma de mama ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8530/3	carcinoma inflamatorio	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	enfermedad ósea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8530/3	carcinoma ductal infiltrante subtipo no especial (tipo inflamatorio)	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8530/3	carcinoma ductal infiltrante subtipo no especial(tipo inflamatorio)	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8530/3	Carcinoma de mama ductal infiltrante (tipo inflamatorio)	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8500/33	carcinoma infiltrante de subtipo histológico no especial grado 3	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	captación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	diseminación leptomeníngea de su neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	captación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	enfermedad a nivel del SNC	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8000/6	nodulares osteoblásticas en columna vertebral	dev-set1-to-publish/cantemist-norm/cc_onco42.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8010/9	carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/1	neoformativa	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8077/2	lesión intraepitelial tipo CIN-3	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/6	CT2B CN0 CMX	dev-set1-to-publish/cantemist-norm/cc_onco933.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9100/3	coriocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9100/3	coriocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9065/3	tumor germinal no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9065/6	recaída tardía de un tumor germinal no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9065/6	metástasis de tumor de células germinales no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9065/3	tumor testicular germinal no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9101/3	coriocarcinoma y probablemente de carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9101/3	coriocarcinoma y probablemente de carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9064/6	tumor germinal metastásico	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
9065/6	metástasis de tumor germinal no seminomatoso	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	adenopatía tumoral paratraqueal	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	masa paratraqueal	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	nódulo apical del pulmón	dev-set1-to-publish/cantemist-norm/cc_onco26.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	progresión hepática	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	adenopatía en región supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8500/6	Recidiva ganglionar supraclavicular de carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	recaída ganglionar supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco753.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8895/0	mioma	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8895/0	miomas	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8931/3	SEE bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8931/3	SEE de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8931/3	SEE bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8931/3	SEE bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco806.ann
8140/6	METÁSTASIS DE ADENOCARCINOMA	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
9530/0	meningioma	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
9530/0	meningioma	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8140/6	infiltración focal ósea por adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8140/33	ADK Gleason 4+5	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8000/6	lesiones osteogénicas	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8140/6	ADK prostático estadío IV, hormonosensible, con diseminación ósea	dev-set1-to-publish/cantemist-norm/cc_onco335.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco557.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco557.ann
8000/1	tumoraciones	dev-set1-to-publish/cantemist-norm/cc_onco557.ann
8800/1	tumoraciones de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco557.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/1	intratumoral	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	suelta de globos	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
9064/3	tumor germinal	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
9064/3	tumor germinal	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	multinodulares pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/3	neoplásica maligna	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
9064/6	tumor germinal con enfermedad secundaria	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	TxNxM1b	dev-set1-to-publish/cantemist-norm/cc_onco501.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8004/1	neoplasia fusocelular	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8990/1	tumoración mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8910/3	rabdomiosarcoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8910/3	Rabdomiosarcoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8910/3	rabdomiosarcoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8912/3	rabdomiosarcoma de variante fusocelular esclerosante	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8900/3	rabdomiosarcoma esclerosante	dev-set1-to-publish/cantemist-norm/cc_onco46.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8310/6	cáncer folicular de tiroides variante de células claras con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8330/3	cáncer folicular	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8370/34	CCS de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
8370/34	CCS de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco274.ann
9080/3	Teratoma inmaduro	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/6	implante tumoral	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
9080/1	teratoma	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8452/1	quístico-sólido	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
9080/63	teratoma inmaduro de ovario grado 3 con implantes en el epiplón	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/6	implantes perihepáticos	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8000/6	implante en el saco de Douglas	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
9080/3/H	tejido adiposo metastatizado por tejido teratomatoso maduro	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
9080/3/H	teratoma inmaduro grado 0	dev-set1-to-publish/cantemist-norm/cc_onco124.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8460/3	carcinoma seroso papilar	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8022/64	metástasis de carcinoma pleomórfico de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8000/6	adenopatía supraclavicluar	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8460/34	adenocarcinoma de ovario seroso-papilar de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco257.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
9064/3	tumor germinal	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco618.ann
8743/3	Melanoma Maligno de extensión superficial	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8840/0	mixoma	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8840/0	mixoma	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/6	cáncer metastásico	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/6	T2aN0M0	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8840/0	Tumor de estroma laxo mucoide	dev-set1-to-publish/cantemist-norm/cc_onco369.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8530/3	carcinoma inflamatorio	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8010/9	carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8460/34	cistoadenocarcinoma seroso papilar de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8000/6	lesiones cutáneas	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8000/6	letálides	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8000/1	tumoraciones	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8460/34	carcinoma de alto grado de patrón seroso papilar	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8441/6	metastásica dérmica de mama bilateral por carcinoma seroso	dev-set1-to-publish/cantemist-norm/cc_onco149.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8319/3	CARCINOMA RENAL DE DUCTOS COLECTORES	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8319/32	carcinoma de ductos colectores pT3b , grado 2 de Fuhrman	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8000/6	enfermedad a nivel peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8319/3	carcinoma de túbulos de Bellini	dev-set1-to-publish/cantemist-norm/cc_onco272.ann
8000/6	afectación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	afectación meníngea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	infiltración de la medula ósea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	infiltración de la médula ósea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	infiltración leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	lesiones líticas	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/3	maligno	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metástasica	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos subcutáneos	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	nódulos subpleurales	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9473/3	tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/6	MO infiltrada por SE	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/6	SE con enfermedad metastásica	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/3	SE	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/6	Sarcoma de Ewing metastásico	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	progresión tumoral ósea	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	infiltración de la MO	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/3	SE	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
9260/3	SE	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8000/6	médula ósea infiltrada	dev-set1-to-publish/cantemist-norm/cc_onco86.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8090/3	carcinomas basocelulares	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8001/1	células neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	lesión lítica en el cuerpo vertebral	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8272/0	macroadenoma hipofisario	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8272/0	macroadenoma hipofisario	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8840/0	mixomas	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8504/31	tumor papilar intraquístico grado I	dev-set1-to-publish/cantemist-norm/cc_onco987.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8804/3	sarcoma epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8000/6	progresión a nivel ganglionar, paraespinal	dev-set1-to-publish/cantemist-norm/cc_onco468.ann
8000/6	lesiones de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8310/33	carcinoma de células claras Fürhmann 3	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8000/6	lesiones en columna vertebral	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8033/6	metástasis de carcinoma sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8964/6	metástasis de carcinoma de células claras con diferenciación sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
8000/6	lesiones situadas a nivel lumbosacro	dev-set1-to-publish/cantemist-norm/cc_onco913.ann
9061/3	Seminoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/6	afectación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9100/3	coriocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9100/3	coriocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/6	diseminación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/6	diseminación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	germinoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/6	infiltración leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9061/3	seminoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9061/3	seminoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9061/3	seminoma	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9080/0	teratoma maduro	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9080/0	teratoma maduro	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	tumores de células germinales	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	GCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	tumores germinales	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	Germ cell tumors	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	GCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	germinomas	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9065/3	non-germinomatous GCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9065/3	NGGCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9071/3	tumor seno endodérmio	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9080/3	teratoma maduro e inmaduro	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8000/1/H	tumores mixtos	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9065/3	NGGCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9061/3	seminomas	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	GCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	germinomas	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	tumores germinales	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9071/3	yolk sac tumor	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3/H	germinomatosos mixtos	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9065/3	germ cell tumors (GCTs) intracraneales non-germinomatous	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	GCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9065/3	NGGCTs	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3	GCT germinomatous	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/3/H	germinomas multifocales	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
9064/6	germinomas multifocales o metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco258.ann
8140/31	adenocarcinoma de próstata Gleason 6	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8140/33	adenocarcinoma de próstata Gleason 8	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	adenopatías cervicales, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
9931/3	mielofibrosis	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8140/6	adenocarcinoma de próstata estadio IV por afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	progresión exclusivamente a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	progresión a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
9931/3	fibrosis medular	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	progresión a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8000/6	lesiones blásticas en columna	dev-set1-to-publish/cantemist-norm/cc_onco757.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8140/0	adenoma	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/3	linfangitis carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8140/6	adenocarcinoma de pulmón estadio IV (derrame pericárdico positivo	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/6	nódulos adrenales	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/6	nódulos suprarrenales	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/6	progresión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco891.ann
8000/1	formación	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	lesiones focales hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	metastasis	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	lesiones hipoecogénicas hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8490/32	adenocarcinoma gástrico moderadamente diferenciado, variante anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/6	focos en el parénquima hepático	dev-set1-to-publish/cantemist-norm/cc_onco144.ann
8000/1	intratumoral	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8895/0	miomas	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8271/0	prolactinoma	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8271/0	macroadenoma hipofisario (2,5x2,0x2,3 cm) secretor de prolactina	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8271/0	Macroprolactinoma	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8272/0	adenoma de hipófisis	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8272/0	adenoma hipofisario	dev-set1-to-publish/cantemist-norm/cc_onco296.ann
8046/3	NSCLC	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8046/3	NSCLC	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8046/3	cáncer de pulmón no microcítico	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8046/3	cáncer de pulmón no microcítico	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8033/3	sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8560/33	carcinoma adenoescamoso pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8000/6	progresión torácica y suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco730.ann
8580/1	timoma	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
8584/1	timoma de fenotipo e inmunofenotipo tipo B2	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	leucemia mielomonocítica crónica (LMMC) tipo mielodisplásica	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	LMMC	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	LMMC-1	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
8584/1	Timoma tipo B2	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	Leucemia mielomonocítica crónica	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	LMMC	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
9945/3	leucemia mielomonocítica crónica	dev-set1-to-publish/cantemist-norm/cc_onco596.ann
8140/0	Adenoma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
9120/0	Hemangioma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/1	peritumoral	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8310/6	Carcinoma renal de células claras, pT3bN0M1	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8310/33	carcinoma renal de células claras, Fuhrman 3	dev-set1-to-publish/cantemist-norm/cc_onco29.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
9751/3	histiocitosis de células de Langerhans	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
9751/3	histiocitosis de células de Langerhans	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/6	metástasis hepáticas de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/6	adenocarcinoma de recto localmente avanzado con afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8000/6	cáncer metastásico	dev-set1-to-publish/cantemist-norm/cc_onco212.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8000/6	afectación pulmonar y ósea	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8000/3	linfangitis carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8140/6	Adenocarcinoma de pulmón cT4cMxpM1b	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8000/6	afectación intersticial pulmonar bilateral	dev-set1-to-publish/cantemist-norm/cc_onco921.ann
8010/3/H	Carcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	cM1	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8010/3/H	carcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8000/6	adenopatías sospechosas axilares, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco321.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/6	Mx	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8140/0	adenoma	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/6	afectación del sistema nervioso central	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8000/6	T1bN1M0	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8550/3	adenocarcinoma pulmonar de patrón acinar	dev-set1-to-publish/cantemist-norm/cc_onco182.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
9050/3	mesotelioma	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
9050/3	mesotelioma maligno	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco625.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco400.ann
8000/6	lesión en pala iliaca izquierda	dev-set1-to-publish/cantemist-norm/cc_onco400.ann
8070/6	carcinoma epidermoide de pulmón estadio IV por afectación suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco400.ann
8000/6	lesión en pared costal	dev-set1-to-publish/cantemist-norm/cc_onco400.ann
8000/6	T1N0M0	dev-set1-to-publish/cantemist-norm/cc_onco752.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco752.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco752.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco752.ann
8000/6	nódulos pleurales bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco752.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/6	lesiones a distancia	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8010/6	metastasis por carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/6	adenopatías axilares, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8500/33	CDI de mama, grado histológico III	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8000/6	ganglionar supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8500/6	CDI de mama oligometastásica	dev-set1-to-publish/cantemist-norm/cc_onco336.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco954.ann
8000/6	enfermedad ósea	dev-set1-to-publish/cantemist-norm/cc_onco954.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco954.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco954.ann
8000/6	enfermedad a nivel cerebral	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	enfermedad pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	implantes pleurales	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	lesiones cerebrales	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/0	neurofibroma	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/0	neurofibroma	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/1	neurofibromatosis	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/1	neurofibromatosis	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8801/3	sarcoma fusocelular	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8802/34	sarcoma pleomórfico de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	suelta de globo	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8004/1	neoplásica de patrón fusocelular	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8802/34	sarcoma retroperitoneal pleomórfico de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
9540/6	tumor maligno de vaina nerviosa periférica estadio IV por la presencia de metástasis	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8000/6	implante en pleura	dev-set1-to-publish/cantemist-norm/cc_onco616.ann
8140/33	adenocarcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/9	neoplasia de origen desconocido	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8162/3	tumor de Klatskin	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8160/33	Colangiocarcinoma extrahepático GHIII	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/6	pT2pN1M0-R0	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8000/6	LOE hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco443.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	masa pélvica	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8895/0	miomas	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8895/0	miomas	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8895/0	miomas	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	progresión peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	recaída pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8895/0	miomatosis	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	uM0	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	ypT3N1M0	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	ypT3N1M0	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	nódulos de 4 y 5 mm en bases pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8140/6	adenocarcinoma gástrico rIV (OTHER	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8140/6	adenocarcinoma gástrico rIV (PULMONAR	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	progresión a nivel peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	implante rectovesical	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	implantes en cara anterior de recto	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8000/6	implante en mesocolon	dev-set1-to-publish/cantemist-norm/cc_onco995.ann
8170/3	CHC	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8170/3	CHC	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8170/32	Carcinoma hepatocelular (CHC) moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8170/6	implante de hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco340.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8000/1	neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8936/3	tumor del estroma gastrointestinal	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
9867/3	leucemia aguda mielomonocítica	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
9930/3	sarcoma mieloide	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
9867/3	leucemia aguda mielomonocítica	dev-set1-to-publish/cantemist-norm/cc_onco932.ann
8071/3	CARCINOMA ESCAMOSO QUERATINIZANTE	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8001/3	CELULAS MALIGNAS	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8070/3	Carcinoma escamoso	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8575/3	Carcinoma metaplásico	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8575/3	carcinoma metaplásico	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8070/3	diferenciación escamosa	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	macrometástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	macrometástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	macrometástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	ypT1cN2M0	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	nódulo en LSD	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/1	neoformativas	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8575/6	metástasis de carcinoma metaplásico	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8000/6	lesión endobronquial	dev-set1-to-publish/cantemist-norm/cc_onco378.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8046/3	carcinoma no microcítico	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8500/6	metástasis de carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8895/0	mioma	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/6	pT1bN0M0	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8000/6	pT2N0M0	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8513/3	carcinoma medular atípico	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8500/33	carcinoma ductal infiltrante pT1bN0M0, grado III	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8140/6	Adenocarcinoma de pulmón metastásico	dev-set1-to-publish/cantemist-norm/cc_onco678.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/3	maligno	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
9270/1	tumor odontogénico sarcomatoso	dev-set1-to-publish/cantemist-norm/cc_onco146.ann
8000/6	T4N0M0	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8001/1	células neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/1	neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/6	progresión pulmonar bilateral	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8250/31	adenocarcinoma de pulmón patrón bronquioalveolar bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8000/6	afectación pulmonar bilateral	dev-set1-to-publish/cantemist-norm/cc_onco30.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco763.ann
8000/6	cM0	dev-set1-to-publish/cantemist-norm/cc_onco763.ann
8070/3	Carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8010/3/H	carcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8070/3	diferenciación escamosa	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/6	lesiones a distancia	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/6	cT3cN0cM0	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8000/6	cT3cN0cM0	dev-set1-to-publish/cantemist-norm/cc_onco813.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	progresión hepática	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	pT4bN+Mx	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8500/31	carcinoma ductal infiltrante, grado I de la clasificación de Nottingham	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesión osteolítica	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	ypT1bN0M0	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	lesión osteolítica	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	enfermedad, esta vez a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	enfermedad a nivel de sacro	dev-set1-to-publish/cantemist-norm/cc_onco415.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco154.ann
8140/33	adenocarcinoma de próstata Gleason (4+5)	dev-set1-to-publish/cantemist-norm/cc_onco154.ann
8140/63	Adenocarcinoma de próstata metastásico (metástasis óseas) Gleason 4+5	dev-set1-to-publish/cantemist-norm/cc_onco154.ann
8140/6	ADC de próstata E-IV (metástasis	dev-set1-to-publish/cantemist-norm/cc_onco154.ann
8000/6	PE ósea	dev-set1-to-publish/cantemist-norm/cc_onco154.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8000/6	macrometástasis	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8500/31	carcinoma ductal infiltrante G1	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8500/31	carcinoma ductal infiltrante de 5,5 mm grado histológico 1	dev-set1-to-publish/cantemist-norm/cc_onco123.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8010/63	implantes peritoneales con diagnóstico de carcinoma de ovario pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8000/6	lesión localizada en el ligamento gastrohepático	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8000/6	masa del ligamento gastrohepático	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8010/33	carcinoma de ovario pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco368.ann
8700/3	Feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	Nódulo hepático	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8700/3	feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	masa mediastínica	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	nódulo hepático	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8700/6	feocromocitoma suprarrenal derecho con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8700/6	Feocromocitoma maligno metastásico	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8700/6	Metástasis de Feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	metastatizante	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8700/6	metástasis de feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	enfermedad a nivel laterocervical y hepático	dev-set1-to-publish/cantemist-norm/cc_onco244.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
9220/3	condrosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
9220/3	condrosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	progresa a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8800/3	proliferación mesenquimal maligna	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8575/3/H	carcinoma metaplásico heterólogo	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8500/33	carcinoma ductal infiltrante grado III	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8800/34/H	sarcoma de alto grado con diferenciación de matriz cartilaginosa	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8801/3	fusocelular mesenquimal neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8575/6	carcinoma de mama metaplásico heterólogo con diferenciación condrosarcomatoide estadio IV con afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8575/3/H	carcinoma de mama metaplásico heterólogo	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
9220/3	carcinoma de mama metaplásico heterólogo con diferenciación condrosarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco725.ann
8000/6	captación ósea	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
9470/34	Meduloblastoma grado IV	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
9470/34	meduloblastoma grado IV	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/6	recidiva a distancia	dev-set1-to-publish/cantemist-norm/cc_onco206.ann
8000/6	cT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
9010/0	fibroadenoma	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/6	lesión lítica	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
9020/1	tumor de Phyllodes	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
9020/3	tumor Phyllodes maligno	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8000/0	benignidad	dev-set1-to-publish/cantemist-norm/cc_onco502.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/3	CM	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	enfermedad a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8520/6	metástasis de carcinoma lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8520/3	patrón difuso tipo lobulillar	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	neoplasia gástrica con enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	adenomegalia supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8145/3	adenocarcinoma difuso	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8145/3	patrón difuso	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8490/3	carcinoma de células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	médula ósea (que aparece masivamente infiltrada	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8520/6	CLI metastásico	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8000/6	lesión gástrica	dev-set1-to-publish/cantemist-norm/cc_onco555.ann
8720/6	Melanoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	focos osteoblásticos	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	masa suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8720/6	metástasis por melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	lesión en cuerpo vertebral	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	masa pararrenal	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	masa pararrenal	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	lesión residual pararrenal	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8000/6	lesión residual pararrenal	dev-set1-to-publish/cantemist-norm/cc_onco965.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	Neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	tumoraciones	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8140/3/H	adenocarcinoma de recto-sigma clásico tipo infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	metastáticos	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	enfermedad secundaria	dev-set1-to-publish/cantemist-norm/cc_onco176.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	M1c	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	T2aN2M0	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8001/3/H	células epiteliales malignas	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	Masa supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	neoplasia de pulmón estadio radiológico T2aN3M1a	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8046/6	metástasis de carcinoma no célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8046/6	carcinoma no célula pequeña metastásico	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	afectación supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco560.ann
8000/6	afectación secundaria	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/6	cM0	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8046/3	carcinoma de célula no pequeña	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/3	tumor maligno	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8140/33	adenocarcinoma de pulmón poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8140/33	adenocarcinoma de pulmón poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8031/3	carcinoma de células gigantes	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8211/0/H	adenoma tubular con displasia de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8210/6	metástasis polipoide del carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco355.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	Progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	Progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	Progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8500/23	carcinoma ductal infiltrante en mama izquierda con componente in situ grado III	dev-set1-to-publish/cantemist-norm/cc_onco462.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco836.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco836.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco836.ann
8072/3	carcinoma epidermoide no queratinizante	dev-set1-to-publish/cantemist-norm/cc_onco836.ann
8585/3	carcinoma epidermoide de timo	dev-set1-to-publish/cantemist-norm/cc_onco836.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8743/3	melanoma de extensión superficial	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8743/3	melanoma maligno de extensión superficial	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	progresión a nivel pleural	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	progresión pleural	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	adenopatías en la región supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	ganglionar supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	ganglionar axilo-supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco145.ann
8000/6	Mx	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8140/3/H	adenocarcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8453/2	neoplasia mucinosa intraductal papilar con displasia de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco935.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8000/6	adenopatías laterocervicales,supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8000/6	enfermedad tumoral diseminada	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8000/6	lesión a nivel del seno esfenoidal	dev-set1-to-publish/cantemist-norm/cc_onco195.ann
8003/3	Tumor de células gigantes	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
9220/3	condrosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	intratumoral	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
9180/3	osteosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8003/3	tumor de células gigantes	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8003/3	tumor de células gigantes	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8003/3	tumor de células gigantes	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
9250/3	Tumor de células gigantes en cóndilo femoral	dev-set1-to-publish/cantemist-norm/cc_onco824.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8240/3	tumor neuroendocrino	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/34/H	Tumor maligno indiferenciado de células redondas inclasificable	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8800/6	recidiva tumoral de sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/34/H	Tumor maligno indiferenciado de células redondas inclasificable	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8800/6	recidiva de sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8000/6	progresión a nivel abdominal	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8370/1	tumor de corteza suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco711.ann
8010/3/H	carcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8010/3/H	carcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8530/3	carcinoma inflamatorio	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	enfermedad diseminada	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	letálides	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	bultoma supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	progresión local en mama, pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	progresión a nivel de SNC	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	lesión única frontal	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	enfermedad estable a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	RC hepática	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	progresión en SNC	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8000/6	RC pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco598.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8000/6	pT2pN1M0	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8162/3	tumor de Klatskin	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8160/31	adenocarcinoma de la vía biliar principal, bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8162/3	tumor de Klatskin	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8160/31	colangiocarcinoma (tumor de Klatskin) pT2pN1M0 bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco833.ann
8000/6	T4N2M0	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8041/33	carcinoma poco diferenciado de células pequeñas	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8002/3	oat cell	dev-set1-to-publish/cantemist-norm/cc_onco203.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8263/3	adenocarcinoma moderadamente diferenciado, que en su superficie muestra patrón túbulo-velloso	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8140/32	adenocarcinoma de uretra moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco472.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco839.ann
8246/33	CNE G3	dev-set1-to-publish/cantemist-norm/cc_onco839.ann
8000/6	afectación multisistémica	dev-set1-to-publish/cantemist-norm/cc_onco839.ann
8580/1	Timoma	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8580/1	Timoma	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8580/1	Timoma	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8583/1	Timoma linfocítico	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8582/1	Timoma mixto linfocítico y epitelial	dev-set1-to-publish/cantemist-norm/cc_onco236.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8140/31	adenocarcinoma de próstata Gleason 6	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	enfermedad sistémica	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	lesiones cerebrales	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	lesión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	oligometastásica	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	progresión sistémica	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/0	benignidad	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/0	benignidad	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8140/6	tejido cerebral infiltrados por un adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	lesión intraparietal	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8140/6	Adenocarcinoma de pulmón cT1pN2 pM1	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	nódulo suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	nódulo suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8000/6	progresión tumoral sistémica	dev-set1-to-publish/cantemist-norm/cc_onco930.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/6	masa pericárdica	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/6	masa pericárdica	dev-set1-to-publish/cantemist-norm/cc_onco455.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8000/6	recaída pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8910/3	rabdomiosarcoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8910/3	Rabdomiosarcoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8000/6	masa parahiliar	dev-set1-to-publish/cantemist-norm/cc_onco648.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	cT4N1M0	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	letálides	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8010/6	metástasis del carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8500/32	carcinoma ductal infiltrante (CDI) de mama derecha, grado 2	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8000/6	cT1bN0M1b	dev-set1-to-publish/cantemist-norm/cc_onco519.ann
8720/3	Melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco346.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco346.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco346.ann
8770/3	Melanoma de células epitelioides y fusiformes	dev-set1-to-publish/cantemist-norm/cc_onco346.ann
8000/6	pT4N3M0	dev-set1-to-publish/cantemist-norm/cc_onco346.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/3	maligno	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco626.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8010/9	carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9061/3	seminoma	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9064/3	tumor de células germinales	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9064/3	tumor germinal	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9085/3	Tumor germinal extragonadal mediastínico mixto	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9085/3	tumor germinal extragonadal mixto	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/6	masa a nivel supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
9080/3	teratoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco76.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/6	T3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8500/34	carcinoma ductal infiltrante de mama derecha grado II	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8140/3/H	adenocarcinoma invasor	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
8000/6	progresión ganglionar, ósea	dev-set1-to-publish/cantemist-norm/cc_onco393.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8001/1	celularidad tumoral	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	implantes en el peritoneo	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	nódulos peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9500/34	neuroblastoma anaplásico	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9500/34	neuroblastoma anaplásico	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	implantes en la superficie del bazo	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9473/6	implantes de tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	implantes en la grasa perihiliar esplénica	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9364/3	tumor neuroectodérmico periférico	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	recaída precoz esplénica	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	enfermedad a nivel abdominal	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9500/34	neuroblastoma anaplásico	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	recidiva precoz peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8000/6	nódulo pélvico	dev-set1-to-publish/cantemist-norm/cc_onco117.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	letálides	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	letálides	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8500/3	cáncer ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	cT4bN1M0	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8500/32/H	carcinoma ductal infiltrante residual multifocal, grado 2 de Bloom-Richardson Modificada	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	lesión en oído	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	cáncer de mama avanzado por metástasis	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8000/6	lesión de oído	dev-set1-to-publish/cantemist-norm/cc_onco692.ann
8140/0	adenoma	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/3	hepatoblastoma	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/6	lesión hepática	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
9835/3	leucemia linfoblástica aguda	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/6	masa hepática	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8960/3	nefroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/3/H	hepatoblastoma embrionario con diferenciación colangiolar	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8000/3	blastoma	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/3/H	hepatoblastoma mixto: epitelial (embrionario y fetal)	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/6	recidiva hepática de hepatoblastoma	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/3/H	hepatoblastoma embrionario con diferenciación colangiolar	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/3	Hepatoblastoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8970/6	Recidiva hepática tardía de Hepatoblastoma Embrionario	dev-set1-to-publish/cantemist-norm/cc_onco229.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco207.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco207.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco207.ann
8802/34	sarcoma pleomórfico indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco207.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco876.ann
8046/3	carcinoma pulmonar de células no pequeñas	dev-set1-to-publish/cantemist-norm/cc_onco876.ann
8070/6	carcinoma escamoso de pulmón T3 N3 M1a	dev-set1-to-publish/cantemist-norm/cc_onco876.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8070/3/H	carcinoma escamoso infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8070/6	carcinoma escamoso de pulmón T4N3M1	dev-set1-to-publish/cantemist-norm/cc_onco653.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco273.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco273.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco273.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco273.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco689.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco689.ann
8265/3	adenocarcinoma de patrón micropapilar	dev-set1-to-publish/cantemist-norm/cc_onco689.ann
8140/6	adenocarcinoma de pulmón cT2aN3M1c	dev-set1-to-publish/cantemist-norm/cc_onco689.ann
8010/3	Carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8500/33	CDI GIII (sistema de Nottingham)	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8500/33	CDI GIII	dev-set1-to-publish/cantemist-norm/cc_onco846.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8041/1	tumor de células redondas	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8805/3	sarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	pMX	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	recidiva pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8800/6	metástasis pulmonares de sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	implante paratraqueal	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	masa subcarinal	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	progresó a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/6	implante subcarinal	dev-set1-to-publish/cantemist-norm/cc_onco552.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/0	neurofibroma	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/0	neurofibromas	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/1	neurofibromatosis	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8800/9	sarcomatosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/3	tumor maligno de la vaina nerviosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/3	tumor maligno de la vaina nerviosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/34	tumor maligno de alto grado de la vaina nerviosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9550/0	neurofibroma plexiforme	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/3	tumor maligno de la vaina nerviosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/6	recaída frontal de tumor maligno de la vaina nerviosa	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8000/6	infiltración parenquimatosa cerebral	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
9540/3	neurofibroma con degeneración maligna	dev-set1-to-publish/cantemist-norm/cc_onco116.ann
8620/1	TCG	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	afectación hepática	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8622/1	tumor de células de la granulosa juvenil	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	Implante en fondo uterino	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	Implantes neoplásicos en subserosa de cérvix	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8622/1	tumor ovárico bilateral de células de la granulosa (TCG) juvenil	dev-set1-to-publish/cantemist-norm/cc_onco303.ann
8000/6	T3N1M0	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8140/6	adenocarcinoma de recto moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco878.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8010/2	carcinoma in situ	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8041/3	carcinoma neuroendocrino de célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	lesión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	lesión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	lesión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	lesión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8077/2	CIN III	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	recidiva tumoral suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8000/6	progresión suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco780.ann
8441/34	carcinoma seroso de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	diseminación peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	implantes peritoneales múltiples	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	progresión peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	implantes sólidos en el peritoneo	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	afectación extensa del meso	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	diseminación meníngea	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8000/6	realces meníngeos	dev-set1-to-publish/cantemist-norm/cc_onco733.ann
8010/9	Carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8010/9	Carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8000/6	afectación peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8010/33	carcinoma pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco126.ann
8033/3	carcinoma sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesiones de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesión de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	progresión radiológica a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
9970/1	síndrome linfoproliferativo	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8004/3	tumor de células fusiformes	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8032/1	tumor fusocelular	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
9831/3	síndrome linfoproliferativo crónico T variedad linfocitos granulares grandes	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8503/3	adenocarcinoma de pulmón infiltrante tipo papilar	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8010/6	metástasis de un carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8033/6	Carcinoma sarcomatoide de origen pulmonar cTx cNx pM1c	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	afectación múltiple en tejidos blandos	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	progresión a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesiones conocidas de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8000/6	lesiones sospechosas en partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco590.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	diseminación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	implantes pleurales	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8140/6	adenocarcinoma de lóbulo superior izquierdo T2aN2M1a	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	progresión sintomática a nivel del sistema nervioso central	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	progresión a nivel del SNC	dev-set1-to-publish/cantemist-norm/cc_onco866.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8001/3	células tumorales malignas	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/6	lesión esplénica	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8721/3	melanoma nodular	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8000/6	pT4bpN1M0	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8720/6	melanoma BRAF no mutado metastásico	dev-set1-to-publish/cantemist-norm/cc_onco523.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/6	recidiva a nivel de hilio pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8800/1	tumor de estirpe mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	PEComa	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	perivascular epithelioid cell neoplasms	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	PEComa	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	PEComa	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	PEComa	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8000/6	recidiva a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8011/1/H	PEComa	dev-set1-to-publish/cantemist-norm/cc_onco412.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	HCC	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8170/3	hepatocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco550.ann
8810/3	fibrosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	implantes mesentéricos	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8800/31	sarcoma retroperitoneal de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8805/3	sarcoma retroperitoneal indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8901/3	Sarcoma indiferenciado pleomórfico con fenotipo epitelioide/rabdoide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8806/3	tumor desmoplásico de células redondas	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8805/3	Sarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8804/3	Sarcoma indiferenciado pleomórfico con fenotipo epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8963/3	tumor desmoplásico de células redondas con fenotipo rabdoide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8805/3	sarcoma retroperitoneal indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8804/3	fibrosarcoma epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8806/3	tumor desmoplásico de células redondas pequeñas	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8810/3/H	fibrosarcoma epitelioide esclerosante	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8800/31	sarcoma de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	progresión radiológica hepática	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8901/3	sarcoma indiferenciado pleomórfico con fenotipo epitelioide/rabdoide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8805/3	sarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8804/3	sarcoma indiferenciado pleomórfico con fenotipo epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8963/3	tumor desmoplásico de células redondas con fenotipo rabdoide	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8806/3	tumor desmoplásico de células redondas	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8806/3	tumor desmoplásico de células redondas	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
9260/3	sarcoma de Ewing	dev-set1-to-publish/cantemist-norm/cc_onco170.ann
8000/6	afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	masa de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8140/33	adenocarcinoma de próstata Gleason 3+5	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	afectación metastásica a nivel cerebral	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/6	lesiones blásticas que afectan a la calota	dev-set1-to-publish/cantemist-norm/cc_onco381.ann
8000/1	Tumor	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
9133/1	hemangioendotelioma epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
9133/1	HE	dev-set1-to-publish/cantemist-norm/cc_onco28.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8720/3	Melanoma	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8743/3	Melanoma de extensión superficial	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8743/3	Melanoma de extensión superficial	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/6	afectación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/1	peritumoral	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8000/6	pT3bpN1b(2/8)M0	dev-set1-to-publish/cantemist-norm/cc_onco367.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8370/3	carcinoma cortical adrenal	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
8370/6	Carcinoma cortical adrenal productor de testosterona pT3pN0M1	dev-set1-to-publish/cantemist-norm/cc_onco904.ann
9370/3	cordoma	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
9590/3	linfoma	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
9731/3	plasmocitoma	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
9250/1	tumor de células gigantes de hueso	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
9250/1	Tumor de células gigantes óseo	dev-set1-to-publish/cantemist-norm/cc_onco68.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8070/6	Carcinoma epidermoide de pulmón izquierdo cT2N3 M1a	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/6	nódulo pulmonar contralateral	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8130/21	carcinoma urotelial de bajo grado no invasivo	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8130/1	tumoración papilar vesical	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8000/6	lesión en cabeza de páncreas	dev-set1-to-publish/cantemist-norm/cc_onco571.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8574/3	diferenciación neuroendocrina	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8574/3	diferenciación neuroendocrina	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8574/3	diferenciación neuroendocrina	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/6	enfermedad ósea	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8140/33	adenocarcinoma de próstata Gleason 9	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/6	CPRC metastásico	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8230/33	carcinoma sólido pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/13	neoplásica de alto grado pobremente diferenciada	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
8000/6	lesión esternal	dev-set1-to-publish/cantemist-norm/cc_onco884.ann
9260/3	Ewing	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9260/3	Ewing	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9260/3	Ewing	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	Melanoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8020/3	carcinoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8010/3	carcinomas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/6	lesiones focales hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9590/3	linfoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/3	maligno	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9040/3	sarcoma sinovial	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9040/3	sarcoma sinovial	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8800/3	sarcomas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/3	tumor maligno	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/34	tumor maligno indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8011/34	tumor maligno indiferenciado, con cierto patrón epiteloide	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8805/3	sarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9040/34	sarcoma indiferenciado (sinovial	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8033/3	carcinoma indiferenciado con patrón sarcomatoide	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9590/34	linfoma anáplasico	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/34	neoplasias indiferenciadas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
9860/3	leucemias granulocíticas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/3	melanomas	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/1	tumores melánicos	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/6	enfermedad hepática	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8000/6	enfermedad hepática	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8720/6	Melanoma primario de mucosa esofágica, enfermedad avanzada (metastasis	dev-set1-to-publish/cantemist-norm/cc_onco299.ann
8140/3/H	adenocarcinoma infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/6	diseminación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	peritumoral	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8263/32	adenocarcinoma moderadamente diferenciado túbulo-papilar	dev-set1-to-publish/cantemist-norm/cc_onco419.ann
8850/0	lipomas	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
8260/6	metástasis de Ca. papilar de tiroides	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
9493/0	gangliocitoma displásico	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
9493/0	gangliocitoma displásico cerebeloso	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
9493/0	enfermedad de Lhermitte-Duclos	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
9493/0	ELD	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
8102/0	tricolemoma	dev-set1-to-publish/cantemist-norm/cc_onco970.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/6	adenopatías cervicales, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
9702/3	linfoma anaplásico de células grandes ALK (-)	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
9718/3	síndrome linfoproliferativo CD 30 (+)	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
9714/3	linfoma anaplásico de células grandes	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
9590/3/H	linfoma anaplásico	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
9702/3	Linfoma anaplásico ALK (-)	dev-set1-to-publish/cantemist-norm/cc_onco293.ann
8140/33	adenocarcinoma poco diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8140/6	adenocarcinoma de pulmón T4N2M1b	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8000/6	captaciones patológicas óseas	dev-set1-to-publish/cantemist-norm/cc_onco797.ann
8000/6	infiltración medular	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
9590/3	linfoma	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
9663/3	linfoma de Hodgkin, esclerosis nodular	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
9663/3	linfoma Hodgkin esclerosis nodular	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	progresión supra e infradiafragmática	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	afectación esplénica	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	afectación esplénica	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	progresión supra e infradiafragmática	dev-set1-to-publish/cantemist-norm/cc_onco829.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
9522/3	estesioneuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
9522/3	estesioneuroblastoma	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
9522/34	estesioneuroblastoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
8002/3	neoplasia maligna de célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
9500/34	neuroblastoma olfatorio de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco210.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8000/6	captación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8000/6	captaciones radiológicas a nivel meníngeo	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8070/6	infiltración meníngea por carcinoma escamoso	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8000/6	neoplasia cerebral diseminada a nivel leptomeníngeo	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8000/3	malignización	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8070/6	carcinoma escamoso y diseminación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco990.ann
8520/3	Carcinoma lobulillar infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8520/3	Carcinoma lobulillar infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8010/6	Metástasis por carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	enfermedad a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	adenopatías axilares, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8520/32	Carcinoma lobulillar infiltrante de mama izquierda, Grado Histológico (GH) II	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8524/3	Carcinoma infiltrante mixto (lobulillar y sin tipo especial)	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	en pala ilíaca derecha un área blástica y lítica	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	lesión en pala ilíaca	dev-set1-to-publish/cantemist-norm/cc_onco342.ann
8000/6	cM0	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8520/3	carcinoma lobulillar infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8520/3	Carcinoma lobullilar infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco121.ann
8890/3	Leiomiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	Metástasis	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8890/34	leiomiosarcoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	lesiones focales hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	recidiva única pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8000/6	nódulos subcentimétricos en cavidad peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8890/6	mucosa bronquial infiltrada por un leiomiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco253.ann
8144/3	adenocarcinoma de tipo intestinal	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8144/3	adenocarcinoma intestinal	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
9070/3	carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/6	masa mediastínica	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
9062/3	seminoma anaplásico	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/6	T2N2M0S1	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
9080/6	metástasis mediastínica por teratoma maduro	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/6	lesión hipodensa en mediastino	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
9081/3	teratoma histológicamente maduro con un foco de carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
9081/3	teratoma maduro, y un foco de carcinoma embrionario	dev-set1-to-publish/cantemist-norm/cc_onco697.ann
8000/6	afectación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8721/3	melanoma de tipo nodular	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8720/6	metástasis por melanoma	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8000/6	T4bN0M0	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8001/1	satelitosis	dev-set1-to-publish/cantemist-norm/cc_onco510.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/6	nódulos pulmonares bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8046/3	Carcinoma de pulmón no Célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/6	cT3N3Mx	dev-set1-to-publish/cantemist-norm/cc_onco325.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco254.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco254.ann
8000/6	lesión nodular frontal	dev-set1-to-publish/cantemist-norm/cc_onco254.ann
8000/6	neoplásico hiliar con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco254.ann
8000/6	neoplasia pulmonar y metástasis	dev-set1-to-publish/cantemist-norm/cc_onco254.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8240/3	TNE	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8240/3	tumor neuroendocrino	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8240/3	tumor neuroendocrino	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8249/6	TNE de páncreas grado 2 estadio IV por múltiples metástasis	dev-set1-to-publish/cantemist-norm/cc_onco602.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8452/1	tumoración sólido-quística	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8452/1	tumoración sólido-quística	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8441/31/H	carcinoma seromucinoso bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8480/1	neoplasia mucinosa apendicular de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8480/1	tumor primario apendicular mucinoso	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8480/1	neoplasia mucinosa apendicular	dev-set1-to-publish/cantemist-norm/cc_onco458.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8490/3	adenocarcinoma de células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	implante tumoral	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	lesiones esplénicas	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	neoproliferativo	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	progresión peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8210/0	pólipo en recto distal de aspecto adenomatoso	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	extensión a distancia	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8480/3	adenocarcinoma de células en anillo de sello y mucinoso	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	T4aN2bMx	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/13	tumoración pobremente diferenciada	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	recidiva peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	implantes subfrénicos	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	implantes pararrenales	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
8000/6	lesiones focales esplénicas	dev-set1-to-publish/cantemist-norm/cc_onco401.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
9364/3	PNET	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
9473/3	tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
9473/3	tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
9473/3	tumor neuroectodérmico primitivo	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco776.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8010/9	carcinomatosis	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8720/3	melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8720/6	melanoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8720/3	neoplasia ileal pigmentada maligna	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/6	lesión frontal	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/6	TxNxM1d	dev-set1-to-publish/cantemist-norm/cc_onco545.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/6	diseminación leptomeníngea	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8265/3	cáncer micropapilar	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8452/1	blastoma pleuropulmonar tipo II (sólido-quístico)	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8973/3	blastoma pleuropulmonar	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8973/3	blastoma pleuropulmonar	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8452/1	blastoma pleuropulmonar tipo II	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8973/6	metástasis de PPB	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/6	masa en región parietal	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/6	recaída intracraneal	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8000/6	recaída a nivel del sistema nervioso central	dev-set1-to-publish/cantemist-norm/cc_onco787.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
8500/32	carcinoma ductal infiltrante de 1,3 cm, moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco699.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
9120/3	Angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	lesiones esplénicas	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	enfermedad a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco348.ann
8000/6	Diseminación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/1	Tumoración	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8310/33	carcinoma renal de células claras grado 3 de Furman	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8310/33	Carcinoma renal de células claras grado 3	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/6	pT2bN0M1	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco483.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8720/6	Melanoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8001/1	células neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8720/3	melanoma maligno	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8771/3	melanoma en el antebrazo derecho de tipo epitelioide	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	nódulos en el pulmón	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	lesión ocupante de espacio hepática	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8000/6	T2N2M1	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8001/1	satelitosis	dev-set1-to-publish/cantemist-norm/cc_onco205.ann
8070/3	Carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8070/33	carcinoma epidermoide pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8000/6	T3N1-2M0	dev-set1-to-publish/cantemist-norm/cc_onco177.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
8000/6	múltiples implantes en omento	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
8000/1	neoplasias	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
9052/3	mesotelioma maligno epitelioide papilar	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
9052/3	MP epitelioide papilar	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
9050/3	mesotelioma peritoneal maligno	dev-set1-to-publish/cantemist-norm/cc_onco773.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/6	diseminación peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
9120/0	hemangioma	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
9121/0	hemangioma cavernoso	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/6	implantes de aspecto gelatinoso - mucoide cubriendo asas intestino	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8480/31	adenocarcinoma apendicular mucinoso invasivo bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8452/1	quístico-sólida	dev-set1-to-publish/cantemist-norm/cc_onco334.ann
8000/6	lesiones cutáneas	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	lesiones osteoblásticas en la calota	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	lesión cutánea	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8010/6	metástasis por carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8120/6	carcinoma de células transicionales de vejiga E-IV (pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8120/6	Progresión cutánea y ósea múltiple de carcinoma de células transicionales	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	progresión a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	cutánides	dev-set1-to-publish/cantemist-norm/cc_onco100.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	progresiones a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8800/3	sarcoma de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8890/34	leiomiosarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8000/6	nódulos milimétricos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco131.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8500/3	Carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8000/6	T2N1M0	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8001/3	células malignas	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8500/3	carcinoma ducal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco18.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	CCR	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8480/3	adenocarcinoma mucinoso	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/1	intratumoral	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
9590/3	linfoma	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/1	peritumoral	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8480/32/H	adenocarcinoma infiltrante moderadamente diferenciado con áreas coloides	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8480/32	adenocarcinoma mucinoso moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8001/3	tumor budding	dev-set1-to-publish/cantemist-norm/cc_onco354.ann
8260/3	carcinoma papilar	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/6	implantes en peritoneo	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8460/3	adenocarcinoma de ovario seroso papilar	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/6	progresión abdominal	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/6	progresión abdominal	dev-set1-to-publish/cantemist-norm/cc_onco857.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8140/6	adenocarcinoma de páncreas metastásico	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	afectación pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	diseminación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	enfermedad pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	micronódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	micronódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8140/31	adenocarcinoma de páncreas bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco786.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
8000/6	afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
9970/1	proceso linfoproliferativo	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
8000/6	adenopatías múltiples a nivel supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
8000/6	ganglionar supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
9663/3	linfoma de Hodgkin clásico subtipo esclerosis nodular	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
8000/6	afectación del cuerpo vertebral	dev-set1-to-publish/cantemist-norm/cc_onco642.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8240/3	carcinoide	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8240/3	carcinoide	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8240/3	carcinoide	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	enfermedad a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8249/32	TNE bien diferenciado G2	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8249/62	TNE de origen en intestino delgado G2 metastásico	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8249/32	TNE G2	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	implantes en intestino	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8249/32	TNE G2	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8249/32	TNE y origen no pancreático G1/2	dev-set1-to-publish/cantemist-norm/cc_onco433.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	oligometastásica	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	recidiva hepática	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	recidiva hepática	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	ypT0N0M0	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8140/62	metástasis de adenocarcinoma grado II	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	lesión a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco198.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	progresión a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8800/1	tumor mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
9040/33/H	sarcoma sinovial monofásico grado 3	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	recidiva peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	lesiones en ambos riñones	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
9040/6	metástasis de sarcoma sinovial	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8000/6	afectación de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco684.ann
8140/32/H	adenocarcinoma moderadamente diferenciado invasor	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	implante peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8140/62	metástasis de adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8140/6	adenocarcinoma de colon estadio IV (metástasis	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	lesión vegetante rugosa en aritenoides	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	lesión vegetante, sésil e irregular sobre aritenoides	dev-set1-to-publish/cantemist-norm/cc_onco372.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8500/33	carcinoma ductal infiltrante pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8000/3	CMOH	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8050/3	CPRH	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8050/3	CPRH	dev-set1-to-publish/cantemist-norm/cc_onco263.ann
8041/3	Carcinoma de célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8140/6	adenocarcinoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8041/3	carcinoma microcítico	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8046/3	carcinoma no célula pequeña	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	lesión lítica	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
9732/3	mieloma	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	nódulos pulmonares subcentimétricos bilaterales	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8140/6	metástasis pleurales izquierdas de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8140/6	adenocarcinoma pulmonar (TXNXM1a)	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	Progresión tras 10 meses a nivel pleural	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	Masa de nueva aparición en ángulo cardiofrénico	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	enfermedad a nivel del SNC	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	enfermedad pleural	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	enfermedad a nivel pleural	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	progresión a nivel de SNC	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	enfermedad pleural	dev-set1-to-publish/cantemist-norm/cc_onco580.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/1	neoproliferativo	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8900/34	rabdomiosarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8900/34	Rabdomiosarcoma indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8000/6	lesiones satélites en la musculatura paraespinal	dev-set1-to-publish/cantemist-norm/cc_onco214.ann
8500/3	adenocarcinoma ductal	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8500/32	adenocarcinoma ductal de páncreas grado 2	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/6	pT3pN0pMx	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8500/32	Adenocarcinoma ductal de páncreas grado 2	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/6	pT3pN0cM0	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/6	lesiones ocupantes de espacio hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco991.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	lesión frontal	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	lesión frontal	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
9800/3	leucemia	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	progresión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	progresión cerebral	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8140/6	adenocarcinoma de pulmón, estadio IV (cT2N2M1)	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	PE pulmonar y hepática	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	lesiones focales corticosubcorticales supratentoriales	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	metástasis cerebrales de su neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8140/6	adenocarcinoma de pulmón estadio IV (cT2N2M1)	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8140/6	PE en el sistema nervioso central (SNC) de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8000/6	PE en SNC	dev-set1-to-publish/cantemist-norm/cc_onco934.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8000/1	neoformación	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8000/6	pT3N2a (4-6/20)M0	dev-set1-to-publish/cantemist-norm/cc_onco252.ann
8000/6	Mx	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	progresión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8200/3	carcinoma adenoide quístico de patrón cilindromatoso	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8200/64	Carcinoma adenoide quístico parotídeo derecho de alto grado de patrón cilindromatoso con adenopatías locorregionales y extensión ósea	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8260/3	carcinoma papilar tiroideo	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	lesión temporal	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8000/6	progresar a nivel pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco297.ann
8720/6	melanoma metastásico	dev-set1-to-publish/cantemist-norm/cc_onco727.ann
8720/6	infiltración de MO por melanoma	dev-set1-to-publish/cantemist-norm/cc_onco727.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco609.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco609.ann
8077/2	CIN III de cérvix	dev-set1-to-publish/cantemist-norm/cc_onco609.ann
9714/3	linfoma anaplásico de células grandes (ALK)	dev-set1-to-publish/cantemist-norm/cc_onco609.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8936/3	GIST	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8800/34	Sarcoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	Tumor	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/6	adenopatías cervicales, supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8001/1	celularidad tumoral	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8312/3	hipernefroma	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8312/3	hipernefroma	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8901/3	rabdomiosarcoma pleomórfico	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8901/3	rabdomiosarcoma pleomórfico	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8901/3	rabdomiosarcoma pleomórfico	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8800/34	sarcoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8800/1	tumoración de partes blandas	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8310/33	Adenocarcinoma renal de célula clara, grado nuclear de Fuhrman 3	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8936/31	Tumor del estroma gastrointestinal (GIST) de células fusiformes de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8004/3	Tumor del estroma gastrointestinal (GIST) de células fusiformes	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8936/31	GIST de células fusiformes de bajo grado	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8004/3	GIST de células fusiformes	dev-set1-to-publish/cantemist-norm/cc_onco343.ann
8000/6	cT1N0M0	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8500/3	carcinoma de mama ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	lesión cerebelosa	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	pT1N1micM0	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8500/33	carcinoma ductal de mama infiltrante grado 3	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	lesión ocupante de espacio a nivel de vermis cerebeloso	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	pT1N1micM0	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8000/6	lesión ocupante de espacio vermiano y cerebeloso	dev-set1-to-publish/cantemist-norm/cc_onco477.ann
8720/3	Melanoma	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	enfermedad hepática	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	enfermedad secundaria	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8720/3	melanoma	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8000/6	lesiones en lóbulo hepático	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8720/6	infiltración difusa por melanoma	dev-set1-to-publish/cantemist-norm/cc_onco764.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8070/3	carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8070/33	carcinoma epidermoide pobremente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	diseminación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8070/6	metástasis de carcinoma de células escamosas	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	recaída mediastínica	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	cT4N2M0	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8070/6	metástasis de carcinoma epidermoide	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	enfermedad mediastínica	dev-set1-to-publish/cantemist-norm/cc_onco551.ann
8000/6	diseminación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8723/3	melanoma en regresión	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8721/3	melanoma nodular	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8721/3	melanoma nodular	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	metastásicos	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8720/6	metástasis cutánea de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8720/6	metástasis de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8720/0	nevus	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	pT3bpN2bM0	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	adenopático en la fosa supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	enfermedad a nivel cutáneo	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8000/6	adenopático en FSC	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8720/6	metástasis múltiples de melanoma	dev-set1-to-publish/cantemist-norm/cc_onco215.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco403.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco403.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco403.ann
8000/6	LOE intracraneales	dev-set1-to-publish/cantemist-norm/cc_onco403.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8160/3	colangiocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8211/32	adenocarcinoma moderadamente diferenciado de patrón tubular	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8160/3/H	colangiocarcinoma intrahepático multifocal	dev-set1-to-publish/cantemist-norm/cc_onco186.ann
8000/6	adenopatía supraclavicular	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8312/3	carcinoma de células renales	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8310/3	carcinoma renal de células claras	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8310/3	carcinoma renal de células claras	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8310/3	carcinoma renal de células claras	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8700/0	feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8700/0	feocromocitoma	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
9161/1	hemangioblastomas	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	lesiones pancreáticas	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	masa suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	masa suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8240/3	tumores neuroendocrinos	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco830.ann
8000/6	adenopatías supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
9120/0	hemangiomas	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/3	linfangitis carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/3	linfangitis carcinomatosa	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/6	metastático	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/6	nódulo subpleural	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8490/3	adenocarcinoma con células en anillo de sello	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8000/6	T3N3Mx	dev-set1-to-publish/cantemist-norm/cc_onco981.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	cM0	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8001/1	células tumorales	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/3	malignas	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	lesión occipital	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	lesión de la cadera	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8000/6	progresión ganglionar y suprarrenal	dev-set1-to-publish/cantemist-norm/cc_onco685.ann
8140/6	adenocarcinoma compatible con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8144/32	adenocarcinoma de tipo intestinal moderadamente diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/6	pT3N1Mo	dev-set1-to-publish/cantemist-norm/cc_onco479.ann
8000/6	M1	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8000/1	neoplásica	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8000/6	Adenopatías en el nivel IIA y supraclaviculares	dev-set1-to-publish/cantemist-norm/cc_onco184.ann
8140/3	Adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	M0	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	Recaída pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	masa pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	masa pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	masa pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8140/6	metástasis de adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	nódulo pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
9823/3	leucemia linfoide crónica B	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8140/31	adenocarcinoma de colon derecho grado 1	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	recidiva pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8000/6	nódulo milimétrico pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco669.ann
8140/3	adenocarcinoma	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8120/3	carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8120/3	carcinoma urotelial	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8120/34	carcinoma urotelial de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8120/34	carcinoma urotelial de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/1	neoplásico	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/6	pT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/6	pT3N0M0	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	síndrome de Lynch	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8120/34	Carcinoma urotelial de vía urinaria (uréter izquierdo) de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	síndrome de Lynch	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	síndrome de Lynch	dev-set1-to-publish/cantemist-norm/cc_onco424.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	enfermedad a distancia	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	lesión parietal	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	lesión parietal	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8010/63	metástasis de carcinoma mal diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8500/33/H	carcinoma ductal infiltrante mal diferenciado, multifocal	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	Recaída cerebral única de cáncer	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
8000/6	recaída cerebral	dev-set1-to-publish/cantemist-norm/cc_onco565.ann
9120/3	angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8001/1	células neoplásicas	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8000/6	implantes peritoneales	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8000/6	omental cake	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8800/3	sarcomas	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8000/1	tumores	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
9120/33	angiosarcoma cardíaco grado 3	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8000/6	progresión a nivel abdominal	dev-set1-to-publish/cantemist-norm/cc_onco156.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	implantes pericárdicos	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	lesión pulmonar	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	progresión ósea	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8800/3	sarcoma	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8800/34	sarcoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	neoplasia cardiaca primaria maligna y metástasis	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8805/3	sarcoma de alto grado indiferenciado	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	recidiva pericárdica	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	progresión de las óseas	dev-set1-to-publish/cantemist-norm/cc_onco688.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
9800/3	leucemia	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	(LOEs) a nivel de parénquima hepático	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	(LOEs) hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8000/6	LOEs del lóbulo hepático	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8574/3	neoplasia epitelial maligna con diferenciación neuroendocrina	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8246/61	carcinoma neuroendocrino de probable origen pancreático con metástasis hepáticas y óseas, G1	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8150/3	TNE no funcionante pancreático	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8151/3	insulinoma maligno metastásico	dev-set1-to-publish/cantemist-norm/cc_onco357.ann
8246/31	carcinoma neuroendocrino bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8246/31	carcinoma neuroendocrino bien diferenciado	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	enfermedad hepática	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	lesiones hepáticas	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	metastásico	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	nódulo mesentérico	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/6	progresión hepática	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8246/61	Carcinoma Neuroendocrino de bajo grado de ileon con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8240/6	tumor neuroendocrino de bajo grado de ileon con metástasis	dev-set1-to-publish/cantemist-norm/cc_onco249.ann
8500/2	CDIS	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/2	CDIS	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8010/3	carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/2	carcinoma ductal in situ	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	metástasica	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	metástasica	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8010/6	metástasis de carcinoma	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoraciones	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8090/3/H	carcinoma basocelular superficial	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/2	Carcinoma de mama izquierda ductal in situ	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	cT2pN0(sn)cM0	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8500/31	carcinoma ductal infiltrante grado I	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	ypT2pN0(sn)cM0	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	lesión a nivel de L1	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
9970/1	proliferación linfoide	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
9591/34	linfoma no Hodgkin de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
9680/3	proceso linfoproliferativo B de células grandes	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
9680/3	Linfoma B difuso de células grandes	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	lesiones hipermetabolicas a nivel óseo	dev-set1-to-publish/cantemist-norm/cc_onco384.ann
8000/6	afectación a distancia	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	neoplasia	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8000/1	tumorales	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8601/0	tecoma luteinizado	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8601/3	tecoma luteinizado	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8601/3	tecoma luteinizado	dev-set1-to-publish/cantemist-norm/cc_onco854.ann
8461/34	carcinoma seroso papilar de ovario de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco388.ann
8000/6	progresión hepática	dev-set1-to-publish/cantemist-norm/cc_onco388.ann
8461/34	carcinoma seroso papilar de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco388.ann
8000/6	infiltración uterina, peritoneal	dev-set1-to-publish/cantemist-norm/cc_onco388.ann
8000/6	recidiva radiológica a nivel hepático	dev-set1-to-publish/cantemist-norm/cc_onco388.ann
8000/3	cáncer	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8935/12	tumor estromal fusocelular de grado histológico intermedio/bajo	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8004/1	tumor estromal fusocelular	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
9020/34	tumor Phyllodes de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
9020/6	Metástasis orbitaria de tumor Phyllodes	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
9020/64	metástasis de tumor Phyllodes de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8000/6	tumoración en región inferolateral de la órbita	dev-set1-to-publish/cantemist-norm/cc_onco522.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8500/3	CDI	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8500/3	carcinoma ductal infiltrante	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/3	malignidad	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/6	cT3NxMx	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8841/1	angiomixoma agresivo	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8841/1	angiomixoma	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8000/6	cT3NxM0	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
8841/1	Angiomixoma vulvar agresivo	dev-set1-to-publish/cantemist-norm/cc_onco976.ann
9120/3	angiosarcoma	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	lesión ósea	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/3	maligna	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8800/34	sarcoma de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8800/3	neoplasia maligna mesenquimal	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	lesión lítica en ala sacra	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	T4N0M1	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	lesión en ala sacra	dev-set1-to-publish/cantemist-norm/cc_onco686.ann
8000/6	afectación ósea	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/1	tumor	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/1	tumoral	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8160/6	adenocarcinoma de vía biliar con afectación pancreática	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8160/3	cáncer avanzado de vía biliar	dev-set1-to-publish/cantemist-norm/cc_onco507.ann
8000/6	T1N0M0	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	lesiones pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	lesiones óseas	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metastásica	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metastásicas	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	metástasis	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8500/6	metástasis de carcinoma ductal	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8500/6	metástasis de carcinoma ductal	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/1	tumoración	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8500/34	carcinoma de tipo ductal infiltrante, de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8500/34	Carcinoma ductal infiltrante de parótida derecha de alto grado	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	nódulos pulmonares	dev-set1-to-publish/cantemist-norm/cc_onco910.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	Mx	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8120/3	carcinoma urotelial	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	lesiones intraparenquimatosas	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	suelta de globo	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
9064/3	tumores germinales	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
9064/3	tumores germinales	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8120/34/H	carcinoma urotelial de alto grado con diferenciación trofoblástica	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8000/6	lesiones nodulares en ambos hemitórax	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8120/34/H	Carcinoma urotelial de alto grado con diferenciación trofoblástica	dev-set2-to-publish/cantemist-norm/cc_onco751.ann
8070/32	carcinoma escamoso moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8010/2	carcinoma in situ	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8070/31	carcinoma escamoso de pene bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8081/2	enfermedad de Bowen	dev-set2-to-publish/cantemist-norm/cc_onco1262.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1328.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1328.ann
8083/3	tumoración de células epiteliales con empalizada periférica basaloide	dev-set2-to-publish/cantemist-norm/cc_onco1328.ann
8123/3	Carcinoma basaloide	dev-set2-to-publish/cantemist-norm/cc_onco1328.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1137.ann
9351/1	Craneofaringioma Adantinomatoso	dev-set2-to-publish/cantemist-norm/cc_onco1137.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8480/3	adenocarcinoma mucinoso	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8480/3	carcinoma mucinoso	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8490/3	células en anillo de sello	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8144/3/H	adenocarcinoma tipo intestinal mixto	dev-set2-to-publish/cantemist-norm/cc_onco1329.ann
8000/6	enfermedad secundaria	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	enfermedad secundaria	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8072/3	carcinoma escamoso no queratinizante	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8072/3	carcinoma escamoso no queratinizante	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8070/6	Carcinoma escamoso de orofaringe (cT3cN2cM1)	dev-set2-to-publish/cantemist-norm/cc_onco1237.ann
8910/3	Rabdomiosarcoma tipo embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/6	lesiones cervicales	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/6	lesión única hepática	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8900/6	metástasis por rabdomiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/3/H	neoplasia maligna de células redondas azules	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/3/H	neoplasia maligna de células redondas azules	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8910/3	rabdomiosarcoma embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
9510/3	retinoblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
9510/3	retinoblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8000/6	nódulos cervicales	dev-set2-to-publish/cantemist-norm/cc_onco1253.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8140/3/H	adenocarcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	lesión frontal	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	lesión única frontal	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	pT3N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	progresión a nivel cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	progresión a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	progresión a nivel de calota	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	lesión de calota	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	progresión a nivel temporobasal	dev-set2-to-publish/cantemist-norm/cc_onco1429.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	M1a	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/6	Melanoma metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	Nódulos subcutáneos	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	masa paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	masa paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	masa paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8720/6	melanoma metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8721/3	melanoma nodular	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulo subcutáneo	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulo subcutáneo	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulo subcutáneo	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulos subcutáneos	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulos subcutáneos	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	nódulos subcutáneos	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/6	tumoración a nivel paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1164.ann
8000/3/H	Cáncer infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8500/3	carcinoma ductal Infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
9010/0	fibroadenomas	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8895/0	mioma	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8000/6	pT3N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8522/3	carcinoma infiltrante con componente mixto (ductal y lobulillar)	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
9866/3	leucemia aguda promielocítica M3	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
9866/3	Leucemia aguda no linfoblástica M3	dev-set2-to-publish/cantemist-norm/cc_onco1350.ann
8000/6	cM1	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8936/3	tumor del estroma gastrointestinal	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8004/14	tumor fusocelular de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8000/6	Neoplasia de sigma T4-N2-M1	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8004/64	metástasis hepática por tumor fusocelular de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8004/34	tumor fusocelular maligno de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8800/3	tumor fusocelular maligno de alto grado, de probable estirpe mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/34	Carcinosarcoma de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8980/6	implantes tumorales de carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1494.ann
8140/3/H	adenocarcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	progresión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8140/6	Adenocarcinoma de la unión gastroesofágica, estadio IV (M1	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1203.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8070/32	carcinoma epidermoide moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8461/31	carcinoma seroso papilar bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8461/31	Carcinoma seroso papilar bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8000/6	pT2N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1267.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8144/3	adenocarcinoma de tipo intestinal	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	pT3N1(2/12)Mx	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	Nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	nódulos infracentimétricos en ambos pulmones	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8010/6	metástasis (de su carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	lesión tiroidea	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	lesión tiroidea	dev-set2-to-publish/cantemist-norm/cc_onco1257.ann
8000/6	Lesiones líticas	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8090/3	carcinoma basocelular	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8090/3	carcinoma basocelular	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8000/3	malignas	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8090/6	Metástasis de carcinoma basocelular	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8090/3	CBC	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8000/6	lesiones líticas de 6.º y 8.º arcos costales	dev-set2-to-publish/cantemist-norm/cc_onco1339.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8154/3	carcinoma acinar pancreático mixto, con áreas de diferenciación neuroendocrina	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8154/3	carcinoma mixto acinar-neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8154/3	carcinoma pancreático acinar mixto con áreas de diferenciación neuroendocrina	dev-set2-to-publish/cantemist-norm/cc_onco1337.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/6	lesión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/6	lesión frontal	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8140/6	tejido cerebral infiltrados por adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
8550/33	adenocarcinoma acinar Gleason 8	dev-set2-to-publish/cantemist-norm/cc_onco1194.ann
9061/3	seminoma	dev-set2-to-publish/cantemist-norm/cc_onco1340.ann
9071/3	tumor del saco vitelino	dev-set2-to-publish/cantemist-norm/cc_onco1340.ann
9064/3/H	tumor germinal mixto	dev-set2-to-publish/cantemist-norm/cc_onco1340.ann
9085/3	tumor germinal mixto	dev-set2-to-publish/cantemist-norm/cc_onco1340.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1420.ann
8140/6	adenocarcinoma unión gastroesofágica uT3uN2 cM1	dev-set2-to-publish/cantemist-norm/cc_onco1420.ann
8000/6	lesión costal	dev-set2-to-publish/cantemist-norm/cc_onco1420.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1228.ann
8000/6	T3N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1228.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1228.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1228.ann
8481/3	adenocarcinoma mucosecretor	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8481/3	adenocarcinoma de colon mucosecretor	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8140/33	adenocarcinoma sincrónico (colon ascendente y ciego) G3	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8000/6	pT3N2Mx	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8140/6	adenocarcinoma de colon estadio IV por metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1427.ann
8070/3	CARCINOMA EPIDERMOIDE	dev-set2-to-publish/cantemist-norm/cc_onco1286.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1286.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1286.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1286.ann
8982/3	carcinoma mioepitelial	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8853/3	liposarcoma de células redondas	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/3	tumor maligno	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8800/3	carcinoma mioepitelial de partes blandas	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/34/H	tumor maligno indiferenciado de predominio epitelioide	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/9	tumor primario de origen desconocido	dev-set2-to-publish/cantemist-norm/cc_onco1025.ann
8000/6	Micrometástasis	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8500/32	carcinoma ductal infiltrante de mama grado II	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8500/3	Adenocarcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8041/3	carcinoma endocrino de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1382.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8744/3	Melanoma lentiginoso acral	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8000/6	afectación a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8000/6	lesiones subcutáneas	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8000/6	lesiones subcutáneas	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8744/3	melanoma lentiginoso acral	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8720/6	metástasis de melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
8000/6	progresión inguinal	dev-set2-to-publish/cantemist-norm/cc_onco1183.ann
9699/3	MALT	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
9699/3	MALT	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
8290/0	signos proliferativos foliculares a células de Hürthle	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
9671/3	linfoma de la zona marginal tipo MALT con prominente diferenciación plasmocítica	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
9699/3	Linfoma de la zona marginal tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
9699/3	linfoma de la zona marginal tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1475.ann
8070/3	carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8077/2	lesión escamosa intraepitelial de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8077/2	lesión intraepitelial escamosa de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8077/2	HSIL, CIN III	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8076/3	carcinoma escamoso microinvasor	dev-set2-to-publish/cantemist-norm/cc_onco1215.ann
8144/3	adenocarcinoma de tipo intestinal	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	masa anexial	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	progresiones a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	progresión a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8140/6	adenocarcinoma de recto superior con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8000/6	pT3pN2M1	dev-set2-to-publish/cantemist-norm/cc_onco1428.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1172.ann
8000/6	lesiones cutáneas	dev-set2-to-publish/cantemist-norm/cc_onco1172.ann
8140/33	adenocarcinoma de próstata Gleason 4 + 5	dev-set2-to-publish/cantemist-norm/cc_onco1172.ann
8140/6	metástasis cutánea de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1172.ann
8140/6	Metástasis cutáneas de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1172.ann
9064/3	Tumor germinal	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
9120/0	hemangioma	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
9071/3	tumor del seno endodérmico	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
9071/3	tumor del seno endodérmico	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8140/61	metástasis de adenocarcinoma bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8211/0	adenomas tubulares	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
9064/3	neoplasia de tipo germinal	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8000/6	afectación adenopática peritoneal múltiple	dev-set2-to-publish/cantemist-norm/cc_onco1255.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8380/3	adenocarcinoma endometrioide	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8140/3/H	adenocarcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	lesión lítica	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1076.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	linfoma B tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	Linfoma tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	linfoma MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	linfoma tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9591/31	linfoma B de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	linfoma tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
9699/3	linfoma tipo MALT	dev-set2-to-publish/cantemist-norm/cc_onco1091.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1234.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1234.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1234.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1234.ann
8000/6	recidiva a nivel óseo	dev-set2-to-publish/cantemist-norm/cc_onco1234.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8140/32/H	adenocarcinoma de recto moderadamente diferenciado e infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8000/6	pT3pN+ (4/8)M0	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8895/0	Mioma	dev-set2-to-publish/cantemist-norm/cc_onco1151.ann
8120/3	Carcinoma urotelial	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8120/3	carcinoma urotelial	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	tumor de pelvis renal metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1356.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
9250/3	tumor de células gigantes del hueso	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
9250/3	tumor de células gigantes del hueso	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8003/6	tumor de células gigantes de húmero derecho con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1490.ann
8000/6	TxN3M0	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8046/3	carcinoma de células no pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco645.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
9591/3	LNH	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8020/3	carcinoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8010/33	carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8010/33	carcinoma poco diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8010/63	metástasis de carcinoma mal diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	tumoraciones	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
9470/3	meduloblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1010.ann
8000/6	enfermedad sistémica	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8120/33	carcinoma urotelial de patrón sólido, grado 3	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8230/3	carcinoma urotelial de patrón sólido	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8000/6	afectación sistémica	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8120/2	carcinoma urotelial in situ	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8000/6	pTisN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8120/6	Metástasis muscular de carcinoma urotelial	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8120/64	metástasis de carcinoma urotelial de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1055.ann
8000/6	captación leptomeníngea	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	lesiones cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	recaída cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	pT3bN1aM0	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	lesiones expansivas intraparenquimatosas	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	captaciones leptomeníngeas	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	progresión leptomeníngea	dev-set2-to-publish/cantemist-norm/cc_onco1028.ann
8000/6	Lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8041/3	carcinoma pulmonar derecho tipo oat-cell	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8041/3	CPCP	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	lesiones focales subependimarias	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/6	lesiones localizada a nivel subependimario	dev-set2-to-publish/cantemist-norm/cc_onco1073.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8800/1	tumor mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8800/1	tumor mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8821/1	fibromatosis invasiva	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8822/1	Fibromatosis invasiva de la raíz del mesenterio	dev-set2-to-publish/cantemist-norm/cc_onco1295.ann
8041/3	carcinoma pulmonar de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1412.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1412.ann
8041/6	metástasis de carcinoma pulmonar de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1412.ann
8000/6	lesión de la vértebra	dev-set2-to-publish/cantemist-norm/cc_onco1412.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8000/6	hígado con múltiples lesiones	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/6	Adenocarcinoma de colon transverso estenosante con metátasis	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8000/6	cT4N1M1	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1256.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8140/0	adenoma	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8380/3	carcinoma endometroide	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8000/3	síndrome de Lynch	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
8380/33	adenocarcinoma endometroide G3	dev-set2-to-publish/cantemist-norm/cc_onco1405.ann
9120/3	Angiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
8000/1	neoformativo	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
9120/34	Angiosarcoma vesical de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
8000/6	afectación linfática locorregional y pleuropulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1444.ann
8830/3	Histiocitoma fibroso maligno	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8000/6	enfermedad secundaria	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8830/3	histiocitoma fibroso maligno	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8830/3	histiocitoma fibroso maligno	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8000/6	progresión a nivel pleural	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8830/3/H	histiocitoma fibroso pleomórfico maligno	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8000/6	recidiva a nivel abdominal	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8000/6	recidiva a nivel retrocecal	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8830/3/H	histiocitoma fibroso maligno pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1323.ann
8140/6	adenocarcinoma compatible con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8140/31	adenocarcinoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8000/6	enfermedad hepática	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8140/6	adenocarcinoma de ciego con diseminación hepática	dev-set2-to-publish/cantemist-norm/cc_onco1449.ann
8370/3	Carcinoma adrenocortical	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8000/6	Lesión lítica mínima en L1	dev-set2-to-publish/cantemist-norm/cc_onco1276.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8140/32	adenocarcinoma colorrectal moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8140/32	adenocarcinoma de próstata (Gleason 4+3)	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
8000/6	MO	dev-set2-to-publish/cantemist-norm/cc_onco1448.ann
9140/3	sarcoma de Kaposi	dev-set2-to-publish/cantemist-norm/cc_onco1418.ann
9140/3	sarcoma de Kaposi	dev-set2-to-publish/cantemist-norm/cc_onco1418.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8000/3/H	tumor maligno de células redondas	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
9522/32	neuroblastoma olfatorio grado 2 de Hymans	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
9522/3	Neuroblastoma olfatorio	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
9522/3	neuroblastoma olfatorio	dev-set2-to-publish/cantemist-norm/cc_onco1147.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/6	T1aN2M0	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8380/3	adenocarcinoma de endometrio endometrioide	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8140/32/H	adenocarcinoma de LSD, de patrón sólido predominante y tubular, moderadamente diferenciado, infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8230/3	adenocarcinoma de LSD, de patrón sólido	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8211/3	adenocarcinoma de LSD, de patrón sólido predominante y tubular	dev-set2-to-publish/cantemist-norm/cc_onco1201.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8500/2	carcinoma ductal in situ	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8500/33	carcinoma ductal infiltrante (CDI), grado III/III	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8501/33	CDI de 7 mm, con comedonecrosis, grado II/III	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/6	recidiva a distancia del primer tumor	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8010/33/H	carcinoma infiltrante grado III	dev-set2-to-publish/cantemist-norm/cc_onco1141.ann
8000/3	Cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8810/0	Fibromas	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8010/33	carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8850/0	lipoma	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/3	malignas	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8246/6	metástasis de carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/14	tumoral muy proliferativa o de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/64	metástasis del cáncer indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8247/3	tumor neuroendocrino cutáneo	dev-set2-to-publish/cantemist-norm/cc_onco1121.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8000/11	neoplasia urotelial de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8070/6	metástasis de carcinoma, sugerente de epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8000/11	tumor urotelial de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1333.ann
8930/34	Sarcoma del estroma endometrial indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	lesión en cuerpo vertebral	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metástasico	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8930/34	sarcoma del estroma endometrial indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/34	tumor maligno indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
8930/34	sarcoma endometrial indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1236.ann
9120/3	angiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8500/3	carcinoma ductal	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8000/6	implante tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
9120/33	Angiosarcoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1047.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8041/6	Carcinoma microcítico pulmonar, en estadio IV, por diseminación pulmonar y en sistema nervioso central	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8041/6	metástasis de un carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1326.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8510/3	carcinoma medular de tiroides	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/6	pT1N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8090/3	carcinoma decélulas basales	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8013/3	Tumor carcinoide atípico neuroendocrino (variante de células grandes)	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8249/3	Tumor carcinoide atípico neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1166.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8144/3	adenocarcinoma tipo intestinal	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/6	lesión cerebelosa	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/6	lesión cerebelosa	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/6	progresión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/6	progresión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8140/6	Adenocarcinoma de unión gastroesofagica EIV ( M1	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8144/6	metástasis de adenocarcinoma intestinal	dev-set2-to-publish/cantemist-norm/cc_onco282.ann
8041/3	Carcinoma neuroendocrino de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/6	adenopatías cervicales, supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8002/3	tumor maligno de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/6	cT2-3N3M0	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8000/6	recidiva a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1093.ann
8070/3	Carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8000/6	T4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8070/3	carcinoma con diferenciación escamosa	dev-set2-to-publish/cantemist-norm/cc_onco1402.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	lesión osteolítica	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/3	maligno	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8000/6	Nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8330/6	Carcinoma folicular de tiroides estadio IV (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1239.ann
8800/31	Sarcoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8000/6	lesiones ocupantes de espacio hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8811/0	neoplasia del estroma fibromixoide	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8800/31	sarcoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8811/0	proliferación fusocelular con patrón de crecimiento infiltrante sobre estroma mixoide	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
9133/3	hemangioendotelioma epiteloide maligno	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1497.ann
9751/3	granuloma eosinófilo	dev-set2-to-publish/cantemist-norm/cc_onco1462.ann
9751/3	histiocitosis X	dev-set2-to-publish/cantemist-norm/cc_onco1462.ann
9751/3	histiocitosis X	dev-set2-to-publish/cantemist-norm/cc_onco1462.ann
8000/6	Adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	Implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	lesión mesentérica	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	lesión suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8240/6	metástasis por carcinoma neuroendocrino bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8000/6	LOE hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8240/6	Tumor neuroendocrino de probable origen gastroenteropancreático bien diferenciado con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8240/6	tumor neruroendocrino bien diferenciado metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1229.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8000/6	lesión pleural	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8000/6	masa subpleural	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8140/6	Adenocarcinoma de pulmón estadio IV (T4N0M1a)	dev-set2-to-publish/cantemist-norm/cc_onco1021.ann
8310/3	carcinoma de células renales tipo células claras	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8000/6	pT2aNxM1	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8318/64	carcinoma de células renales tipo células claras con áreas desdiferenciadas y sarcomatoides, con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1331.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8247/3	carcinoma de células de Merkel	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8247/3	carcinoma de células de Merkel	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	implantes pleurales	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	lesión subcutánea	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	letálides	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8247/6	metástasis de carcinoma de Merkel	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	nódulo mamario	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8247/6	metástasis de carcinoma de células de Merkel	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	lesión en la espalda	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8000/6	lesión en espalda	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8247/6	metastásica visceral del carcinoma de células de Merkel	dev-set2-to-publish/cantemist-norm/cc_onco1478.ann
8580/1	Timoma	dev-set2-to-publish/cantemist-norm/cc_onco1293.ann
8580/1	timoma	dev-set2-to-publish/cantemist-norm/cc_onco1293.ann
8582/1	timoma tipo AB	dev-set2-to-publish/cantemist-norm/cc_onco1293.ann
8582/1	timoma tipo AB	dev-set2-to-publish/cantemist-norm/cc_onco1293.ann
8580/1	síndrome de Good	dev-set2-to-publish/cantemist-norm/cc_onco1293.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
8310/3	carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
8310/3	carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
9110/3	adenocarcinoma mesonéfrico	dev-set2-to-publish/cantemist-norm/cc_onco1016.ann
8860/0/H	Angiomiolipoma epitelioide	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8860/0/H	angiomiolipoma epitelioide	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8720/6	metástasis de melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8860/6/H	angiomiolipoma epitelioide maligno con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/6	LOE hepática	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/6	masas pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
8000/6	Progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1094.ann
9064/3	Germinoma	dev-set2-to-publish/cantemist-norm/cc_onco1353.ann
9064/3	germinoma	dev-set2-to-publish/cantemist-norm/cc_onco1353.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1353.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1353.ann
8720/3	Melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1315.ann
8000/6	afectación ósea	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
9530/0	meningioma	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
9530/6	meningioma con afectación ósea	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/6	lesiones hiperatenuadas en la columna	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
9532/6	metástasis de meningioma tipo fibroso	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
9532/6	meningioma tipo fibroso con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1150.ann
8000/6	enfermedad hepática	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/1	tumor de células de la granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/3	carcinoma de células de la granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/31	carcinoma de células de la granulosa de ovario E.IIA G1	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/63	metástasis por tumor de células de la granulosa pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/63	metástasis por carcinoma de células de la granulosa pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8000/6	(LOE) hepática	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8620/63	recaída tumoral abdominal por tumor de células de la granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1171.ann
8120/3	carcinoma urotelial	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8070/3	carcinoma urotelial sólido con diferenciación escamosa	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8000/6	pT4N2M1	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8230/3	carcinoma urotelial sólido	dev-set2-to-publish/cantemist-norm/cc_onco1222.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
9380/1	tumor de origen gliomatoso	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
9440/34	glioblastoma multiforme (grado IV de la WHO)	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8500/3/H	carcinoma ductal infiltrante multicéntrico	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
9440/3	glioblastoma multiforme	dev-set2-to-publish/cantemist-norm/cc_onco691.ann
8520/3	Carcinoma lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/6	metastatizado	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8520/3	carcinoma lobular	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8010/3/H	carcinoma de mama infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8520/3	carcinoma lobular infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8000/6	LOE óseas	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8022/3	carcinoma lobular tipo pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8520/3	carcinoma lobular	dev-set2-to-publish/cantemist-norm/cc_onco1123.ann
8500/3	Carcinoma de mama ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	Lesiones focales hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/1	Neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	cT1N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8170/3	hepatocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8170/3	hepatocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/3	malignas	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8500/31	carcinoma ductal infiltrante G1	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8140/6	Adenocarcinoma estenosante de sigma cT3cN2M1	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8500/31	carcinoma ductal infiltrante de 1,2 cm G1	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8170/32/H	hepatocarcinoma multicéntrico, moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1145.ann
8000/6	adenopatías axilares, supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9970/1	enfermedad linfoproliferativa	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9690/3	linfoma folicular	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9695/3	linfoma folicular grado 1	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9695/3	linfoma no Hodgkin de células B centrofolicular grado 1	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9670/3	proceso linfoproliferativo de células pequeñas B	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9698/3	linfoma B centrofolicular grado 3a	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
9970/1	síndrome linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1035.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8145/6	Adenocarcinoma gástrico difuso IV (pT3 pN2 M1	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8145/6	adenocarcinoma difuso e infiltrante en anillo de sello con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8490/3	adenocarcinoma difuso e infiltrante en anillo de sello	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8000/6	metástasi,s	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8000/6	lesiones pumonares	dev-set2-to-publish/cantemist-norm/cc_onco1188.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1034.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1034.ann
9120/0	Hemangioma	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8520/3	carcinoma lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8520/3	carcinoma de mama lobulillar infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8000/6	ypT0N1Mx	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8010/6	Infiltración meníngea por carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1032.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
9084/0	tumor dermoide	dev-set2-to-publish/cantemist-norm/cc_onco1131.ann
8490/3	adenocarcinoma de células en anillo de sello	dev-set2-to-publish/cantemist-norm/cc_onco1152.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1152.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1152.ann
8000/6	T4aN2M0	dev-set2-to-publish/cantemist-norm/cc_onco1152.ann
8000/6	metastásica de su neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1152.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/6	Lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8850/0	lipoma	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/6	metástásica	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/6	micrometástasis	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1391.ann
8171/3	hepatocarcinoma fibrolamelar	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8171/3	hepatocarcinoma fibrolamelar	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8001/1	satelitosis	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8001/1	satelitosis	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8171/3	FLC	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8171/3	FLC	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8171/6	Recidiva pulmonar y retroperitoneal irresecable de hepatocarcinoma fibrolamelar	dev-set2-to-publish/cantemist-norm/cc_onco1330.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8140/0	macroadenoma	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8720/6	melanoma coroideo derecho estadio IV por diseminación hepática	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8272/0	macroadenoma de la hipófisis	dev-set2-to-publish/cantemist-norm/cc_onco994.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1142.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1142.ann
9100/3	coriocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
9120/0	hemangiomas	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
9120/0	hemangiomas	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/6	lesión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/6	lesión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	neoformativo	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
9100/6	Coriocarcinoma extragonadal de probable origen duodenal con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
9064/3	tumor de estirpe germinal	dev-set2-to-publish/cantemist-norm/cc_onco1072.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1318.ann
9070/3	carcinoma embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1318.ann
9070/3	carcinoma embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1318.ann
8000/1/H	tumor embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1318.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1007.ann
9140/3	sarcoma de Kaposi	dev-set2-to-publish/cantemist-norm/cc_onco1007.ann
9140/3	sarcoma de Kaposi	dev-set2-to-publish/cantemist-norm/cc_onco1007.ann
9140/3	sarcoma de Kaposi	dev-set2-to-publish/cantemist-norm/cc_onco1007.ann
8310/6	Metástasis de adenocarcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8310/3	carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8310/3	adenocarcinoma de ovario derecho tipo células claras	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8310/3	Adenocarcinoma de ovario de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1008.ann
8260/3	carcinoma papilar	dev-set2-to-publish/cantemist-norm/cc_onco1088.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1088.ann
8000/6	lesión dorsal	dev-set2-to-publish/cantemist-norm/cc_onco1088.ann
8000/6	pT3N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1088.ann
8140/33	adenocarcinoma mal diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	diseminación hepática	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8000/6	lesiones hipervasculares hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8150/6	Tumor neuroendocrino de páncreas diseminado hepático	dev-set2-to-publish/cantemist-norm/cc_onco1492.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1138.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8140/33	adenocarcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/6	lesiones focales hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8000/6	cT2N2M1	dev-set2-to-publish/cantemist-norm/cc_onco1014.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8000/6	implante peritoneal	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8480/3	adenocarcinoma de células caliciformes con componente mucinoso	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8245/6	Adenocarcinoide apendicular estadio IV por afectación peritoneal	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8245/6	adenocarcinoide apendicular estadio IV por afectación peritoneal	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8481/6	implantes peritoneales múltiples por adenocarcinoma mucosecretor	dev-set2-to-publish/cantemist-norm/cc_onco1226.ann
8000/6	T4N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	afectación suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	lesión suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8140/6	metástasis por adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	progresión a nivel suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8140/6	adenocarcinoma de pulmon E-IVb, por metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	progresión única a nivel suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8000/6	lesiones a nivel suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1221.ann
8310/3	carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8312/3	hipernefroma	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8312/3	carcinoma de células claras renales	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	masa intramiocárdica	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	Neoformación cardíaca	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	tumoración intracardíaca	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8000/6	tumoración intraventricular	dev-set2-to-publish/cantemist-norm/cc_onco1368.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	lesión cutánea	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	lesión cutánea	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/3	neoformación maligna	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	progresión a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8319/34	carcinoma de los túbulos colectores de Bellini de 7,2 cm de diámetro mayor, grado 4 de Furhman	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	pT3bNxM1	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8319/3	carcinoma de túbulos colectores	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1484.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
8000/1	neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9680/3	linfoma no Hodgkin B de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9591/3	linfoma B	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9680/3	Linfoma no Hodgkin B de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
9680/3	linfoma difuso de células grandes B	dev-set2-to-publish/cantemist-norm/cc_onco1111.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/6	lesiones pleurales	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	sarcoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	SCC	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/6	adenopatías a nivel cervical, supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	sarcoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	sarcoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	sarcoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/6	recidiva de sarcoma de células claras a nivel pleural	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
9044/3	sarcomas de partes blandas	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/6	nódulos pleurales	dev-set2-to-publish/cantemist-norm/cc_onco1058.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
9360/1	tumoración sólida de la región pineal	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
9360/1	tumor de la región pineal	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
9360/13/H	tumor pineal tipo pleomórfico grado II-III	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
9360/13	tumor pineal parenquimatoso de diferenciación intermedia grado II-III	dev-set2-to-publish/cantemist-norm/cc_onco1198.ann
9522/3	Estesioneuroblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
8000/6	T4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
9522/3	estesioneuroblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
9522/32	estesioneuroblastoma GI-II de Hyams	dev-set2-to-publish/cantemist-norm/cc_onco1355.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
8800/1	tumor de partes blandas	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
9130/1	hemangioendotelioma	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
9120/3	hemangiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1018.ann
8000/6	2M0	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8000/3	maligna	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1042.ann
8700/3	feocromocitoma	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8700/3	feocromocitoma	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8700/3	feocromocitoma	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8700/6	feocromocitoma maligno con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1308.ann
8140/6	adenocarcinoma metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8140/32	adenocarcinoma moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8000/6	pT2bpN2M0	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8140/6	diseminación intracraneal de su adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1045.ann
8041/34	Carcinoma indiferenciado de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1104.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1104.ann
8000/6	pT2N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1104.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1104.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1118.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1118.ann
8041/6	carcinoma microcítico de pulmón diseminado	dev-set2-to-publish/cantemist-norm/cc_onco1118.ann
8000/6	progresión adenopática locorregional y ósea	dev-set2-to-publish/cantemist-norm/cc_onco1118.ann
8140/3	ADC	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8010/6	Metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1036.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/6	T2N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8500/2	carcinoma intraductal	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8441/3	carcinoma seroso	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8460/3	cistoadenocarcinoma seroso papilar	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/6	pT2pN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8500/3/H	carcinoma ductal infiltrante de mama derecha multicéntrico	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8452/1	quístico y sólido	dev-set2-to-publish/cantemist-norm/cc_onco1067.ann
8000/0	benignidad	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8500/32	carcinoma ductal infiltrante grado 2	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8500/33	carcinoma ductal infiltrante grado 3	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8010/3/H	carcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	lesión occipital	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
9016/0	fibroadenoma gigante	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
9020/1	cistosarcoma phyloides	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8500/63	Carcinoma ductal infiltrante de mama derecha grado 3, pT2N1(2/16)M1	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8000/6	lesión descrita previamente occipital	dev-set2-to-publish/cantemist-norm/cc_onco1181.ann
8246/3	Carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8510/3	carcinoma medular	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8000/6	diseminación ósea	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8000/6	LOE hepática	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8510/6	metástasis de carcinoma medular de tiroides	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8000/6	afectación ganglionar cervical y supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8510/6	Carcinoma medular de tiroides estadio IV (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8510/6	carcinoma medular de tiroides con diseminación hepática	dev-set2-to-publish/cantemist-norm/cc_onco1424.ann
8041/6	Carcinoma microcítico de pulmón, enfermedad extendida	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8041/6	cáncer microcítico de pulmón con evidencia de metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1186.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8070/31	carcinoma epidermoide G1	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	pT2bN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8261/3	adenocarcinoma sobre adenoma velloso	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8140/33	adenocarcinoma G3	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8000/6	pT4pN1Mx	dev-set2-to-publish/cantemist-norm/cc_onco1189.ann
8010/9	Carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
9065/3	TGNS	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
9065/3	TGNS	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
9071/3	tumor del seno endodérmico	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
9065/3	tumor germinal no seminomatoso	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
9071/3	TGNS subtipo seno endodérmico	dev-set2-to-publish/cantemist-norm/cc_onco1011.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8010/3/H	carcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8520/3	carcinoma lobulillar infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8520/6	metástasis de carcinoma lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8010/3/H	Carcinoma mamario infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8022/3	carcinoma lobulillar infiltrante de tipo pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/6	lesión proliferativa estenosante en colon	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8000/6	recidiva única cecal	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
8520/6	metástasis de carcinoma lobulillar infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1258.ann
9220/3	Condrosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8211/0	adenoma tubular	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
9220/3	condrosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8850/0	lipoma	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
8000/1/H	tumor de estirpe cartilaginosa	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
9220/31	condrosarcoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
9220/31	condrosarcoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1097.ann
9400/34	Astrocitoma de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
9400/31	astrocitoma de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
9380/1	tumoración glial	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
9400/34	astrocitoma grado IV	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
9400/34	astrocitoma que ha virado a alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1319.ann
8312/3	hipernefroma	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8310/6	metástasis de carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/6	pT3N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8270/32	Carcinoma renal izquierdo de células claras convencional con zonas cromófobas G2	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8000/6	pT2N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8310/3	Carcinoma renal izquierdo de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8140/32	Adenocarcinoma de próstata, Gleason 3 + 4	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8270/3	carcinoma renal izquierdo de células claras convencional con zonas cromófobas	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8310/3	carcinoma renal izquierdo de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
8140/32	adenocarcinoma de próstata Gleason 3 + 4	dev-set2-to-publish/cantemist-norm/cc_onco1254.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1304.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1304.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1304.ann
9680/3	linfoma no Hodgkin B difuso de célula grande	dev-set2-to-publish/cantemist-norm/cc_onco1304.ann
9680/3	Linfoma no Hodgkin B difuso de célula grande	dev-set2-to-publish/cantemist-norm/cc_onco1304.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1054.ann
8000/6	Adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	adenopático supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	afectación visceral	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8230/3	carcinoma sólido	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	masa en la región supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	tumoración supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	ganglio supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8140/34	adenocarcinoma de patrón indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8163/3	Adenocarcinoma de origen desconocido, probablemente de origen biliopancreático	dev-set2-to-publish/cantemist-norm/cc_onco1184.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
9061/3	seminoma	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
9070/6	metástasis por carcinoma embrionario	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
9085/6	Tumor germinal mixto S2pT2N2M1a	dev-set2-to-publish/cantemist-norm/cc_onco1264.ann
8312/3	CCR	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/3	CCR	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/3	CCR	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8310/3	carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/3	carcinoma de células renales	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/3	hipernefroma	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/6	metastatiza	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/6	CCR metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/6	CCR metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8312/6	metástasis nasal del hipernefroma	dev-set2-to-publish/cantemist-norm/cc_onco1260.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/1	neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8963/3	rabdoide	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8963/3	rabdoide	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8500/33	carcinoma ductal infiltrante de mama izquierda GIII	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8140/33	Adenocarcinoma muy escasamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8963/3	Carcinoma rabdoide	dev-set2-to-publish/cantemist-norm/cc_onco1419.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8260/3	carcinoma renal papilar	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8000/6	progresión a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8260/33	carcinoma papilar de células renales tipo 2, de 55 x 50 x 45 mm, de grado 3 de Führman	dev-set2-to-publish/cantemist-norm/cc_onco1376.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1314.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8936/3	tumores del estroma gastrointestinal	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8800/1	tumoración sólida, estirpe mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8890/34	Leiomiosarcoma yeyunal de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1488.ann
8220/0	PAF	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8220/0	PAF	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/0	fibromatosis	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/0	fibromatosis	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8220/0	poliposis adenomatosa familiar	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8821/1	tumor desmoide	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1115.ann
8046/3	Carcinoma de pulmón no microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8070/32	carcinoma epidermoide moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8070/6	metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
9680/3	linfoma B difuso de célula grande	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
9680/3	Linfoma no Hodgkin B difuso de célula grande	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8070/3	Carcinoma de pulmón no microcítico subtipo epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8000/6	cT3cN1M0	dev-set2-to-publish/cantemist-norm/cc_onco1311.ann
8041/3	Carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8010/9	Carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8000/6	T3N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8000/6	T3N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8041/3	carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8041/3	carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8041/6	afectación masiva meníngea por carcinoma de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1312.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8000/6	progresión a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8000/6	progresión a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
8246/6	carcinoma neuroendocrino (sinaptofisina +, cromogranina -), estadio diseminado	dev-set2-to-publish/cantemist-norm/cc_onco1404.ann
9364/3	PNET	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9473/3	PNET	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	nódulos subpleurales	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9260/3	Sarcoma Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9184/3	enfermedad de Paget	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9184/3	enfermedad de Paget	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9184/3	enfermedad de Paget	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8002/1/H	neoplásica infiltrante de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
9473/3	tumor neuroectodérmico primitivo	dev-set2-to-publish/cantemist-norm/cc_onco1022.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8010/6	carcinoma suprarrenal derecho, funcionante, estadio IV, con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	nódulos nuevos en cúpula hepática	dev-set2-to-publish/cantemist-norm/cc_onco1482.ann
8000/6	Macrometástasis	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	afectación a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	lesión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/3	maligno	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8010/6	micrometástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8010/3/H	carcinoma infiltrante de subtipo no especial	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8010/3/H	Carcinoma infiltrante (SNE)	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	lesión ocupante de espacio intraaxial	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8010/6/H	metástasis de carcinoma infiltrante SNE	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8010/3/H	carcinoma infiltrante SNE	dev-set2-to-publish/cantemist-norm/cc_onco1049.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8720/3	Melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/6	micrometástasis	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8743/3	melanoma maligno tipo histológico de extensión superficial	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8720/0	nevus pigmentado	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8740/0	nevus de unión	dev-set2-to-publish/cantemist-norm/cc_onco1451.ann
8260/3	adenocarcinoma papilar	dev-set2-to-publish/cantemist-norm/cc_onco1415.ann
8000/6	diseminación ósea	dev-set2-to-publish/cantemist-norm/cc_onco1415.ann
8000/3	linfangitis carcinomatosa	dev-set2-to-publish/cantemist-norm/cc_onco1415.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1415.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1415.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
9400/32	astrocitoma grado II	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
9450/32	oligodendroglioma grado II	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
9400/32	astrocitoma grado II	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
9400/32	astrocitoma cerebral grado II	dev-set2-to-publish/cantemist-norm/cc_onco735.ann
8500/3	Carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
8000/6	T2N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1043.ann
9591/3	LNH	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	lesiones a nivel cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	lesión focal hepática	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/6	metástasis de melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/6	metástasis de melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	progresión a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	pT4aN1aM0	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8000/6	enfermedad a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
8720/6	Progresión cerebral de melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1241.ann
9120/3	angiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	enfermedad ósea	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	masa pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/6	nodulares pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
9120/6	Angiosarcoma mediastínico estadio IV por metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1474.ann
8010/3/H	carcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1061.ann
8000/3	malignas	dev-set2-to-publish/cantemist-norm/cc_onco1061.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1061.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1061.ann
8000/6	metástasis de cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1061.ann
8150/1	TNEP	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8150/1	TNEP	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8310/3	adenocarcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8860/0	angiomiolipomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8860/0	angiomiolipomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
9161/1	hemangioblastomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
9161/1	hemangioblastomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
9161/1	hemangioblastomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8150/3	tumor neuroendocrino de páncreas no funcionante	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8140/0	adenomas	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
8150/31	tumor neuroendocrino de páncreas (TNEP) bien diferenciado G1 (Ki67 2 %) no funcionante	dev-set2-to-publish/cantemist-norm/cc_onco1296.ann
9364/3	PNET	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	intratumoral	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/3	maligno	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8982/3	mioepitelioma	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9473/3	tumor neuroectodérmico primitivo	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3/H	sarcoma de Ewing (SE) atípico, variante de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3	SE	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3/H	SE atípico, variante células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3	SE	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3/H	SE atípico	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9260/3	SE	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9185/3	osteosarcoma de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9191/0	osteoide maligno	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8804/3	sarcoma epitelial	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9240/3	condrosarcoma mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
9040/3/H	sarcoma sinovial atípico	dev-set2-to-publish/cantemist-norm/cc_onco1077.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
8000/3	linfangitis carcinomatosa	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
9970/1	proceso linfoproliferativo	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
9837/3	LNH linfoblástico T	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
9837/3	Linfoma no Hodgkin linfoblástico T	dev-set2-to-publish/cantemist-norm/cc_onco1373.ann
8041/3	Carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	T4N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	lesión cerebelosa	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	lesiones focales intraaxiales	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/6	lesiones en la calota craneal	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8041/6	Carcinoma pulmonar microcítico estadio diseminado	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8041/6	carcinoma microcítico pulmonar (estadio diseminado)	dev-set2-to-publish/cantemist-norm/cc_onco1062.ann
8000/3	maligna	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8004/3	tumor de células fusiformes	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8936/3	tumor del estroma gastrointestinal	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8936/3	tumor del estroma gastrointestinal	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8936/6	Tumor del estroma gastrointestinal avanzado (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1390.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8010/3/H	carcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/6	progresión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1359.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
8000/6	extensión a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
8000/1	neoformativa	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
8000/1	neoformativo	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
9040/3	sarcoma sinovial	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
9040/3	sarcoma sinovial	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
9041/3	sarcoma sinovial monofáscio fusocelular	dev-set2-to-publish/cantemist-norm/cc_onco1245.ann
8310/3	carcinoma renal de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	lesión única frontal	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	pT3aNxMx	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8310/34	carcinoma de células claras de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8310/6	metástasis de carcinoma renal convencional (célula clara)	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8310/6	Carcinoma renal izquierdo de células claras, estadio IV (M1	dev-set2-to-publish/cantemist-norm/cc_onco1227.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8000/6	enfermedad hepática	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8140/6	adenocarcinoma T4N3M1b	dev-set2-to-publish/cantemist-norm/cc_onco1001.ann
8120/3	carcinoma de células transicionales	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8010/33	carcinoma poco diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8240/3	tumor neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1154.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8000/1/H	tumor multicéntrico	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8000/1/H	tumor multicéntrico	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8500/32	carcinoma ductal infiltrante de 15 mm grado II	dev-set2-to-publish/cantemist-norm/cc_onco1199.ann
8010/6	carcinoma compatible con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8310/31	carcinoma renal de células claras grado I de Fuhrmann	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8310/6	carcinoma renal de células claras estadio IV (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8000/6	lesión endotraqueal	dev-set2-to-publish/cantemist-norm/cc_onco1275.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco734.ann
8000/6	infiltración meníngea	dev-set2-to-publish/cantemist-norm/cc_onco734.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/3	neoplasia maligna	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1170.ann
8721/3	Melanoma nodular	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/1	intratumoral	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/3	linfangitis carcinomatosa	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	masa suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8721/3	melanoma nodular	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8720/6	metástasis por melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	pT2 pN0[0/2]M0	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/6	nodulares milimétricas en ambos pulmones	dev-set2-to-publish/cantemist-norm/cc_onco1235.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1393.ann
8825/1	tumor miofibroblastico inflamatorio	dev-set2-to-publish/cantemist-norm/cc_onco1393.ann
8825/1	TMI	dev-set2-to-publish/cantemist-norm/cc_onco1393.ann
8825/1	TMI	dev-set2-to-publish/cantemist-norm/cc_onco1393.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
9540/1	Neurofibromas múltiples	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
9540/1	neurofibromatosis	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
9540/1	neurofibromatosis	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
9540/1	neurofibromatosis	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8936/3	tumores del estroma gastrointestinal	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
9540/1	NF-1	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8693/1	paraganglioma extraadrenal	dev-set2-to-publish/cantemist-norm/cc_onco1435.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8460/3	Cistoadenocarcinoma papilar seroso	dev-set2-to-publish/cantemist-norm/cc_onco1069.ann
8000/6	cT4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/6	cT4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8041/3	carcinoma de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8240/34	carcinoma neuroendocrino de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8041/3	cáncer microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8574/34	carcinoma de rasgos neuroendocrinos de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
8000/6	tumoral metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1175.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1225.ann
9680/3	linfoma B difuso de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1225.ann
9680/34	Linfoma no Hodking B difuso de células grandes CD 20 + de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1225.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8350/6	carcinoma papilar de tiroides variante esclerosante difusa con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8350/3	Carcinoma papilar de tiroides, variante esclerosante difusa	dev-set2-to-publish/cantemist-norm/cc_onco1090.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	Neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	Neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8550/3	carcinoma de células acinares	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
9121/0	cavernoma	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8440/3	cistoadenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/6	ganglionar supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
9120/0	hemangioma	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8230/3	carcinoma de células acinares de patrón sólido	dev-set2-to-publish/cantemist-norm/cc_onco1101.ann
8000/6	afectación cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8620/63	metástasis de neoplasia poco diferenciada de tumor de la capa granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8000/6	masas pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8620/1	tumor de la granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8620/6	Progresión pulmonar y adenopática de un tumor testicular de la capa de la granulosa	dev-set2-to-publish/cantemist-norm/cc_onco1351.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	T4N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	lesión hipodensa en cuerpo de páncreas	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	masa pancreática	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	masa pancreática	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	masa pancreática	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8070/6	metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8070/6	metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8070/62	metástasis de carcinoma escamoso moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1/H	neoplasia mucinosa	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8452/1	neoplasia sólido-quística	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8070/6	Carcinoma epidermoide de pulmón derecho T4N2M1	dev-set2-to-publish/cantemist-norm/cc_onco1438.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/6	lesiones cutáneas	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/1	neoplásicos	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/1	tumoraciones	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/6	ypT3N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8000/6	cT3N+M0	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
8140/6	metástasis cutánea de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1063.ann
9065/3	Tumor germinal no seminomatoso	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
9100/3	coriocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8000/6	nódulo pararrenal	dev-set2-to-publish/cantemist-norm/cc_onco1392.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8072/3	carcinoma epidermoide no queratinizante	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8260/3	carcinoma papilar de tiroides	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
9800/3	leucemia	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1033.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	lesiones cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	metástasis cerebelosas en paciente con cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	lesiones cerebelosas	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8000/6	LOES cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1437.ann
8240/3	carcinoide	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	enfermedad a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	recidiva a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8150/1	tumor neuroendocrino pancreático	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8150/1	TNE-P	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8240/6	Tumor carcinoide pancreatico E-IV (pT2N0M1) no funcionante de bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8150/6	Tumor carcinoide pancreatico E-IV (pT2N0M1) no funcionante	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
8000/6	lesiones nodulares a nivel segmentos hepáticos	dev-set2-to-publish/cantemist-norm/cc_onco1354.ann
9120/3	Angiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
9120/34	angiosarcoma de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
9120/0	hemangiomas	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
9020/1	tumor filodes	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8000/6	pT2bN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1271.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
8140/6	adenocarcinoma de pulmón, estadio IV (pulmón, pleura	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
8972/3/H	blastoma pulmonar con diferenciación rabdomiosarcomatosa	dev-set2-to-publish/cantemist-norm/cc_onco1187.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1388.ann
9591/3	linfoma no Hodgkin	dev-set2-to-publish/cantemist-norm/cc_onco1388.ann
9698/3	linfoma no Hodgkin B folicular de grado 3a	dev-set2-to-publish/cantemist-norm/cc_onco1388.ann
8920/3/H	Rabdomiosarcoma sólido alveolar	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/6	infiltración de médula ósea	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/6	infiltración de médula ósea	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/6	infiltración de médula ósea	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/3	maligna	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8900/3	rabdomiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8920/3/H	rabdomiosarcoma alveolar de muy alto riesgo (patrón sólido	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8920/3/H	rabdomiosarcoma sólido alveolar	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8900/3	rabdomiosarcomas	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8806/3	sarcoma desmoplásico de células redondas	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/1/H	tumor de células pequeñas redondas	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/34/H	tumor indiferenciado formado por células redondas	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/3	tumor maligno	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/1	tumoraciones	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8800/3	sarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8000/6	afectación ganglionar a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1179.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1371.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1371.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1371.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8500/24	carcinoma intraductal de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/6	progresión a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8802/3	sarcoma en el glúteo izquierdo pleomorfo	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8830/3/H	fibrohistiocitoma maligno pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8802/3	Sarcoma en el glúteo izquierdo pleomorfo	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8830/3/H	fibrohistiocitoma maligno pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8830/3/H	fibrohistiocitoma maligno pleomórfico	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8830/6	metástasis de fibrohistiocitoma	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8500/32	CDI G2	dev-set2-to-publish/cantemist-norm/cc_onco1338.ann
8000/6	Lesión suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8140/6	Metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8070/6	Metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	adenopatías laterocervicales, supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	LOES hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	Tumoración en relación con glándula suprarrenal	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	LOE hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco657.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco898.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco898.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco898.ann
8140/33	adenocarcinoma de próstata T3b Gleason 5+4	dev-set2-to-publish/cantemist-norm/cc_onco898.ann
8000/6	nódulos pulmonares paramediastínicos apicales bilaterales	dev-set2-to-publish/cantemist-norm/cc_onco898.ann
9590/3	linfoma	dev-set2-to-publish/cantemist-norm/cc_onco1143.ann
9401/3	astrocitoma anaplásico	dev-set2-to-publish/cantemist-norm/cc_onco1143.ann
9401/33	astrocitoma anaplásico GIII	dev-set2-to-publish/cantemist-norm/cc_onco1143.ann
8000/6	Diseminación neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	afectación meníngea	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8010/6	metástasis de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	pT1pN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8010/6	carcinoma de mama oculto con diseminación a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	lesiones a nivel dural	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	afectación orbitaria	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	infiltración de la duramadre	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8000/6	masa intraobitaria	dev-set2-to-publish/cantemist-norm/cc_onco1280.ann
8310/3	carcinoma renal de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8000/6	lesión osteolítica en la cara interna del clivus	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8000/6	pT1aN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
9062/6	seminoma anaplásico pT2pN3M1b	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8000/6	lesión en clivus	dev-set2-to-publish/cantemist-norm/cc_onco1384.ann
8720/3	melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8720/0	nevus	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8770/0	nevus de Spitz	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8000/6	adenopatías laterocervicales infra y supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8000/6	bulto supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8720/6	ganglio supraclavicular izquierdo con afectación de melanoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8720/6	melanoma maligno estadio IV (por afectación ganglionar, TxNxM1a	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8000/6	adenopatías supra e infraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1159.ann
8010/33	Carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8010/33	carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8010/63	metástasis de carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	múltiples pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	progresión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	cTxN2aM0	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8072/34	carcinoma nasofaríngeo indiferenciado no queratinizante	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8082/3	linfoepitelioma	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	T2N2bM0	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8000/6	lesión blástica dolorosa en el húmero	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8010/6	metástasis (M1) de carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1432.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8070/3	Carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8070/6	metástasis de carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8070/31	carcinoma escamoso bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/6	T3bN1M0	dev-set2-to-publish/cantemist-norm/cc_onco1397.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1459.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1459.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1459.ann
8310/34	carcinoma renal de células claras, grado 4 Fuhrman	dev-set2-to-publish/cantemist-norm/cc_onco1459.ann
8000/6	T2bN1M0	dev-set2-to-publish/cantemist-norm/cc_onco1459.ann
8890/3	Leiomiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	Lesión lítica en el cuerpo vertebral	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8890/3	leiomiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	lesión osteolítica	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8895/0	miomas	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8895/0	miomas	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/3	neoplasia maligna	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8890/32	leiomiosarcoma grado 2 (sistema de grado FNCLCC)	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8890/32	leiomiosarcoma grado 2	dev-set2-to-publish/cantemist-norm/cc_onco1098.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8000/3	tumor maligno	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8041/34	Carcinoma poco diferenciado de tipo neuroendocrino/oat cell de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8041/3	carcinoma supraglótico tipo microcítico	dev-set2-to-publish/cantemist-norm/cc_onco874.ann
8140/3	Adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8144/3	Adenocarcinoma de tipo intestinal	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1102.ann
8260/3	carcinoma papilar de tiroides	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8260/3	carcinoma papilar de tiroides	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	enfermedad a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	implantes pleurales	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8260/32	carcinoma papilar clásico moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8000/6	pT2N1bM1	dev-set2-to-publish/cantemist-norm/cc_onco945.ann
8832/3	dermatofibrosarcoma protuberans	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8832/3	dermatofibrosarcoma protuberans	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8832/6	metástasis de dermatofibrosarcoma protuberans	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8000/6	implante neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8000/6	nódulo en el mediastino	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8000/6	nódulo en el mediastino	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8000/6	nódulo en el mediastino	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8000/6	nódulo mediastínico	dev-set2-to-publish/cantemist-norm/cc_onco1463.ann
8010/3	Carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8140/31	adenocarcinoma bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/6	afectación pleural	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/6	afectación pleural	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/6	cT1N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8500/32	carcinoma ductal infiltrante grado 2	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/6	enfermedad a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8140/6	adenocarcinoma pulmonar cT3N2M1	dev-set2-to-publish/cantemist-norm/cc_onco1307.ann
8140/6	adenocarcinoma metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8441/34	adenocarcinoma seroso de ovario de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	implante tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	implantes peritoneales	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	lesión categoría BI-RADS 4A en mama	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8441/6	metástasis de adenocarcinoma seroso	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8441/6	Adenocarcinoma seroso de ovario estadio IV con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1336.ann
8000/6	afectación cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	lesiones cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	lesiones supratentoriales	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8140/32	adenocarcinoma de próstata (pT2bN0M0), Gleason 7	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	pT2bN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8140/6	Metástasis cerebrales múltiples de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	lesiones dispersas por el parénquima cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1283.ann
8000/6	Metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	Mx	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8070/31	carcinoma epidermoide bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	extensión a distancia	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	metastásicos	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8070/6	metástasis de carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/1	neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8070/6	Carcinoma epidermoide de vulva estadio IV (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	recidiva tumoral a nivel del periné, bronquial	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	lesión lítica en el tercio interno de la clavícula	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	lesiones de carácter infiltrante en la clavícula	dev-set2-to-publish/cantemist-norm/cc_onco1124.ann
8000/6	T2N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1377.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1377.ann
8500/33	carcinoma ductal infiltrante clásico con GN II y GH II-III	dev-set2-to-publish/cantemist-norm/cc_onco1377.ann
8500/3	Adenoarcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1377.ann
8500/3	carcinoma ductal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	lesión retroperitoneal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	lesión retroperitoneal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	masa paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	masa retroperitoneal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	masa retroperitoneal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/1	neoplásico	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	cN1cM0	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8010/33	carcinoma escasamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8500/6	Carcinoma ductal de mama triple negativo con recaída retroperitoneal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8500/6	recaída retroperitoneal de carcinoma ductal	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	masa retrocrural	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8000/6	masa retrocrural	dev-set2-to-publish/cantemist-norm/cc_onco1168.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8001/3	celularidad maligna	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8000/6	metastásis	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8520/6	metástasis de un carcinoma lobulillar infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8520/6	Carcinoma lobulillar infiltrante de mama cT2N1M1	dev-set2-to-publish/cantemist-norm/cc_onco1324.ann
8000/6	enfermedad pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	infiltración hepática	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metastásico	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
9040/3	sarcoma sinovial	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8800/1	tumoración blanda	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
9043/3	sarcoma sinovial bifásico	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
9043/3	sarcoma sinovial de patrón bifásico	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/6	masas pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1070.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8041/34	carcinoma indiferenciado de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	diseminación ósea	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	lesiones óseas	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metastásicas	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metastático	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metastático	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8041/64	carcinoma indiferenciado de célula pequeña de mucosa yugal T4aN2bM1	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	lesiones a nivel hepático	dev-set2-to-publish/cantemist-norm/cc_onco1467.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1361.ann
8140/6	metástasis de adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1361.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1361.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1361.ann
8140/6	Adenocarcinoma de origen intestinal estadio IV (pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1361.ann
8000/6	M1	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
9970/1	síndromes linfoproliferativos	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8312/6	neoplasia de células renales con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8310/34	carcinoma renal de células claras Fuhrman 4	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8310/64	Carcinoma renal de células claras Fuhrman 4 (estadio T4 N2 M1	dev-set2-to-publish/cantemist-norm/cc_onco1130.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8070/6	carcinoma epidermoide de pulmón diseminado	dev-set2-to-publish/cantemist-norm/cc_onco1383.ann
8041/3	carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8044/3	carcinoma neuroendocrino de célula intermedia	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1173.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1074.ann
8310/6	carcinoma renal de células claras con diseminación hepática	dev-set2-to-publish/cantemist-norm/cc_onco1074.ann
8936/3	GIST	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8130/2	Carcinoma transicional de vejiga pTaG2	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8800/1	tumoración sólida, de estirpe mesenquimal	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8890/34	Leiomiosarcoma yeyunal distal de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1487.ann
8000/6	T3N2M0	dev-set2-to-publish/cantemist-norm/cc_onco1208.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1208.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1208.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8144/3	adenocarcinoma de tipo intestinal	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8140/0	adenoma	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	lesión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	lesión única a nivel cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulo hepático	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulo pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	progresión cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	progresión pleuropulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8140/31	adenocarcinoma grado 1	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1041.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8246/3	carcinoma neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesiones hepáticas	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8240/3	neuroendocrino	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8240/3	neoplasia neuroendocrina	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8249/6	metástasis de carcinoma neuroendocrino grado II	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8249/3	carcinoma neuroendocrino moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8249/3	carcinoma neuroendocrino moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8000/6	lesiones en el parénquima hepático	dev-set2-to-publish/cantemist-norm/cc_onco1230.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1272.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1272.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1272.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1272.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8000/1	tumoraciones	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8935/1	tumor estromal	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8936/34	sarcoma del estroma gastrointestinal de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8935/14	tumor estromal de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1079.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8980/3	carcinosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8000/34	tumor maligno indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8950/3	tumor mulleriano mixto maligno	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8140/32	adenocarcinoma moderamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
8951/3	tumor mesodérmico mixto maligno	dev-set2-to-publish/cantemist-norm/cc_onco1387.ann
9591/3	Linfoma no Hodgkin	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
8001/3	células tumorales malignas	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
9766/1	proliferación tumoral linfoide con un patrón predominantemente angiocéntrico	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
9719/3	Linfoma no Hodgkin NT/K extranodal de tipo nasal	dev-set2-to-publish/cantemist-norm/cc_onco1132.ann
8012/3	Carcinoma de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/6	T1bN0M0	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/6	T4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8012/3	carcinoma de células grandes	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/1	neoplasias	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8140/32/H	adenocarcinoma, variante mixta, moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1068.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/6	diseminación tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8140/33	adenocarcinoma de colon derecho G3	dev-set2-to-publish/cantemist-norm/cc_onco1052.ann
8000/3	maligna	dev-set2-to-publish/cantemist-norm/cc_onco1317.ann
8583/1	timoma linfocítico	dev-set2-to-publish/cantemist-norm/cc_onco1317.ann
8583/3	timoma de predominio linfocítico (compatible con B1)	dev-set2-to-publish/cantemist-norm/cc_onco1317.ann
8583/3	timoma linfocítico (B1)	dev-set2-to-publish/cantemist-norm/cc_onco1317.ann
8312/3	carcinoma de células renales	dev-set2-to-publish/cantemist-norm/cc_onco1277.ann
8310/3	carcinoma renal de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1277.ann
8000/6	metastático	dev-set2-to-publish/cantemist-norm/cc_onco1277.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1277.ann
9861/3	LMA	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
9861/3	LMA	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8000/6	T2N1M0	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
9930/3	sarcoma mieloide	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8500/21	carcinoma intraductal de grado I	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8001/1	células mieloides neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
9930/3	Sarcomas mieloides	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
9920/3	leucemia mieloide aguda (LMA) relacionada con la terapéutica	dev-set2-to-publish/cantemist-norm/cc_onco1358.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8520/3	CLI	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8000/6	T2N1M0	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8520/3	carcinoma lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8520/3	carcinoma lobulillar infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco65.ann
8140/33	Adenocarcinoma poco diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8211/0	Adenoma tubular	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/6	pT3N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	peritumorales	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8210/0	poliposis	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8210/0	poliposis	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	síndrome de Lynch	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	síndrome de Lynch	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/3	síndrome de Lynch	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8000/1	intratumorales	dev-set2-to-publish/cantemist-norm/cc_onco1117.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8041/3	carcinoma de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8001/1	células tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8010/6	carcinoma vesicular con invasión hepática	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8010/6	carcinoma de vesícula T3 N1 M1	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8002/34	tumoral maligna indiferenciada de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8002/1	neoplasia de célula pequeña	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
9473/6	metástasis hepática por tumor PNET	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1089.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	Mx	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	T2N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	T4N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8070/3	carcinoma de células escamosas	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8070/3	carcinoma escamoso	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8070/32	carcinoma escamoso moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8046/3	carcinoma no microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	pT3N0M0	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8070/31	carcinoma de células escamosas (epidermoide) bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8140/33	adenocarcinoma escasamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8000/6	MX	dev-set2-to-publish/cantemist-norm/cc_onco1177.ann
8020/3	Carcinoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8140/0	adenomatosa	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/6	cTxN3M0	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8020/3	carcinoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8020/3	carcinoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8020/3	carcinoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
9732/3	mieloma	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
9732/3	mieloma múltiple	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/6	adenopatía a nivel supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8010/33	carcinoma mal diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco437.ann
8000/14	Neoplasia indiferenciada	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9930/3	sarcoma granulocítico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9930/3	sarcoma granulocítico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9930/3	sarcoma granulocítico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9930/3	sarcoma granulocítico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9930/3	sarcoma granulocítico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
8001/3	células con caracteres citológicos de malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9364/3	tumor neuroectodérmico	dev-set2-to-publish/cantemist-norm/cc_onco1495.ann
9120/3	angiosarcoma	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
9120/34	angiosarcoma de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1500.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8140/3	adenocarcinoma	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8246/34	carcinoma neuroendocrino de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/6	lesiones ocupantes de espacio supratentoriales	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8240/34	tumor neuroendocrino de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8010/13/H	neoformación epitelial moderada/pobremente diferenciada, de hábito glandular	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8046/33	carcinoma pobremente diferenciado no microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8140/6	adenocarcinoma de pulmón estadio IV por afectación pleural	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/6	implante en la pleura	dev-set2-to-publish/cantemist-norm/cc_onco1020.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1320.ann
9470/3	meduloblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1320.ann
8000/6	foco satélite	dev-set2-to-publish/cantemist-norm/cc_onco1320.ann
9470/3	Meduloblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1320.ann
8000/6	masa paravertebral	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
9500/3	neuroblastoma	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8000/6	progresión a nivel óseo	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
9500/31	neuroblastoma bien diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8000/6	lesiones vertebrales	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8000/6	lesión infiltrativa intertrocantérea	dev-set2-to-publish/cantemist-norm/cc_onco1363.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1273.ann
8000/6	enfermedad a nivel óseo	dev-set2-to-publish/cantemist-norm/cc_onco1273.ann
8000/6	lesiones cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1273.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1273.ann
9120/0	hemangiomas	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8310/6	metástasis de carcinoma de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8312/6	metástasis de carcinoma de células renales	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8000/1	neoplásicos	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8005/1	tumor de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8005/33	cáncer renal de células claras grado III de Furhman	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8005/34	neoplasia de células claras con áreas de alto y bajo grado	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8310/6	metástasis resecada en el yeyuno de carcinoma renal de células claras	dev-set2-to-publish/cantemist-norm/cc_onco1071.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1217.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1217.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1217.ann
9052/3	mesotelioma maligno de tipo epitelial	dev-set2-to-publish/cantemist-norm/cc_onco1217.ann
9052/3	Mesotelioma pleural maligno de tipo epitelial	dev-set2-to-publish/cantemist-norm/cc_onco1217.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1211.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1211.ann
8010/2	carcinoma in situ	dev-set2-to-publish/cantemist-norm/cc_onco1211.ann
8070/6	metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1211.ann
8000/6	Masa mediastínica	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	Tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	lesiones pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	masa mediastínica	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	masa mediastínica	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	masa pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	progresión pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
9061/3	seminoma	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
9061/6	Seminoma testicular derecho cT3-4N3M1a	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8000/6	Nódulos pulmonares	dev-set2-to-publish/cantemist-norm/cc_onco1127.ann
8500/3	CDI	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8500/2	carcinoma ductal in situ	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/6	lesiones cerebrales	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8500/33	carcinoma ductal infiltrante tipo común (CDI) grado 3	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8500/31	CDI grado 1	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8500/33	CDI grado 3	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8010/33	carcinoma pulmonar pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8500/33	CDI en la mama contralateral, grado 3	dev-set2-to-publish/cantemist-norm/cc_onco1012.ann
8000/6	cT2N1M0	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8010/3	carcinoma	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/3	carcinoma ductal infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8530/3	carcinoma inflamatorio	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8530/3	carcinoma inflamatorio	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/32	carcinoma ductal infiltrante grado II	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8500/33	carcinoma ductal infiltrante (GII-GIII)	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/6	afectación axilar contralateral	dev-set2-to-publish/cantemist-norm/cc_onco639.ann
8000/6	Adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8000/6	adenopatía supraclavicular	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8000/6	adenopatías supraclaviculares	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8010/33	carcinoma pobremente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8895/0	miomatoso	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8000/1	neoplasia	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
8010/6	carcinoma de ovario enfermedad diseminada	dev-set2-to-publish/cantemist-norm/cc_onco1009.ann
9473/3	PNET	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1/H	neoplasia primitiva	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9061/3	seminoma	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9080/1	teratoma	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9064/3	tumor germinal	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumorales	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9473/3	tumor neuroendocrino primitivo	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9085/3	neoplasia germinal mixta (seminoma y teratoma)	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8000/6	pT2NxM1a	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9473/3	tumores neuroendocrinos primitivos	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
9473/3	tumor neuroendocrino primitivo	dev-set2-to-publish/cantemist-norm/cc_onco1461.ann
8003/3	Tumor de células gigantes	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8000/6	suelta de globos	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8003/3	tumor de células gigantes	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8003/33	tumor de células gigantes grado tres de Sanerkin	dev-set2-to-publish/cantemist-norm/cc_onco1163.ann
8070/3	Carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8070/3	carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/6	lesión ósea	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8070/6	metástasis de carcinoma epidermoide	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1048.ann
8041/3	Carcinoma de células pequeñas	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8000/1	neoplásica	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8130/2	Tumor vesical (PTA G2)	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8041/3	Carcinoma microcítico	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8000/6	TxN2M0	dev-set2-to-publish/cantemist-norm/cc_onco1031.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	enfermedad a nivel cerebral	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	enfermedad a nivel pulmonar	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	implantes pleurales	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/1	tumoral	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8580/3	timoma maligno	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8000/6	lesiones a nivel vertebral	dev-set2-to-publish/cantemist-norm/cc_onco1232.ann
8805/3	Sarcoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8800/34/H	sarcoma de células redondas grandes de alto grado	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8800/3/H	sarcoma Ewing-like	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
9260/3	sarcoma de Ewing	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8800/34/H	Sarcoma indiferenciado de células redondas grandes de alto grado tipo Ewing-like	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8805/6	metástasis por sarcoma indiferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8800/3/H	Ewing-like	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/6	T2aN1M0	dev-set2-to-publish/cantemist-norm/cc_onco1325.ann
8000/6	M0	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8010/3/H	carcinoma infiltrante	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8001/1	células neoplásicas	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8000/3	malignidad	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8000/1	tumoración	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8522/33	carcinoma intraductal grupo 3 de Van Nuys con cancerización lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8522/33	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar y sólido de alto grado citológico con necrosis) con cancerización lobulillar	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8265/23	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8230/23	carcinoma intraductal predominantemente grupo 3 de Van Nuys (micropapilar y sólido	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8500/31	Carcinoma ductal infiltrante de 1 cm G1	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8500/33	Carcinoma ductal infiltrante de 2,5 mm G3	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8500/3/H	carcinoma de mama ductal infiltrante (multifocal)	dev-set2-to-publish/cantemist-norm/cc_onco1218.ann
8010/9	Carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/1	NEOPLASIA	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8140/3	adenocarcinomas	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8010/9	carcinomatosis	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/3	cáncer	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8001/3	células malignas	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/3	maligno	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8720/3	melanoma	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/6	metastásica	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/1	neoformación	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/1	neoformativo	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/1	tumores	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8000/3	enfermedad de Paget	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8070/33	Carcinoma escamoso poco diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1133.ann
8271/0	macroprolactinoma	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
9530/0	meningioma	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
9530/0	meningioma	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	nódulo subcutáneo	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/1	tumor	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8140/62	metástasis de adenocarcinoma de origen pulmonar, moderadamente diferenciado	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8973/6	neoplasia pleuropulmonar en lóbulo superior derecho con metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8140/6	Adenocarcinoma de pulmón estadio IV (metástasis	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	enfermedad abdominal	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/6	enfermedad peritoneal	dev-set2-to-publish/cantemist-norm/cc_onco1019.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco819.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco819.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco819.ann
8262/3	adenocarcinoma de colon en fragmentos de tumor velloso	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/6	pT2N0(0/12)M0	train-set-to-publish/cantemist-norm/cc_onco819.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco819.ann
8000/6	enfermedad a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco819.ann
8070/3	Carcinoma Escamoso	train-set-to-publish/cantemist-norm/cc_onco217.ann
8070/3	carcinoma de células escamosas	train-set-to-publish/cantemist-norm/cc_onco217.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco217.ann
8000/6	progresión mediastínica y ósea	train-set-to-publish/cantemist-norm/cc_onco217.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco316.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco316.ann
9064/3	tumor de células germinales	train-set-to-publish/cantemist-norm/cc_onco316.ann
9065/3	neoplasia germinal no seminomatosa	train-set-to-publish/cantemist-norm/cc_onco316.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco316.ann
8000/6	implantes en la superficie hepática	train-set-to-publish/cantemist-norm/cc_onco316.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco3.ann
8140/6	adenocarcinoma pulmonar metastásico	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco3.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco3.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco592.ann
8000/0	sinovitis villonodular pigmentada	train-set-to-publish/cantemist-norm/cc_onco592.ann
8000/0	sinovitis villonodular pigmentada	train-set-to-publish/cantemist-norm/cc_onco592.ann
8000/0	sinovitis villonodular pigmentada	train-set-to-publish/cantemist-norm/cc_onco592.ann
8000/0	sinovitis villonodular pigmentada	train-set-to-publish/cantemist-norm/cc_onco592.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/3	tumor neuroendocrino bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco767.ann
8249/3	carcinoide atípico	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco767.ann
8249/61	tumor carcinoide atípico pulmonar bien diferenciado con metástasis	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/6	metástasis de tumor neuroendocrino bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco767.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco767.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco767.ann
8041/3	carcinoma de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco848.ann
9500/3	neuroblastoma	train-set-to-publish/cantemist-norm/cc_onco848.ann
8140/33	adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco848.ann
8140/6	adenocarcinoma de pulmón cT3N2M1b	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	enfermedad pulmonar, hepática	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	progresión sistémica	train-set-to-publish/cantemist-norm/cc_onco848.ann
8000/6	lesiones hepática	train-set-to-publish/cantemist-norm/cc_onco848.ann
8021/3	Carcinoma anaplásico	train-set-to-publish/cantemist-norm/cc_onco405.ann
8021/3	carcinoma anaplásico	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/6	pT3NxM0	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/6	diseminación a distancia	train-set-to-publish/cantemist-norm/cc_onco405.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	implante tumoral	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	T2bN2M1b	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/3	malignas	train-set-to-publish/cantemist-norm/cc_onco107.ann
8012/3	carcinoma de células grandes	train-set-to-publish/cantemist-norm/cc_onco107.ann
8012/6	Carcinoma de pulmón de células grandes estadio IV (T2B N3 M1B)	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	progresión ganglionar, ósea	train-set-to-publish/cantemist-norm/cc_onco107.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco475.ann
8240/3	tumor carcinoide	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco475.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco475.ann
8240/6	metástasis de TNE bien diferenciado grado 1 (OMS	train-set-to-publish/cantemist-norm/cc_onco475.ann
8240/6	Tumor neuroendocrino ileoyeyunal bien diferenciado grado 1 (Ki-67 1-2 %) con afectación metastásica	train-set-to-publish/cantemist-norm/cc_onco475.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco475.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco882.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco882.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco882.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco882.ann
8860/0/H	angiomiolipoma epitelioide	train-set-to-publish/cantemist-norm/cc_onco882.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco882.ann
8860/0	AML	train-set-to-publish/cantemist-norm/cc_onco882.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco882.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco141.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco141.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco141.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco141.ann
8000/6	cT2aN2M0	train-set-to-publish/cantemist-norm/cc_onco141.ann
8000/6	T1N1M0	train-set-to-publish/cantemist-norm/cc_onco141.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco141.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco709.ann
8000/6	M1b	train-set-to-publish/cantemist-norm/cc_onco979.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco979.ann
9070/3	carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco979.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco979.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco979.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco979.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco979.ann
9080/0	teratoma quístico	train-set-to-publish/cantemist-norm/cc_onco979.ann
9071/3	tumor del seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	suelta de globos	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco979.ann
9065/3/H	tumor mixto de células germinales no seminomatoso	train-set-to-publish/cantemist-norm/cc_onco979.ann
9065/3	Tumor germinal no seminomatoso	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco979.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco892.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco892.ann
8461/34	carcinoma seroso papilar de ovario de alto grado	train-set-to-publish/cantemist-norm/cc_onco892.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco942.ann
8890/0	leiomiomas	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco942.ann
8140/6	metástasis ovárica de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco942.ann
8140/32	adenocarcinoma intestinal medianamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco942.ann
8001/3	citología maligna	train-set-to-publish/cantemist-norm/cc_onco942.ann
8140/6	metástasis en ovario derecho de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco942.ann
8140/6	adenocarcinoma de colon sigmoide estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	recaída ósea	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco942.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco36.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco36.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco36.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco36.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco36.ann
8070/32	carcinoma escamoso moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco36.ann
8000/6	cT4N2M	train-set-to-publish/cantemist-norm/cc_onco36.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco796.ann
8500/32	carcinoma ductal infiltrante grado 2	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco796.ann
8380/3	adenocarcinoma ovárico tipo endometrioide	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	implante de 1,2 cm en el fondo de saco de Douglas	train-set-to-publish/cantemist-norm/cc_onco796.ann
8380/3	adenocarcinoma tipo endometrioide	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	recaída pélvica	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	implante subcapsular hepático	train-set-to-publish/cantemist-norm/cc_onco796.ann
8020/6	metástasis de carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco796.ann
8020/6	implantes de carcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	nódulo peritoneal	train-set-to-publish/cantemist-norm/cc_onco796.ann
8000/6	enfermedad a nivel peritoneal	train-set-to-publish/cantemist-norm/cc_onco796.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco802.ann
8140/33	adenocarcinoma mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco802.ann
8140/33	adenocarcinoma mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco802.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco802.ann
8046/3	carcinoma de célula no pequeña	train-set-to-publish/cantemist-norm/cc_onco802.ann
8070/3	carcinoma escamoso	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco802.ann
8240/3	tumor carcinoide típico	train-set-to-publish/cantemist-norm/cc_onco802.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco802.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	lesiones supra e infratentoriales	train-set-to-publish/cantemist-norm/cc_onco802.ann
8249/3	carcinoide atípico	train-set-to-publish/cantemist-norm/cc_onco802.ann
8000/6	diseminación mediastínica	train-set-to-publish/cantemist-norm/cc_onco802.ann
8249/3	tumor carcinoide atípico	train-set-to-publish/cantemist-norm/cc_onco802.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco955.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco955.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco955.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco955.ann
8090/3	carcinoma basocelular	train-set-to-publish/cantemist-norm/cc_onco955.ann
9680/3	linfoma no Hodgkin B difuso de células grandes	train-set-to-publish/cantemist-norm/cc_onco955.ann
9590/3	Linfoma	train-set-to-publish/cantemist-norm/cc_onco955.ann
9680/3	linfoma no Hodgkin B difuso de células grandes	train-set-to-publish/cantemist-norm/cc_onco955.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco319.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco319.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco319.ann
8500/24	carcinoma intraductal de alto grado	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	lesión parietal	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco319.ann
8500/24	intraductal de alto grado	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco319.ann
8010/6	metástasis cerebrales múltiples de carcinoma	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	lesión cerebelosa	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	lesiones intratentoriales	train-set-to-publish/cantemist-norm/cc_onco319.ann
8500/6	metástasis cerebrales de carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco319.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco643.ann
9691/3	linfoma folicular grado 2	train-set-to-publish/cantemist-norm/cc_onco643.ann
8247/3	carcinoma de células de Merkel	train-set-to-publish/cantemist-norm/cc_onco643.ann
8246/34	carcinoma anaplásico neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco643.ann
8247/6	Carcinoma de células de Merkel estadio IV por afectación hepática	train-set-to-publish/cantemist-norm/cc_onco643.ann
9690/3	linfoma folicular	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/6	CMM	train-set-to-publish/cantemist-norm/cc_onco643.ann
8000/6	afectación ganglionar, ósea	train-set-to-publish/cantemist-norm/cc_onco427.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco427.ann
8000/6	infiltración de médula ósea	train-set-to-publish/cantemist-norm/cc_onco427.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco427.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco427.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco427.ann
8000/6	síndrome leucoeritroblástico	train-set-to-publish/cantemist-norm/cc_onco427.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco23.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco23.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco23.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco23.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco23.ann
8500/32	carcinoma ductal infiltrante, de grado 2	train-set-to-publish/cantemist-norm/cc_onco23.ann
8500/32	carcinoma ductal infiltrante de mama, de grado 2	train-set-to-publish/cantemist-norm/cc_onco23.ann
8000/6	cT2N1M0	train-set-to-publish/cantemist-norm/cc_onco23.ann
8500/32	carcinoma ductal infiltrante de grado 2	train-set-to-publish/cantemist-norm/cc_onco23.ann
8010/3	Carcinoma	train-set-to-publish/cantemist-norm/cc_onco673.ann
9540/0	neurofibroma	train-set-to-publish/cantemist-norm/cc_onco673.ann
8310/6	carcinoma renal de células claras izquierdo, estadio IV, con afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco673.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco673.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco673.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco673.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	Lesión ocupante de espacio en segmento VIII hepático	train-set-to-publish/cantemist-norm/cc_onco765.ann
8140/6	Adenocarcinoma de colon pT3pN1aM1	train-set-to-publish/cantemist-norm/cc_onco765.ann
8140/33	adenocarcinoma de colon sincrónico G2 y áreas focales G3	train-set-to-publish/cantemist-norm/cc_onco765.ann
8000/6	progresión mediastínica	train-set-to-publish/cantemist-norm/cc_onco765.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco6.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco6.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco6.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco6.ann
8010/6	carcinoma de próstata metastásico	train-set-to-publish/cantemist-norm/cc_onco6.ann
8010/6	carcinoma de próstata metastásico	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	progresión radiológica a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco6.ann
8010/6	carcinoma de próstata metastásico	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	progresión radiológica (ósea	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	enfermedad prostática a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	lesiones blásticas óseas	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	lesión a nivel suprarrenal	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	nódulo suprarrenal	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	nódulo suprarrenal	train-set-to-publish/cantemist-norm/cc_onco6.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco98.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco98.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco98.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco98.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco98.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco98.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco98.ann
8000/6	neoplásica metastásica	train-set-to-publish/cantemist-norm/cc_onco98.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco98.ann
8070/6	carcinoma epidermoide cutáneo estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco98.ann
8000/6	enfermedad extendida	train-set-to-publish/cantemist-norm/cc_onco98.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco62.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco62.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco62.ann
8046/3	carcinoma no microcítico	train-set-to-publish/cantemist-norm/cc_onco62.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco62.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco62.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco62.ann
8000/3	tumoral maligna	train-set-to-publish/cantemist-norm/cc_onco62.ann
9872/3	leucemia aguda mieloblástica	train-set-to-publish/cantemist-norm/cc_onco62.ann
8070/33	metástasis de carcinoma epidermoide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco62.ann
9872/3	leucemia aguda mieloblástica	train-set-to-publish/cantemist-norm/cc_onco62.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco62.ann
8070/6	carcinoma epidermoide estadio IV al diagnóstico por nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco62.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco62.ann
8000/6	nódulo en la región axilar	train-set-to-publish/cantemist-norm/cc_onco62.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco873.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco873.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco873.ann
8936/3	GANT	train-set-to-publish/cantemist-norm/cc_onco873.ann
8936/6	metástasis de GIST	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	recaída a nivel perihepático	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	lesiones pélvicas	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	recaída a nivel sacro	train-set-to-publish/cantemist-norm/cc_onco873.ann
8936/6	metástasis de GIST	train-set-to-publish/cantemist-norm/cc_onco873.ann
8000/6	masa en fosa iliaca	train-set-to-publish/cantemist-norm/cc_onco873.ann
8720/3	MELANOMA	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco337.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco337.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco337.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/34	tumor maligno muy indiferenciado	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/6	masa pulmonar	train-set-to-publish/cantemist-norm/cc_onco337.ann
8000/6	masa pulmonar	train-set-to-publish/cantemist-norm/cc_onco337.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco406.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco406.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco406.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/33	carcinoma renal de células claras (CRCC) grado 3 de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/3	CRCC	train-set-to-publish/cantemist-norm/cc_onco406.ann
8000/6	extensión extrarrenal	train-set-to-publish/cantemist-norm/cc_onco406.ann
8000/6	pT1bN0M0	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/6	metástasis de CRCC	train-set-to-publish/cantemist-norm/cc_onco406.ann
8000/6	oligometastásico	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/6	metastásicas para CRCC	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/3	CRCC	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/3	CRCC	train-set-to-publish/cantemist-norm/cc_onco406.ann
8310/6	Carcinoma renal de células claras pT1bN1M1	train-set-to-publish/cantemist-norm/cc_onco406.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco630.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco630.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco630.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco630.ann
8441/34	carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/6	implante omental	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/6	afectación tumoral peritoneal	train-set-to-publish/cantemist-norm/cc_onco227.ann
8000/6	omental cake	train-set-to-publish/cantemist-norm/cc_onco227.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco492.ann
8243/3	carcinoide de células caliciformes	train-set-to-publish/cantemist-norm/cc_onco492.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco492.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco492.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco492.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco80.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco80.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco80.ann
8780/0	nevus azul	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco80.ann
8743/3	melanoma de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco80.ann
8743/3	melanoma de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco80.ann
8720/6	metástasis cutánea de melanoma	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco80.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco80.ann
8010/3	Carcinoma	train-set-to-publish/cantemist-norm/cc_onco460.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco460.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco460.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco460.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco460.ann
8940/0	adenoma pleomorfo	train-set-to-publish/cantemist-norm/cc_onco460.ann
8940/0	adenoma pleomorfo	train-set-to-publish/cantemist-norm/cc_onco460.ann
8000/6	T4bN2bM0	train-set-to-publish/cantemist-norm/cc_onco460.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco460.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco480.ann
8140/6	adenocarcinoma de pulmón estadio IV (TxNxM1a)	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/6	nódulo subpleural	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/6	lesión pleural	train-set-to-publish/cantemist-norm/cc_onco480.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco97.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco97.ann
8000/1	neoformativa	train-set-to-publish/cantemist-norm/cc_onco97.ann
8010/33	carcinoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco97.ann
8010/33	Carcinoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco97.ann
8000/6	cT1N0M0	train-set-to-publish/cantemist-norm/cc_onco97.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco204.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco204.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	pT2N0M0	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	progresión locorregional y a distancia	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	micronódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco204.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco204.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco771.ann
8720/3/H	melanoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	realce ependimario	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco771.ann
8000/6	invasión leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco771.ann
8720/6	recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central	train-set-to-publish/cantemist-norm/cc_onco771.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco731.ann
9173/0	higroma	train-set-to-publish/cantemist-norm/cc_onco731.ann
8000/6	neoplásica diseminada	train-set-to-publish/cantemist-norm/cc_onco731.ann
8000/6	metástasis de neoplasia	train-set-to-publish/cantemist-norm/cc_onco731.ann
8000/6	infiltración de la MO	train-set-to-publish/cantemist-norm/cc_onco731.ann
8490/3	anillo de sello	train-set-to-publish/cantemist-norm/cc_onco731.ann
8000/6	invasión de médula ósea	train-set-to-publish/cantemist-norm/cc_onco731.ann
8000/6	neoplasia gástrica diseminada	train-set-to-publish/cantemist-norm/cc_onco731.ann
9120/0	angioma	train-set-to-publish/cantemist-norm/cc_onco155.ann
9120/0	angioma	train-set-to-publish/cantemist-norm/cc_onco155.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco155.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco155.ann
8500/3	adenocarcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco155.ann
8500/3	adenocarcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco155.ann
8500/3	Adenocarcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco155.ann
8010/9	Carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco155.ann
8000/6	adenopatías cervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco155.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco231.ann
8290/0	Oncocitoma	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco231.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	Nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	enfermedad a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	progresión tras 3 ciclos a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	Afectación adenopática mediastínica y supraclavicular	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/6	nódulos pulmonar	train-set-to-publish/cantemist-norm/cc_onco231.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco790.ann
9064/3	tumor de células germinales	train-set-to-publish/cantemist-norm/cc_onco790.ann
9064/3	tumor germinal	train-set-to-publish/cantemist-norm/cc_onco790.ann
9071/3/H	tumor del saco vitelino (Yolk sac tumor) tipo glandular	train-set-to-publish/cantemist-norm/cc_onco790.ann
8800/9	sarcomatosa	train-set-to-publish/cantemist-norm/cc_onco790.ann
9065/3	tumor germinal no seminoma	train-set-to-publish/cantemist-norm/cc_onco790.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco790.ann
9071/3	Yolk sac tumor	train-set-to-publish/cantemist-norm/cc_onco790.ann
9071/3/H	tumor del saco vitelino (seno endodérmico), variante glandular	train-set-to-publish/cantemist-norm/cc_onco790.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco790.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco790.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco790.ann
8000/1	neoproliferativo	train-set-to-publish/cantemist-norm/cc_onco790.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/6	Recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco159.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco159.ann
8000/6	Progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco159.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco432.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco432.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco432.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco432.ann
8500/33	CDI de mama, grado histológico 3	train-set-to-publish/cantemist-norm/cc_onco432.ann
8000/6	T3N1M0	train-set-to-publish/cantemist-norm/cc_onco432.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco432.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco45.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco45.ann
8490/33	adenocarcinoma gástrico con células en anillo de sello, grado 3	train-set-to-publish/cantemist-norm/cc_onco45.ann
8140/6	Adenocarcinoma gástrico reintervenido estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/6	pT2bN0/15M0	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco45.ann
8142/3	linitis plástica	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/6	afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco45.ann
8000/3	malignos	train-set-to-publish/cantemist-norm/cc_onco45.ann
9530/0	Meningioma	train-set-to-publish/cantemist-norm/cc_onco338.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco338.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco338.ann
8070/33	carcinoma de células escamosas pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/6	mestastásica	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/6	cT4cN0M0	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco338.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco390.ann
8140/62	adenocarcinoma de próstata grado combinado de Gleason 7 (3+4) estadio IV (OSS	train-set-to-publish/cantemist-norm/cc_onco390.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco390.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco390.ann
8140/62	adenocarcinoma de próstata grado histológico combinado de Gleason 7 (3+4)	train-set-to-publish/cantemist-norm/cc_onco390.ann
8000/6	adenopatías cervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco390.ann
8140/62	ADENOCARCINOMA DE PÓSTATA GRADO HISTOLÓGICO COMBINADO DE GLEASON 7 (3+4) ESTADIO IV (OSS	train-set-to-publish/cantemist-norm/cc_onco390.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco896.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco896.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco896.ann
8240/3	TNEp	train-set-to-publish/cantemist-norm/cc_onco896.ann
8240/3	TNEp bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco896.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco896.ann
9522/3	estesioneuroblastoma	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/1	intratumoral	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/13	tumor mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco360.ann
9522/34	estesioneuroblastoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco360.ann
9522/3	Estesioneuroblastoma	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	Adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	afectación de glándula hipofisaria	train-set-to-publish/cantemist-norm/cc_onco360.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco951.ann
8144/3	adenocarcinoma de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco951.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	recidiva hepática	train-set-to-publish/cantemist-norm/cc_onco951.ann
8000/6	lesión en pene	train-set-to-publish/cantemist-norm/cc_onco951.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco115.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco115.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco115.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco115.ann
9727/3	neoplasia de células dendríticas plasmocitoides blásticas	train-set-to-publish/cantemist-norm/cc_onco115.ann
9727/3	linfoma de células dendríticas	train-set-to-publish/cantemist-norm/cc_onco115.ann
9800/3	leucemia	train-set-to-publish/cantemist-norm/cc_onco115.ann
9727/3	Neoplasia de células dendríticas plasmocitoides blásticas	train-set-to-publish/cantemist-norm/cc_onco115.ann
9727/3	NCDPB	train-set-to-publish/cantemist-norm/cc_onco115.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco789.ann
8380/32	ADC endometrioide moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/6	pT1b1N0M0	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/6	implante en pared abdominal	train-set-to-publish/cantemist-norm/cc_onco789.ann
8380/6	adenocarcinoma endometrioide en implantes tumorales intestinales	train-set-to-publish/cantemist-norm/cc_onco789.ann
8263/3	adenocarcinoma túbulo-papilar	train-set-to-publish/cantemist-norm/cc_onco789.ann
8570/3	adenocarcinoma túbulo-papilar con metaplasia escamosa	train-set-to-publish/cantemist-norm/cc_onco789.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco152.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco152.ann
8380/3	Adenocarcinoma de endometrio tipo endometrioide	train-set-to-publish/cantemist-norm/cc_onco152.ann
8380/31	adenocarcinoma bien diferenciado de endometrio, tipo endometrioide	train-set-to-publish/cantemist-norm/cc_onco152.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/3	tumoral maligna	train-set-to-publish/cantemist-norm/cc_onco264.ann
9680/3	LBDCG	train-set-to-publish/cantemist-norm/cc_onco264.ann
9687/3	LB	train-set-to-publish/cantemist-norm/cc_onco264.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco937.ann
8312/33	carcinoma de células renales tipo células claras grado 3 de Fürhman	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/6	T3N0M1	train-set-to-publish/cantemist-norm/cc_onco937.ann
8312/3	CCR	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/6	lesión cutánea	train-set-to-publish/cantemist-norm/cc_onco937.ann
8005/3	cáncer de células claras	train-set-to-publish/cantemist-norm/cc_onco937.ann
8310/3	carcinoma de células renales tipo células claras	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/6	lesión supraciliar	train-set-to-publish/cantemist-norm/cc_onco937.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco267.ann
9020/11	tumor Phyllodes de bajo grado	train-set-to-publish/cantemist-norm/cc_onco267.ann
8010/32/H	carcinoma infiltrante grado II	train-set-to-publish/cantemist-norm/cc_onco267.ann
8575/3	carcinoma metaplásico	train-set-to-publish/cantemist-norm/cc_onco267.ann
8575/3	carcinoma metaplásico	train-set-to-publish/cantemist-norm/cc_onco267.ann
9020/11	tumor Phyllodes de bajo grado	train-set-to-publish/cantemist-norm/cc_onco267.ann
9020/11	tumor Phyllodes de bajo grado	train-set-to-publish/cantemist-norm/cc_onco267.ann
8070/3/H	carcinoma ecriescamoide ductal	train-set-to-publish/cantemist-norm/cc_onco267.ann
8502/3	carcinoma secretor	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/6	cT4N1M0	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/6	cT2N0M0	train-set-to-publish/cantemist-norm/cc_onco267.ann
8001/1	celularidad tumoral	train-set-to-publish/cantemist-norm/cc_onco267.ann
8000/6	Adenopatía axilar y en fosa supraclavicular	train-set-to-publish/cantemist-norm/cc_onco267.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco180.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco180.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco180.ann
9699/6	linfoma tipo B de la zona marginal extraganglionar (MALT) con afectación gástrica	train-set-to-publish/cantemist-norm/cc_onco180.ann
9699/3	MALT	train-set-to-publish/cantemist-norm/cc_onco180.ann
8380/31	adenocarcinoma de endometrio tipo endometroide bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco180.ann
8410/0	epitelioma sebáceo	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	lesiones intraparenquimatosas	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	lesiones de parénquima cerebral	train-set-to-publish/cantemist-norm/cc_onco180.ann
9424/32	Xantroastrocitoma pleomórfico grado II de la OMS	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco180.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco739.ann
8815/0	tumor fibroso solitario	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco739.ann
8815/6	metástasis de tumor fibroso solitario	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	recidiva hepática	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco739.ann
8815/6	Recidiva hepática y pulmonar de tumor fibroso solitario	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/6	Nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco739.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco311.ann
8070/64	metástasis de carcinoma indiferenciado de alto grado de estirpe epitelial	train-set-to-publish/cantemist-norm/cc_onco311.ann
8020/34	CARCINOMA INDIFERENCIADO DE ALTO GRADO	train-set-to-publish/cantemist-norm/cc_onco311.ann
8033/3	sarcomatoide	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/3	Tumoración de características malignas	train-set-to-publish/cantemist-norm/cc_onco311.ann
8963/3	TUMOR RABDOIDE	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/6	enfermedad residual y a distancia	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco311.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco311.ann
8460/3	adenocarcinoma seroso papilar	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco108.ann
8460/32	adenocarcinoma de ovario seroso papilar G2	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco108.ann
8460/64	Metástasis cerebral única de adenocarcinoma seroso papilar de ovario de alto grado	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/6	lesión ocupante de espacio nodular en el lóbulo frontal	train-set-to-publish/cantemist-norm/cc_onco108.ann
8000/6	LOE cerebral	train-set-to-publish/cantemist-norm/cc_onco108.ann
8460/34	adenocarcinoma seroso papilar de alto grado	train-set-to-publish/cantemist-norm/cc_onco108.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco56.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco56.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco56.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco56.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco56.ann
9120/3	Angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco56.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco774.ann
9970/1	enfermedad linfoproliferativa	train-set-to-publish/cantemist-norm/cc_onco774.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco774.ann
8800/9	sarcomatosa	train-set-to-publish/cantemist-norm/cc_onco774.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco774.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco774.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco774.ann
8800/1	tumoración de partes blandas	train-set-to-publish/cantemist-norm/cc_onco774.ann
9970/1/H	proceso linfoproliferativo de diferenciación plasmablástica	train-set-to-publish/cantemist-norm/cc_onco774.ann
9735/3	linfoma plasmablástico	train-set-to-publish/cantemist-norm/cc_onco774.ann
9732/3	mieloma plasmablástico	train-set-to-publish/cantemist-norm/cc_onco774.ann
9591/3	linfoma B difuso	train-set-to-publish/cantemist-norm/cc_onco774.ann
9591/3/H	linfoma B difuso ALK+	train-set-to-publish/cantemist-norm/cc_onco774.ann
9735/3	linfoma plasmablástico	train-set-to-publish/cantemist-norm/cc_onco774.ann
9735/6	linfoma plasmablástico estadio IV por afectación hepática	train-set-to-publish/cantemist-norm/cc_onco774.ann
8000/3	neoplásica	train-set-to-publish/cantemist-norm/cc_onco774.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco852.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco92.ann
8000/6	adenopatías cervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco92.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco92.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco844.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco844.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco844.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco844.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco844.ann
8170/3	hepatocarcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8000/6	pM0	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco844.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco48.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco48.ann
8890/3	leiomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco48.ann
8500/33	CDI de mama derecha grado III	train-set-to-publish/cantemist-norm/cc_onco48.ann
8500/33	CDI de mama izquierda grado III	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco48.ann
8500/33	CDI de mama derecha grado III	train-set-to-publish/cantemist-norm/cc_onco48.ann
8500/33	CDI de mama izquierda grado III	train-set-to-publish/cantemist-norm/cc_onco48.ann
8460/34	cistoadenocarcinoma seroso papilar de alto grado	train-set-to-publish/cantemist-norm/cc_onco48.ann
8323/3	adenocarcinoma mixto	train-set-to-publish/cantemist-norm/cc_onco48.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco567.ann
8310/6	metástasis de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco567.ann
8310/6	metástasis de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco567.ann
8310/32	carcinoma de células claras grado 2 de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	nódulos subpleurales	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	masa abdominal	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	masa infradiafragmática	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	masa infradiafragmática	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	lesiones subpleurales	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	masa pulmonar	train-set-to-publish/cantemist-norm/cc_onco567.ann
8000/6	masa pulmonar	train-set-to-publish/cantemist-norm/cc_onco567.ann
8312/3	carcinoma de células renales	train-set-to-publish/cantemist-norm/cc_onco912.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco912.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco912.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco912.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco912.ann
8005/0	tumor renal, variante histológica, células claras	train-set-to-publish/cantemist-norm/cc_onco912.ann
8000/6	pT3aN0M0	train-set-to-publish/cantemist-norm/cc_onco912.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco847.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco847.ann
8520/3	carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco847.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco847.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco847.ann
8520/6	metástasis de carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco847.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco847.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco847.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco847.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco847.ann
8010/33	carcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco847.ann
8520/3	cáncer de mama lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco847.ann
8520/6	metástasis pilórica-duodenal de carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco847.ann
8010/3	carcinomas	train-set-to-publish/cantemist-norm/cc_onco847.ann
8500/2	carcinoma ductal in situ	train-set-to-publish/cantemist-norm/cc_onco331.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco331.ann
8010/2	carcinoma in situ	train-set-to-publish/cantemist-norm/cc_onco331.ann
8500/32	carcinoma ductal infiltrante, grado histológico (GH) II	train-set-to-publish/cantemist-norm/cc_onco331.ann
8010/6	metástasis por carcinoma	train-set-to-publish/cantemist-norm/cc_onco331.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco331.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco331.ann
8010/2	Carcinoma in situ	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco614.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco614.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco614.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco614.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco614.ann
8140/6	adenocarcinoma de pulmón con afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco614.ann
8140/6	Adenocarcinoma de pulmón estadio IVB (cT2 CN2 M1c)	train-set-to-publish/cantemist-norm/cc_onco614.ann
8260/3	adenocarcinoma de patrón papilar	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	lesión ocupante de espacio (LOE) en hemisferio cerebeloso	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	progresión radiológica (pulmonar y cerebral)	train-set-to-publish/cantemist-norm/cc_onco614.ann
8000/6	afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco614.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco894.ann
8010/3	Carcinoma	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco894.ann
8140/33	adenocarcinoma de próstata Gleason 8	train-set-to-publish/cantemist-norm/cc_onco894.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	T2N0M0	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	adenopatías laterocervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco894.ann
8010/3/H	carcinoma invasor	train-set-to-publish/cantemist-norm/cc_onco894.ann
8500/33	carcinoma ductal infiltrante de 1,5 cm, grado histológico 3	train-set-to-publish/cantemist-norm/cc_onco894.ann
8550/63	adenocarcinoma acinar Gleason 9 con infiltración bilateral, con extensión extraprostática	train-set-to-publish/cantemist-norm/cc_onco894.ann
8000/6	letálides	train-set-to-publish/cantemist-norm/cc_onco894.ann
8041/3	carcinoma de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco931.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco931.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco931.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco931.ann
8041/6	carcinoma microcítico de pulmón estadio IV (T4, N3, M1b)	train-set-to-publish/cantemist-norm/cc_onco931.ann
8000/6	focos hipermetabólicos en distintos territorios ganglionares (supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco931.ann
8220/0	poliposis adenomatosa familiar	train-set-to-publish/cantemist-norm/cc_onco841.ann
8821/1	fibromatosis desmoide	train-set-to-publish/cantemist-norm/cc_onco841.ann
8800/1	neoplásica mesenquimal	train-set-to-publish/cantemist-norm/cc_onco841.ann
8821/1	tumor desmoide	train-set-to-publish/cantemist-norm/cc_onco841.ann
8220/0	poliposis adenomatosa familiar	train-set-to-publish/cantemist-norm/cc_onco841.ann
8220/0	síndrome de Gardner	train-set-to-publish/cantemist-norm/cc_onco841.ann
8000/6	diseminación tumoral	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco277.ann
9180/3	Sarcoma osteogénico	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	progresión pleuropulmonar	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco277.ann
9180/6	metástasis de Sarcoma osteogénico	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	progresión peritoneal	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	implantes calcificados en ángulo cardiofrénico	train-set-to-publish/cantemist-norm/cc_onco277.ann
9180/6	progresión peritoneal extensa de sarcoma osteogénico	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	afectación hiliar hepática	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	nódulos peritoneales	train-set-to-publish/cantemist-norm/cc_onco277.ann
8000/6	afectación calcificante peritoneal	train-set-to-publish/cantemist-norm/cc_onco277.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco871.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco871.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco871.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	cT1cN2aM0	train-set-to-publish/cantemist-norm/cc_onco871.ann
8010/6/H	metástasis por carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	recaída cutánea	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	afectación pleuropulmonar	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	enfermedad a nivel cutáneo	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	afectación pleuropulmonar	train-set-to-publish/cantemist-norm/cc_onco871.ann
8500/6	metástasis por carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8500/6	metástasis por carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8500/6	Metástasis en colon por carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	enfermedad a nivel cutáneo	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	enfermedad cutánea	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco871.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco521.ann
8806/6	Tumor desmoplásico abdominal de células pequeñas y redondas estadio IV (afectación hepática	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	(LOE) hepáticas	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	masa pélvica	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	masa pélvica	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	masa pélvica	train-set-to-publish/cantemist-norm/cc_onco521.ann
8000/6	diseminación tumoral	train-set-to-publish/cantemist-norm/cc_onco320.ann
9391/3	ependimoma	train-set-to-publish/cantemist-norm/cc_onco320.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco320.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco320.ann
9064/3	germinoma	train-set-to-publish/cantemist-norm/cc_onco320.ann
8000/3	pinealoblastoma	train-set-to-publish/cantemist-norm/cc_onco320.ann
9064/3	GERMINOMA	train-set-to-publish/cantemist-norm/cc_onco320.ann
9360/1	tumoral pineal	train-set-to-publish/cantemist-norm/cc_onco320.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	masa hepática	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	lesión pseudonodular heterogénea en región frontal	train-set-to-publish/cantemist-norm/cc_onco295.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco385.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco385.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco385.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco385.ann
8120/34	carcinoma urotelial de vejiga superficial de alto grado	train-set-to-publish/cantemist-norm/cc_onco385.ann
8120/34	carcinoma transicional de alto grado	train-set-to-publish/cantemist-norm/cc_onco385.ann
8140/31	adenocarcinoma de próstata multifocal gleason 6	train-set-to-publish/cantemist-norm/cc_onco385.ann
8120/33	carcinoma transicional de vejiga, G3	train-set-to-publish/cantemist-norm/cc_onco385.ann
8120/6	metástasis de carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco385.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco385.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco385.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco486.ann
9085/3	neoplasia testicular germinal mixta	train-set-to-publish/cantemist-norm/cc_onco486.ann
9061/6	seminoma testicular derecho estadio IIIC (metástasis	train-set-to-publish/cantemist-norm/cc_onco486.ann
8000/6	lesiones líticas desde primera vértebra	train-set-to-publish/cantemist-norm/cc_onco486.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco13.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco13.ann
8970/6	hepatoblastoma metastásico	train-set-to-publish/cantemist-norm/cc_onco13.ann
8002/1	tumor de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco13.ann
8970/3	hepatoblastoma	train-set-to-publish/cantemist-norm/cc_onco13.ann
8970/3	hepatoblastoma	train-set-to-publish/cantemist-norm/cc_onco13.ann
8000/6	afectación extrahepática	train-set-to-publish/cantemist-norm/cc_onco13.ann
8000/6	afectación pancreática	train-set-to-publish/cantemist-norm/cc_onco13.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco237.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco237.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco237.ann
8004/3	Tumor fusiforme	train-set-to-publish/cantemist-norm/cc_onco237.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco237.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco237.ann
8936/3	tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/1	peritumorales	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/6	implantes presacros	train-set-to-publish/cantemist-norm/cc_onco237.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco449.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco449.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco449.ann
8070/63	carcinoma epidermoide pobremente diferenciado, metastásico	train-set-to-publish/cantemist-norm/cc_onco449.ann
8083/33	carcinoma de células escamosas basaloide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco449.ann
8070/33	carcinoma escamoso pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	pT2N1M0	train-set-to-publish/cantemist-norm/cc_onco449.ann
8070/6	carcinoma epidermoide de cabeza y cuello metastásico	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	lesiones nodulares a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco449.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco754.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco754.ann
8806/3	tumor desmoplásico de células pequeñas y redondas	train-set-to-publish/cantemist-norm/cc_onco754.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco754.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco754.ann
8000/6	diseminación a distancia	train-set-to-publish/cantemist-norm/cc_onco754.ann
9260/3	sarcoma de Ewing	train-set-to-publish/cantemist-norm/cc_onco754.ann
9260/3	Sarcoma de Ewing	train-set-to-publish/cantemist-norm/cc_onco754.ann
8000/6	T3bN0M0	train-set-to-publish/cantemist-norm/cc_onco754.ann
9260/3	sarcomas de Ewing	train-set-to-publish/cantemist-norm/cc_onco754.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco529.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco529.ann
8140/6	adenocarcinoma pulmonar categoría cT2bN3M1c	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	diseminación pleural	train-set-to-publish/cantemist-norm/cc_onco529.ann
8140/33	adenocarcinoma mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	lesiones líticas a nivel de axis	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	lesiones en la región costal	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco529.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco906.ann
8070/6	carcinoma epidermoide de pulmón cT4N2M1a	train-set-to-publish/cantemist-norm/cc_onco906.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco906.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco197.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco197.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco197.ann
8000/6	T1N2M1a	train-set-to-publish/cantemist-norm/cc_onco197.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco162.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco162.ann
8211/0	adenoma tubular	train-set-to-publish/cantemist-norm/cc_onco162.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco162.ann
8000/1	neoplásicas	train-set-to-publish/cantemist-norm/cc_onco162.ann
8140/6	adenocarcinoma de vesícula biliar E IV (pT2N1M1	train-set-to-publish/cantemist-norm/cc_onco162.ann
8000/6	adenopatías a distancia	train-set-to-publish/cantemist-norm/cc_onco162.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco313.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco313.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco313.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco313.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco313.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco313.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco851.ann
8140/62	infiltración por adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco851.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco851.ann
8000/6	adenopatías hiliares, mediastínicas, supraclavicular	train-set-to-publish/cantemist-norm/cc_onco851.ann
8000/6	TxN3M1a	train-set-to-publish/cantemist-norm/cc_onco851.ann
8441/34	Adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco407.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco407.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco407.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco407.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco407.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco407.ann
8441/34	metástasis de carcinoma seroso de ovario de alto grado	train-set-to-publish/cantemist-norm/cc_onco407.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8440/3	cistoadenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8440/3	cistoadenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco439.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	neoplásicas	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/3	Adenocarcinoma endometrioide	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/32	Adenocarcinoma endometrioide de endometrio G2	train-set-to-publish/cantemist-norm/cc_onco439.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/3	adenocarcinoma endometrioide	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/3	adenocarcinoma endometrioide	train-set-to-publish/cantemist-norm/cc_onco439.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/32	adenocarcinoma endometrioide moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco439.ann
8000/6	implantes a nivel de colon	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/3	adenocarcinoma endometrioide	train-set-to-publish/cantemist-norm/cc_onco439.ann
8380/32	adenocarcinoma endometrioide de endometrio G2	train-set-to-publish/cantemist-norm/cc_onco439.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco439.ann
8620/1	tumor de células de la granulosa	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/3	tumoral maligna	train-set-to-publish/cantemist-norm/cc_onco306.ann
8631/3	tumor de células de Sertoli, estroma gonadal pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco306.ann
8590/1	tumor de cordones sexuales / estroma gonadal maligno	train-set-to-publish/cantemist-norm/cc_onco306.ann
8590/6	Tumor de cordones sexuales / estroma gonadal maligno (OMS 2004) pT3 cN1 cM1a	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/6	lesión osteolítica en L5	train-set-to-publish/cantemist-norm/cc_onco306.ann
8000/1	Neoformación	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/0	tumoración cerebral benigna	train-set-to-publish/cantemist-norm/cc_onco444.ann
8500/33	carcinoma ductal infiltrante grado III	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	pT1bN1M0	train-set-to-publish/cantemist-norm/cc_onco444.ann
8500/33	carcinoma ductal infiltrante grado III	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	pT1bN1M0	train-set-to-publish/cantemist-norm/cc_onco444.ann
8500/33	Carcinoma ductal infiltrante poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco444.ann
8010/6	macrometástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	infiltración de médula ósea	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	infiltración de médula ósea	train-set-to-publish/cantemist-norm/cc_onco444.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco444.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco667.ann
9800/3	leucemia	train-set-to-publish/cantemist-norm/cc_onco667.ann
8140/6	adenocarcinoma (ADK) metastásico	train-set-to-publish/cantemist-norm/cc_onco667.ann
8140/3	ADK	train-set-to-publish/cantemist-norm/cc_onco667.ann
8140/3	ADK	train-set-to-publish/cantemist-norm/cc_onco667.ann
8140/6	adenocarcinoma de origen desconocido con metástasis	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco667.ann
8140/3	ADK	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/6	infiltración tumoral de medula ósea	train-set-to-publish/cantemist-norm/cc_onco667.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco19.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	enfermedad ganglionar retrocrural	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	gammagrafía ósea positiva	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	progresión ganglionar, ósea	train-set-to-publish/cantemist-norm/cc_onco19.ann
8000/6	afectación difusa de la calota craneal	train-set-to-publish/cantemist-norm/cc_onco19.ann
8140/6	Adenocarcinoma de próstata estadio IV por metástasis	train-set-to-publish/cantemist-norm/cc_onco19.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco78.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/64	metástasis de carcinoma indiferenciado de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/64	metástasis de carcinoma indiferenciado de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/3	neoplásica	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/3	cáncer microcítico	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/34	Carcinoma indiferenciado de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco78.ann
8041/64	Carcinoma indiferenciado de célula pequeña de pulmón (carcinoma microcítico) estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/6	lesiones focales en lóbulo derecho	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco78.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco832.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco832.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco832.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco832.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco832.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco832.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco832.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/6	progresión locorregional y hepática	train-set-to-publish/cantemist-norm/cc_onco832.ann
8140/32	adenocarcinoma bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco832.ann
8000/6	adenopatías hipermetabólicas supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco832.ann
8490/3	adenocarcinoma de pulmón, con presencia de células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco832.ann
8680/1	Paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco999.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco999.ann
8680/1	paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8680/1	paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8680/1	paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8680/1	paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8680/1	paraganglioma	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	infiltración ósea	train-set-to-publish/cantemist-norm/cc_onco999.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco310.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco310.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco310.ann
9101/3	tumor mixto maligno de células germinales (coriocarcinoma 60% + teratoma maduro 40%)	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/6	pT2cN0M0	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco310.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco504.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	cT2aN0M0	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesión de partes blandas	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco504.ann
8720/6	metástasis por melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	lesión retroesternal	train-set-to-publish/cantemist-norm/cc_onco504.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco504.ann
9751/3	histiocitosis de células de Langerhans	train-set-to-publish/cantemist-norm/cc_onco710.ann
9085/3	tumor de células germinales mixto	train-set-to-publish/cantemist-norm/cc_onco710.ann
8000/6	pT2cN0M0	train-set-to-publish/cantemist-norm/cc_onco710.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco710.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco862.ann
8490/3	células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	cT3dN2M1	train-set-to-publish/cantemist-norm/cc_onco862.ann
8490/3	carcinoma con células con citoplasma vacuolado en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco862.ann
8001/3	células epiteliales malignas	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	afectación secundaria	train-set-to-publish/cantemist-norm/cc_onco862.ann
8490/6	Metástasis cutánea de adenocarcinoma de origen intestinal con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	Nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	Nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	implante en mesosigma	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	progresión exclusivamente ósea	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	nódulos cutáneos	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	progresión tumoral a nivel cutáneo	train-set-to-publish/cantemist-norm/cc_onco862.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco862.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco77.ann
9180/34	osteosarcoma convencional de alto grado	train-set-to-publish/cantemist-norm/cc_onco77.ann
9180/34	osteosarcoma convencional de alto grado	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/6	pT2N0M0	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/6	enfermedad a nivel mediastínico	train-set-to-publish/cantemist-norm/cc_onco77.ann
8000/6	enfermedad mediastínica	train-set-to-publish/cantemist-norm/cc_onco77.ann
8070/3	carcinoma escamocelular	train-set-to-publish/cantemist-norm/cc_onco289.ann
8046/6	carcinoma pulmonar no microcítico (CPNM) de tipo escamoso Estadio IV (T4N3M1)	train-set-to-publish/cantemist-norm/cc_onco289.ann
8046/3	CPNM	train-set-to-publish/cantemist-norm/cc_onco289.ann
8070/3	carcinoma pulmonar no microcítico (CPNM) de tipo escamoso	train-set-to-publish/cantemist-norm/cc_onco289.ann
8000/6	nódulos pulmonares múltiples bilaterales	train-set-to-publish/cantemist-norm/cc_onco289.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco289.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	cáncer de sigma estadio IV cT3N1bM1	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco315.ann
8140/61	adenocarcinoma de sigma pT3N2b (7/20) M1 (enfermedad hepática bilobar) de bajo grado	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco315.ann
8010/6	carcinoma colorrectal metastásico	train-set-to-publish/cantemist-norm/cc_onco315.ann
8140/6	adenocarcinoma colorrectal metastásico	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	Progresión hepática	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco315.ann
8000/6	lesión en pala ilíaca izquierda	train-set-to-publish/cantemist-norm/cc_onco315.ann
8120/3	Carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco628.ann
8010/2	carcinoma in situ	train-set-to-publish/cantemist-norm/cc_onco628.ann
8010/2	carcinoma in situ	train-set-to-publish/cantemist-norm/cc_onco628.ann
8120/3	carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco628.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco628.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco628.ann
8130/34	carcinoma papilar urotelial (CUP) de alto grado	train-set-to-publish/cantemist-norm/cc_onco628.ann
8130/3	CUP	train-set-to-publish/cantemist-norm/cc_onco628.ann
8120/34	carcinoma urotelial de alto grado	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/6	pT1cN0cM0	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/6	pT1cN0cM0	train-set-to-publish/cantemist-norm/cc_onco628.ann
8120/34	CUP de alto grado	train-set-to-publish/cantemist-norm/cc_onco628.ann
8130/24	carcinoma urotelial papilar no invasivo de alto grado	train-set-to-publish/cantemist-norm/cc_onco628.ann
8130/34	carcinoma papilar urotelial de alto grado	train-set-to-publish/cantemist-norm/cc_onco628.ann
8120/3/H	carcinoma urotelial infiltrante	train-set-to-publish/cantemist-norm/cc_onco628.ann
8550/3	adenocarcinoma prostático acinar	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/6	oligometastásica	train-set-to-publish/cantemist-norm/cc_onco628.ann
8000/6	progresión hepática única y pulmonar	train-set-to-publish/cantemist-norm/cc_onco628.ann
8010/2	pTis	train-set-to-publish/cantemist-norm/cc_onco628.ann
8010/2	pTis	train-set-to-publish/cantemist-norm/cc_onco628.ann
8070/3	Carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/1	Neoplasia	train-set-to-publish/cantemist-norm/cc_onco353.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco353.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco353.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco353.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/6	T2N1M0	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco353.ann
8070/33	Carcinoma epidermoide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco353.ann
8070/33	Carcinoma epidermoide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/6	T2N1Mx	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/6	T2N1M0	train-set-to-publish/cantemist-norm/cc_onco353.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco724.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco724.ann
8140/32	adenocarcinoma de ciego moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	afectación pélvica ósea	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	masa en psoas	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	masa en el psoas	train-set-to-publish/cantemist-norm/cc_onco724.ann
8010/3	síndrome de Lynch	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	masa del psoas	train-set-to-publish/cantemist-norm/cc_onco724.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco138.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco138.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco138.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco138.ann
8144/3	adenocarcinoma de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	metastasis	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco138.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	lesión frontoparietal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	lesión frontoparietal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8144/6	metástasis de adenocarcinoma de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	LOE cerebral	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	lesión parietal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8144/62	metástasis por adenocarcinoma moderadamente diferenciado de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	T3N0M1	train-set-to-publish/cantemist-norm/cc_onco138.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco138.ann
8440/3	Cistoadenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco183.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco183.ann
8460/3	cistoadenocarcinoma seroso papilar	train-set-to-publish/cantemist-norm/cc_onco183.ann
8010/33/H	carcinoma infiltrante pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco183.ann
8440/3	cistoadenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco183.ann
8246/62	metástasis cutánea de carcinoma neuroendocrino moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco183.ann
8510/6	Carcinoma medular de tiroides metastásico	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco183.ann
8240/3	tumor tiene rasgos neuroendocrinos	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	mestástasis	train-set-to-publish/cantemist-norm/cc_onco183.ann
8510/6	carcinoma medular de tiroides metastásico	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	afectación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	progresion a nivel del SNC	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	afectación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa a nivel del ovario	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa anexial	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masas suprarrenales	train-set-to-publish/cantemist-norm/cc_onco183.ann
8000/6	masa anexial	train-set-to-publish/cantemist-norm/cc_onco183.ann
8070/3	Carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco638.ann
8070/33	carcinoma pobremente diferenciado compatible con estirpe epidermoide	train-set-to-publish/cantemist-norm/cc_onco638.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco638.ann
8000/6	T2aT4N0M0	train-set-to-publish/cantemist-norm/cc_onco638.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco201.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco201.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco201.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco201.ann
8000/6	pT3N2M0	train-set-to-publish/cantemist-norm/cc_onco201.ann
8000/6	afectación hiliar izquierda, ganglionar torácica, supraclavicular	train-set-to-publish/cantemist-norm/cc_onco201.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco375.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco375.ann
8012/33	carcinoma mal diferenciado de célula grande	train-set-to-publish/cantemist-norm/cc_onco375.ann
8046/6	carcinoma de pulmón de célula no pequeña (CPCNP) extendido a pleura	train-set-to-publish/cantemist-norm/cc_onco375.ann
8046/3	CPCNP	train-set-to-publish/cantemist-norm/cc_onco375.ann
8012/63	carcinoma de célula grande LSD pulmón G3 cT1bN1M1a	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	afectación del sistema nervioso central	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	progresión pulmonar (basal derecha) y meníngea	train-set-to-publish/cantemist-norm/cc_onco375.ann
8000/6	progresión meníngea	train-set-to-publish/cantemist-norm/cc_onco375.ann
8550/32	adenocarcinoma acinar G2	train-set-to-publish/cantemist-norm/cc_onco375.ann
8140/6	Adenocarcinoma LSD pulmón Estadio IV por afectación meníngea	train-set-to-publish/cantemist-norm/cc_onco375.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco650.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco650.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco650.ann
8070/32	carcinoma epidermoide moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco650.ann
8070/32	carcinoma epidermoide moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco650.ann
8010/33	carcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/6	pT2N0M0	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco650.ann
8000/6	pT4N2M0	train-set-to-publish/cantemist-norm/cc_onco650.ann
8070/33	carcinoma epidermoide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco650.ann
8070/33	carcinoma epidermoide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco650.ann
9121/0	cavernoma	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco903.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco903.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco903.ann
8720/0	nevus	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/0	tumoración benigna	train-set-to-publish/cantemist-norm/cc_onco903.ann
8771/3/H	Neoplasia de melanocitos epitelioides con pleomorfismo	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco903.ann
8720/3	Melanoma	train-set-to-publish/cantemist-norm/cc_onco903.ann
8720/6	melanoma metastásico	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco903.ann
8000/6	afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco903.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco603.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco603.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco603.ann
8046/3	CPNCP	train-set-to-publish/cantemist-norm/cc_onco603.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco603.ann
8041/34	carcinoma indiferenciado de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco603.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco220.ann
8160/3	colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco220.ann
8160/3	colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco220.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco220.ann
8249/6	metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco220.ann
8240/6	metástasis de tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	pT3N1Mx	train-set-to-publish/cantemist-norm/cc_onco220.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco220.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco220.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/1/H	tumor heterogéneo	train-set-to-publish/cantemist-norm/cc_onco220.ann
8244/3	carcinoma mixto (adeno-neuroendocrino)	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco220.ann
8000/6	infiltración medular	train-set-to-publish/cantemist-norm/cc_onco220.ann
8140/6	adenocarcinoma de pulmón izquierdo cT4 N2 M1c	train-set-to-publish/cantemist-norm/cc_onco784.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco784.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco784.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco760.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco760.ann
9680/3	linfoma difuso de células grandes B	train-set-to-publish/cantemist-norm/cc_onco760.ann
9590/3	Linfoma	train-set-to-publish/cantemist-norm/cc_onco760.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco760.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco760.ann
9590/3	LOP	train-set-to-publish/cantemist-norm/cc_onco760.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco88.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco88.ann
8310/34	carcinoma renal papilar de células claras y eosinofílicas grado 3-4 de Furhman	train-set-to-publish/cantemist-norm/cc_onco88.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco88.ann
8280/3	carcinoma renal papilar de células claras y eosinofílicas	train-set-to-publish/cantemist-norm/cc_onco88.ann
8260/3	carcinoma renal papilar	train-set-to-publish/cantemist-norm/cc_onco88.ann
8070/3	Carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco825.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco825.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco825.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminoma clásico	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco825.ann
9064/3	tumores germinales	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/3	seminomas	train-set-to-publish/cantemist-norm/cc_onco825.ann
9061/6	metástasis del seminoma	train-set-to-publish/cantemist-norm/cc_onco825.ann
8070/3	Ca. epidermoide	train-set-to-publish/cantemist-norm/cc_onco825.ann
8000/3	Ca.	train-set-to-publish/cantemist-norm/cc_onco825.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco266.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco266.ann
8140/33	adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco266.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco266.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco266.ann
8170/3	hepatocarcinoma	train-set-to-publish/cantemist-norm/cc_onco266.ann
8070/3	Ca epidermoide	train-set-to-publish/cantemist-norm/cc_onco266.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	metástasis de neoplasia	train-set-to-publish/cantemist-norm/cc_onco640.ann
8490/33	adenocarcinoma pobremente diferenciado con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco640.ann
8490/63	metástasis por un carcinoma pobremente diferenciado con presencia de abundantes células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco640.ann
8490/3	neoplásica con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco640.ann
8490/33	adenocarcinoma de colon pobremente diferenciado con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	lesiones intraparenquimatosas	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	adenomegalias laterocervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	infiltración medular	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	afectación meníngea	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	infiltración de la médula ósea	train-set-to-publish/cantemist-norm/cc_onco640.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco959.ann
8140/32/H	adenocarcinoma infiltrante, moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco959.ann
8140/32	adenocarcinoma de colon sub-estenosante moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	afectación la hepática	train-set-to-publish/cantemist-norm/cc_onco959.ann
8140/31	adenocarcinoma de bajo grado	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	(LOES) hepáticas	train-set-to-publish/cantemist-norm/cc_onco959.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco635.ann
8720/6	metástasis en tránsito en pierna derecha de melanoma	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco635.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco635.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco868.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco868.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco868.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco868.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco868.ann
8895/0	mioma	train-set-to-publish/cantemist-norm/cc_onco868.ann
8520/2	carcinoma lobulillar in situ	train-set-to-publish/cantemist-norm/cc_onco868.ann
8520/2	CLIS	train-set-to-publish/cantemist-norm/cc_onco868.ann
8520/2	CLIS	train-set-to-publish/cantemist-norm/cc_onco868.ann
8000/6	cT1bN0Mx	train-set-to-publish/cantemist-norm/cc_onco868.ann
8500/32	carcinoma ductal infiltrante grado dos	train-set-to-publish/cantemist-norm/cc_onco868.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco234.ann
8041/3	carcinoma de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco234.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco234.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco234.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco234.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco927.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco927.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco927.ann
8895/0	mioma	train-set-to-publish/cantemist-norm/cc_onco927.ann
8310/33	carcinoma renal de células claras grado nuclear 3 de Furhman	train-set-to-publish/cantemist-norm/cc_onco927.ann
8000/6	tumor como estadio IV, pT3aN0M1	train-set-to-publish/cantemist-norm/cc_onco927.ann
8000/6	masa vertebral	train-set-to-publish/cantemist-norm/cc_onco927.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco996.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco996.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco996.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco996.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco356.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco356.ann
8936/3	Tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco356.ann
8004/1	Neoplasia predominantemente fusocelular	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco356.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco140.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco140.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco140.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco140.ann
8720/6	melanoma metastásico	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco140.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco140.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco140.ann
8744/3	melanoma lentiginoso acral	train-set-to-publish/cantemist-norm/cc_onco140.ann
8744/3	Melanoma acral	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	progresión a nivel de la cápsula esplénica	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	nódulo de 35,4 mm en el hipocondrio	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	lesión periesplénica	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	nódulo en el hipocondrio	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	progresión a nivel del hipocondrio	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	afectación muscular	train-set-to-publish/cantemist-norm/cc_onco140.ann
8000/6	enfermedad a nivel de la cápsula esplénica	train-set-to-publish/cantemist-norm/cc_onco140.ann
9699/3	MALT	train-set-to-publish/cantemist-norm/cc_onco464.ann
9400/3	astrocitoma	train-set-to-publish/cantemist-norm/cc_onco464.ann
9765/1	gammapatía monoclonal	train-set-to-publish/cantemist-norm/cc_onco464.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco464.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco464.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco464.ann
9735/3	linfoma plasmablástico	train-set-to-publish/cantemist-norm/cc_onco464.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco464.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco464.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco464.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco464.ann
9699/3	linfoma de la zona marginal extranodal	train-set-to-publish/cantemist-norm/cc_onco464.ann
9735/3	LPB	train-set-to-publish/cantemist-norm/cc_onco464.ann
9400/3	astrocitoma difuso	train-set-to-publish/cantemist-norm/cc_onco464.ann
9380/3	neoplasia glial	train-set-to-publish/cantemist-norm/cc_onco464.ann
9380/34	glioma de alto grado	train-set-to-publish/cantemist-norm/cc_onco464.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco798.ann
8800/1	tumor mesenquimal	train-set-to-publish/cantemist-norm/cc_onco798.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco798.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco279.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/6	cT3N1M0	train-set-to-publish/cantemist-norm/cc_onco279.ann
8000/6	ypT0N0(0/5)M0	train-set-to-publish/cantemist-norm/cc_onco279.ann
8010/6	Recidiva local, ganglionar y pulmonar de carcinoma	train-set-to-publish/cantemist-norm/cc_onco279.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco886.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco886.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco886.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco886.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco886.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco886.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco915.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco915.ann
8500/33	carcinoma ductal infiltrante de mama derecha (cuadrante supero-externo) grado 3	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	progresión múltiple a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	lesiones de cavidad glenoide	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	lesión de L1	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	lesión en región sacroiliaca	train-set-to-publish/cantemist-norm/cc_onco915.ann
8000/6	Metástasis intracardiaca en neoplasia	train-set-to-publish/cantemist-norm/cc_onco915.ann
9120/0	Angioma	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco889.ann
8720/0	nevus melanocítico	train-set-to-publish/cantemist-norm/cc_onco889.ann
8720/6	Melanoma estadio IV TxN2bM1c	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión sacroiliaca	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	conglomerado supraclavicular	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión sacroiliaca	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión supraclavicular	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	letálides	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	letálides	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	Lesión lítica	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión de partes blandas	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	masa de partes blandas en arco posterior de 9ª costilla	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión lítica ya conocida en hueso iliaco	train-set-to-publish/cantemist-norm/cc_onco889.ann
8000/6	lesión probable en el cuerpo vertebral	train-set-to-publish/cantemist-norm/cc_onco889.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco347.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco347.ann
8500/6	metástasis por carcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco347.ann
8010/1	proliferacion epitelial neoplásica	train-set-to-publish/cantemist-norm/cc_onco347.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	ypM0	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	Progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	Progresión de enfermedad ganglionar y hepática	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	enfermedad cerebral	train-set-to-publish/cantemist-norm/cc_onco347.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco702.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco702.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco702.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco702.ann
8140/6	Adenocarcinoma de pulmón E-IV (cT3cN2cM1)	train-set-to-publish/cantemist-norm/cc_onco702.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco702.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco702.ann
8000/6	Diseminación micronodular pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco702.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco702.ann
8000/6	lesión a nivel de la calota	train-set-to-publish/cantemist-norm/cc_onco702.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco718.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco718.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco718.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco718.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco718.ann
8000/6	M1a	train-set-to-publish/cantemist-norm/cc_onco818.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco818.ann
8723/3	melanoma en regresión	train-set-to-publish/cantemist-norm/cc_onco818.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco818.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco818.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco818.ann
8720/6	melanoma retroauricular izquierdo pT2bNxM1a	train-set-to-publish/cantemist-norm/cc_onco818.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco818.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco818.ann
8720/3	Melanoma	train-set-to-publish/cantemist-norm/cc_onco818.ann
8743/3	melanoma de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco818.ann
8000/6	Recaída única cutánea	train-set-to-publish/cantemist-norm/cc_onco818.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco619.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco619.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco619.ann
8140/6	Adenocarcinoma de pulmón estadio IVA por metástasis	train-set-to-publish/cantemist-norm/cc_onco619.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco619.ann
8000/6	lesión cerebelosa	train-set-to-publish/cantemist-norm/cc_onco619.ann
8000/6	lesión cerebelosa	train-set-to-publish/cantemist-norm/cc_onco619.ann
8000/6	progresión se había dado exclusivamente a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco619.ann
8000/6	Implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco803.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco803.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	enfermedad sistémica	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	progresión peritoneal	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/3	tumor maligno	train-set-to-publish/cantemist-norm/cc_onco803.ann
8950/3	tumor mülleriano mixto maligno	train-set-to-publish/cantemist-norm/cc_onco803.ann
8950/3	tumor mülleriano mixto maligno	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	nódulos omentales	train-set-to-publish/cantemist-norm/cc_onco803.ann
8950/3	tumor mülleriano mixto	train-set-to-publish/cantemist-norm/cc_onco803.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco308.ann
8720/3	Melanoma	train-set-to-publish/cantemist-norm/cc_onco308.ann
9530/0	meningioma	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco308.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco308.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco308.ann
8260/3	adenocarcinoma de pulmón de tipo papilar	train-set-to-publish/cantemist-norm/cc_onco308.ann
8050/3	carcinoma de patrón papilar	train-set-to-publish/cantemist-norm/cc_onco308.ann
8500/21	carcinoma ductal in situ de bajo grado	train-set-to-publish/cantemist-norm/cc_onco308.ann
8260/3	adenocarcinoma de pulmón papilar	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	pT2aN0M0	train-set-to-publish/cantemist-norm/cc_onco308.ann
8500/33	Carcinoma ductal infiltrante grado III	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco308.ann
8230/3	carcinoma de patrón papilar sólido	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	nódulo peritoneal	train-set-to-publish/cantemist-norm/cc_onco308.ann
8000/6	nódulo mesentérico	train-set-to-publish/cantemist-norm/cc_onco308.ann
8090/3	síndrome de Gorlin	train-set-to-publish/cantemist-norm/cc_onco125.ann
8090/1	tumores basocelulares	train-set-to-publish/cantemist-norm/cc_onco125.ann
8090/3	carcinomas basocelulares	train-set-to-publish/cantemist-norm/cc_onco125.ann
8090/3	Síndrome de Gorlin-Goltz	train-set-to-publish/cantemist-norm/cc_onco125.ann
9301/0	quistes odontogénicos	train-set-to-publish/cantemist-norm/cc_onco125.ann
9301/0	quistes odontogénicos	train-set-to-publish/cantemist-norm/cc_onco125.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco259.ann
8163/3	adenocarcinoma de probable origen pancreato-biliar	train-set-to-publish/cantemist-norm/cc_onco259.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco690.ann
8000/6	recidiva hepática	train-set-to-publish/cantemist-norm/cc_onco690.ann
8480/3	adenocarcinoma de colon mixto mucinoso	train-set-to-publish/cantemist-norm/cc_onco690.ann
8323/3	adenocarcinoma de colon mixto	train-set-to-publish/cantemist-norm/cc_onco690.ann
8510/3	carcinoma medular de tiroides	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco949.ann
8510/6	metástasis de CMT	train-set-to-publish/cantemist-norm/cc_onco949.ann
8510/6	metástasis de CMT	train-set-to-publish/cantemist-norm/cc_onco949.ann
8510/6	CMT (pT3), con afectación metastásica	train-set-to-publish/cantemist-norm/cc_onco949.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco858.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco858.ann
8500/33	carcinoma ductal infiltrante micropapilar grado III	train-set-to-publish/cantemist-norm/cc_onco858.ann
8265/3	carcinoma ductal infiltrante micropapilar	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	enfermedad a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	lesiones blásticas óseas	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	hígado con múltiples lesiones	train-set-to-publish/cantemist-norm/cc_onco858.ann
8000/6	Cáncer de mama metastásico	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco147.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco147.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco147.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco147.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/3/H	cáncer infiltrante	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	PE a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	afectación linfática axilar, mamaria interna, supraclavicular	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	enfermedad a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	enfermedad torácica	train-set-to-publish/cantemist-norm/cc_onco147.ann
8000/6	T1N0M0	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	lesiones del intestino delgado	train-set-to-publish/cantemist-norm/cc_onco171.ann
8772/3	tumoración melanocítica atípica, fundamentalmente fusiforme	train-set-to-publish/cantemist-norm/cc_onco171.ann
8720/6	Recidiva peritoneal de un melanoma	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	recidiva intestinal	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/1	peritumoral	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	recidiva en fosa nasal	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	progresión tumoral pulmonar	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco171.ann
8000/6	nódulo mesentérico	train-set-to-publish/cantemist-norm/cc_onco171.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco150.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco150.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco150.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco150.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco150.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco150.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco150.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco150.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco150.ann
8574/3	carcinoma ductal infiltrante (CDI) con diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco150.ann
8500/32	carcinoma ductal infiltrante (CDI), grado 2	train-set-to-publish/cantemist-norm/cc_onco150.ann
8574/32	carcinoma ductal infiltrante, pT2 (23 mm), con diferenciación neuroendocrina, grado 2	train-set-to-publish/cantemist-norm/cc_onco150.ann
8574/3	carcinoma ductal infiltrante con diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco150.ann
8000/6	proceso infiltrativo a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco150.ann
8010/3	Carcinoma	train-set-to-publish/cantemist-norm/cc_onco153.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco153.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco153.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco153.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco920.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	implantes nodulares	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	nódulos epiploicos	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	lesiones esplénicas	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	lesión esplénica	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	lesiones esplénicas	train-set-to-publish/cantemist-norm/cc_onco920.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco118.ann
8240/6	metástasis de tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/6	metastásico por tumor	train-set-to-publish/cantemist-norm/cc_onco118.ann
8246/31	carcinoma neuroendocrino bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco118.ann
8151/6	Insulinoma maligno estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco118.ann
8151/6	insulinoma pancreático maligno con metástasis	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco118.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco883.ann
9064/3	tumor germinal	train-set-to-publish/cantemist-norm/cc_onco883.ann
9064/3	TCG	train-set-to-publish/cantemist-norm/cc_onco883.ann
9085/6	TCG mixto de testículo izquierdo Estadio IIIA (pT3N2M1aS0)	train-set-to-publish/cantemist-norm/cc_onco883.ann
9085/6	TCG mixto pT3 N2 M1a	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/6	M1a	train-set-to-publish/cantemist-norm/cc_onco883.ann
9085/3/H	TCG mixto (90 % seminoma y 10 % teratoma con diferenciación escamosa)	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/6	PE pulmonar, hepática	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/6	PE a nivel retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco883.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco966.ann
8726/0	melanocitoma	train-set-to-publish/cantemist-norm/cc_onco966.ann
8726/0	melanocitoma	train-set-to-publish/cantemist-norm/cc_onco966.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco966.ann
8728/32	melanocitoma de grado intermedio	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/11	tumor de bajo grado	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	diseminación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco966.ann
8728/32	melanocitoma cerebral de grado intermedio	train-set-to-publish/cantemist-norm/cc_onco966.ann
9530/0/H	meningioma pigmentado	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/1/H	neoplasias pigmentadas	train-set-to-publish/cantemist-norm/cc_onco966.ann
8720/3	melanoma cerebral maligno	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco966.ann
8720/6	metástasis de melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	lesiones múltiples a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco966.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco966.ann
8140/0	Adenoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco380.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco380.ann
8010/2	carcinoma in situ	train-set-to-publish/cantemist-norm/cc_onco380.ann
8077/2	displasia severa	train-set-to-publish/cantemist-norm/cc_onco380.ann
8144/62	Adenocarcinoma moderadamente diferenciado de patrón intestinal compatible con metástasis	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	neoplasia de hipofaringe en estadio cT3N2 con una metástasis	train-set-to-publish/cantemist-norm/cc_onco380.ann
8140/6	metástasis hepática resecable de un adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco380.ann
8144/6	adenocarcinoma de patrón intestinal, metastásico	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	Masa hepática	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/1	Neoplasia	train-set-to-publish/cantemist-norm/cc_onco380.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco85.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco85.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco85.ann
8000/6	infiltración médula ósea	train-set-to-publish/cantemist-norm/cc_onco85.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco85.ann
8010/6	Carcinoma de mama cT4b N2a M1	train-set-to-publish/cantemist-norm/cc_onco85.ann
8000/6	infiltración de médula ósea	train-set-to-publish/cantemist-norm/cc_onco85.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco997.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco997.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco997.ann
9140/3	sarcoma de Kaposi	train-set-to-publish/cantemist-norm/cc_onco997.ann
9140/3	Sarcoma de Kaposi	train-set-to-publish/cantemist-norm/cc_onco997.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco835.ann
8247/3	células de Meckel	train-set-to-publish/cantemist-norm/cc_onco835.ann
8490/3	adenocarcinoma gástrico difuso con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco835.ann
8145/3	adenocarcinoma gástrico difuso	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco835.ann
8490/6	Adenocarcinoma gástrico difuso con células en anillo de sello estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco835.ann
8145/3	Adenocarcinoma gástrico difuso	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/6	lesiones en la cavidad oral	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/6	lesión en la cavidad oral	train-set-to-publish/cantemist-norm/cc_onco835.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco41.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco41.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco41.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco41.ann
8500/32	carcinoma ductal infiltrante G2	train-set-to-publish/cantemist-norm/cc_onco41.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco41.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco969.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco969.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco969.ann
8310/31	carcinoma de células claras, Führman I	train-set-to-publish/cantemist-norm/cc_onco969.ann
8310/33	carcinoma de células claras, Führman 3	train-set-to-publish/cantemist-norm/cc_onco969.ann
8005/6	tumor renal de células claras pT3a pN1 M1	train-set-to-publish/cantemist-norm/cc_onco969.ann
8000/6	progresión neoplásica tanto a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco969.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco591.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco591.ann
8000/11	tumor vascular de bajo grado	train-set-to-publish/cantemist-norm/cc_onco591.ann
9120/31	angiosarcoma de bajo grado	train-set-to-publish/cantemist-norm/cc_onco591.ann
9120/0/H	hemangioma multicéntrico	train-set-to-publish/cantemist-norm/cc_onco591.ann
9120/3/H	Angiosarcoma óseo multicéntrico	train-set-to-publish/cantemist-norm/cc_onco591.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco591.ann
8041/3	carcinoma de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco239.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco239.ann
8041/3	CCP	train-set-to-publish/cantemist-norm/cc_onco239.ann
8041/3	CARCINOMA PULMONAR DE CÉLULA PEQUEÑA	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	neoplasia de pulmón en LSI T4 N2 M1b	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	metastásica hepática de tumor	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	enfermedad secundaria	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	enfermedad secundaria	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco239.ann
8000/9	metastásica hepática de tumor primario desconocido	train-set-to-publish/cantemist-norm/cc_onco239.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco670.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco670.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco670.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco670.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco670.ann
8806/3	tumor desmoplásico de células pequeñas y redondas	train-set-to-publish/cantemist-norm/cc_onco670.ann
8806/3	TDCPR	train-set-to-publish/cantemist-norm/cc_onco670.ann
8806/6	TDCPR intraabdominal estadio IV por afectación pleural	train-set-to-publish/cantemist-norm/cc_onco670.ann
9970/1	síndrome linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco670.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco105.ann
9064/2	neoplasia de células germinales intratubulares	train-set-to-publish/cantemist-norm/cc_onco105.ann
9064/3/H	tumor testicular germinal regresado burned-out	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/3/H	Tumor testicular burned-out	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco105.ann
8000/6	afectación visceral únicamente a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco105.ann
9801/3	leucemia aguda	train-set-to-publish/cantemist-norm/cc_onco376.ann
9801/3	leucemia aguda	train-set-to-publish/cantemist-norm/cc_onco376.ann
8920/6	rabdomiosarcoma subtipo alveolar en estadio IV, con infiltración medular	train-set-to-publish/cantemist-norm/cc_onco376.ann
8000/6	neoplasia sólida con infiltración masiva de médula ósea	train-set-to-publish/cantemist-norm/cc_onco376.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco617.ann
9380/3/H	Glioma difuso	train-set-to-publish/cantemist-norm/cc_onco617.ann
9380/3/H	glioma difuso	train-set-to-publish/cantemist-norm/cc_onco617.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco17.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco17.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco17.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco17.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco17.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco17.ann
8500/32	CDI de mama izquierda estadio IIIA Grado 2	train-set-to-publish/cantemist-norm/cc_onco17.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco556.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	diseminación	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	enfermedad secundaria	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesión ósea	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco556.ann
8120/3/H	carcinoma urotelial no infiltrante	train-set-to-publish/cantemist-norm/cc_onco556.ann
8012/33	carcinoma no microcítico poco diferenciado de célula grande	train-set-to-publish/cantemist-norm/cc_onco556.ann
8140/33	adenocarcinoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco556.ann
8046/33	carcinoma no microcítico poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco556.ann
8012/33	Carcinoma poco diferenciado de célula grande	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesiones a nivel pancreático	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesiones renal	train-set-to-publish/cantemist-norm/cc_onco556.ann
8000/6	lesiones focales hipervasculares hepáticas	train-set-to-publish/cantemist-norm/cc_onco556.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco223.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco223.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco223.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco223.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco223.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco223.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco223.ann
8140/31	Adenocarcinoma de 2,4 cm bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco223.ann
8312/3	Hipernefroma	train-set-to-publish/cantemist-norm/cc_onco15.ann
8310/3	adenocarcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco15.ann
8310/3	adenocarcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/6	pT3NxMx	train-set-to-publish/cantemist-norm/cc_onco15.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco636.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco636.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco636.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco636.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco636.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/6	cT3N1M0	train-set-to-publish/cantemist-norm/cc_onco636.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco696.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco696.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco696.ann
8520/3	carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco696.ann
8520/3	carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	tumoral a distancia	train-set-to-publish/cantemist-norm/cc_onco696.ann
8010/6	metastásica por carcinoma	train-set-to-publish/cantemist-norm/cc_onco696.ann
8520/3	CLI	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	adenopatías en regiones supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	lesión orbitaria	train-set-to-publish/cantemist-norm/cc_onco696.ann
8520/6	Carcinoma lobulillar infiltrante estadio IV (por afectación orbitaria)	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/9	cáncer de origen desconocido	train-set-to-publish/cantemist-norm/cc_onco696.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco666.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco666.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco666.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco666.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco666.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco666.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco666.ann
8580/3	timoma	train-set-to-publish/cantemist-norm/cc_onco666.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco666.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco666.ann
8581/3	timoma tipo A	train-set-to-publish/cantemist-norm/cc_onco666.ann
8580/3	timoma tipo A	train-set-to-publish/cantemist-norm/cc_onco666.ann
9120/0	angiomas	train-set-to-publish/cantemist-norm/cc_onco666.ann
9120/0	angiomas	train-set-to-publish/cantemist-norm/cc_onco666.ann
9120/0	angiomas	train-set-to-publish/cantemist-norm/cc_onco666.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco226.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco226.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	progresa a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	progresión iridiana	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco226.ann
8000/6	enfermedad pulmonar	train-set-to-publish/cantemist-norm/cc_onco226.ann
8010/6	Metastasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco362.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco362.ann
8010/3/H	carcinoma no queratinizante	train-set-to-publish/cantemist-norm/cc_onco362.ann
8010/6	Carcinoma nasofaríngeo estadio IV con metástasis	train-set-to-publish/cantemist-norm/cc_onco362.ann
8010/6	carcinoma nasofaríngeo estadio IV con metástasis	train-set-to-publish/cantemist-norm/cc_onco362.ann
9970/1	proceso medular proliferativo	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	LOEs hepáticas	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	focos blasticos en columna	train-set-to-publish/cantemist-norm/cc_onco362.ann
8000/6	focos blasticos oseos	train-set-to-publish/cantemist-norm/cc_onco362.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco860.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco860.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco860.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco860.ann
8140/6	ADC pulmonar metastásico	train-set-to-publish/cantemist-norm/cc_onco860.ann
8000/6	afectación nodular pleural	train-set-to-publish/cantemist-norm/cc_onco860.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco946.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco946.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco946.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco946.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco946.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco946.ann
8140/6	metástasis por adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/6	lesión en vulva	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/6	lesión en labio mayor	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/6	lesión vulvar	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/6	lesión vulvar	train-set-to-publish/cantemist-norm/cc_onco946.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco946.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco672.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco672.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco672.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco672.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco672.ann
8500/3	carcinoma de mama ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	Lesión lítica subcondral	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	lesión lítica subcondral	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	micronódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	nódulos pulmonares milimétricos bilaterales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	cT3N2M0	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	foco óseo en cabeza femoral	train-set-to-publish/cantemist-norm/cc_onco672.ann
8000/6	Implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	M1b	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco547.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco547.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco547.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco547.ann
8010/3/H	Carcinoma pulmonar multicéntrico	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	implante muscular	train-set-to-publish/cantemist-norm/cc_onco547.ann
8070/3/H	Carcinoma epidermoide de pulmón multicéntrico	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	implantes musculares	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	neoplásica	train-set-to-publish/cantemist-norm/cc_onco547.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco129.ann
8490/3	células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	neoplásicas	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	afectación osteolítica	train-set-to-publish/cantemist-norm/cc_onco129.ann
8490/33	adenocarcinoma pobremente diferenciado con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/9	sin un tumor primario conocido	train-set-to-publish/cantemist-norm/cc_onco129.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco413.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco413.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco413.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco413.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco413.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco413.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco413.ann
8010/32/H	carcinoma infiltrante grado histológico II	train-set-to-publish/cantemist-norm/cc_onco413.ann
8010/6	metástasis hepáticas por carcinoma	train-set-to-publish/cantemist-norm/cc_onco413.ann
8010/32/H	Carcinoma infiltrante mama izquierda grado histológico 2	train-set-to-publish/cantemist-norm/cc_onco413.ann
8500/6	carcinoma ductal infiltrante de mama hormonosensible con afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco413.ann
8120/6	carcinoma vesical urotelial en estadio pT2N1M1	train-set-to-publish/cantemist-norm/cc_onco728.ann
8070/3	carcinoma escamoso	train-set-to-publish/cantemist-norm/cc_onco134.ann
8120/3	carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco134.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco134.ann
8070/3	diferenciación escamosa	train-set-to-publish/cantemist-norm/cc_onco134.ann
8033/3	sarcomatoides	train-set-to-publish/cantemist-norm/cc_onco134.ann
8033/6	carcinoma sarcomatoide de vejiga pT3aN0M1	train-set-to-publish/cantemist-norm/cc_onco134.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco134.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco134.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco134.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco687.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco687.ann
8720/6	melanoma metastásico	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco687.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco687.ann
8720/6	metástasis de melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco687.ann
8800/3	sarcoma de partes blandas	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco687.ann
8821/1	tumor de tipo desmoide	train-set-to-publish/cantemist-norm/cc_onco687.ann
9540/33	tumor maligno de la vaina nerviosa periférica, epitelioide, G-3 de la OMS	train-set-to-publish/cantemist-norm/cc_onco687.ann
9540/33	Tumor maligno de la vaina nerviosa periférica epitelioide grado 3	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/63	metástasis cutánea pobremente diferenciada	train-set-to-publish/cantemist-norm/cc_onco687.ann
9540/3	TMVNP	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/6	lesiones de la zona frontal	train-set-to-publish/cantemist-norm/cc_onco687.ann
8000/6	lesión frontal	train-set-to-publish/cantemist-norm/cc_onco687.ann
9220/0	encondroma	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco133.ann
8990/1	tumoración de partes blandas de naturaleza mixta probablemente mesenquimal	train-set-to-publish/cantemist-norm/cc_onco133.ann
8800/1	tumor mesenquimal	train-set-to-publish/cantemist-norm/cc_onco133.ann
8800/1	neoformación mesenquimal	train-set-to-publish/cantemist-norm/cc_onco133.ann
8800/3	tumor mesenquimal maligno	train-set-to-publish/cantemist-norm/cc_onco133.ann
8800/3	Tumor mesenquimal maligno	train-set-to-publish/cantemist-norm/cc_onco133.ann
8800/1	tumor mesenquimal	train-set-to-publish/cantemist-norm/cc_onco133.ann
8032/1	tumor fusocelular	train-set-to-publish/cantemist-norm/cc_onco133.ann
8830/3	histiocitoma fibroso maligno	train-set-to-publish/cantemist-norm/cc_onco133.ann
8802/34	sarcoma pleomórfico de alto grado	train-set-to-publish/cantemist-norm/cc_onco133.ann
8802/34	sarcoma pleomórfico de alto grado	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	Nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco133.ann
8000/6	siembra hematógena pulmonar	train-set-to-publish/cantemist-norm/cc_onco133.ann
8720/3	Melanoma	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco682.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco682.ann
8720/0	nevus	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco682.ann
8070/2	carcinoma epidermoide in situ	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco682.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco791.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco791.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco791.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco791.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco791.ann
8825/0	miofibroblastoma	train-set-to-publish/cantemist-norm/cc_onco791.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco967.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco967.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco967.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco967.ann
8524/3	carcinoma lobulillar infiltrante tipo mixto (ductal y lobulillar)	train-set-to-publish/cantemist-norm/cc_onco967.ann
8524/3	carcinoma lobulillar infiltrante tipo mixto (ductal y lobulillar)	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/6	masas ováricas	train-set-to-publish/cantemist-norm/cc_onco967.ann
8000/6	masas ováricas	train-set-to-publish/cantemist-norm/cc_onco967.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco577.ann
8745/3	melanoma de células fusiformes desmoplásico	train-set-to-publish/cantemist-norm/cc_onco577.ann
8772/3	melanoma de células fusiformes	train-set-to-publish/cantemist-norm/cc_onco577.ann
8720/3/H	melanoma no desmoplásico	train-set-to-publish/cantemist-norm/cc_onco577.ann
8720/6	Melanoma con enfermedad metastásica	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	M1c	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	lesiones cutáneas y pulmonares	train-set-to-publish/cantemist-norm/cc_onco577.ann
8000/6	N0M0	train-set-to-publish/cantemist-norm/cc_onco300.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco300.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco300.ann
8000/6	metastasis	train-set-to-publish/cantemist-norm/cc_onco300.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco300.ann
8721/3	melanoma maligno nodular	train-set-to-publish/cantemist-norm/cc_onco300.ann
8720/6	Melanoma cutáneo metastásico	train-set-to-publish/cantemist-norm/cc_onco300.ann
8441/34	Carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco984.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	T3cN1M0	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	ypT3cN1M0	train-set-to-publish/cantemist-norm/cc_onco984.ann
8460/34	adenocarcinoma seroso papilar de alto grado	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	Omental Cake	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	implantes omentales	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco984.ann
8000/6	enfermedad a nivel pélvico y hepático	train-set-to-publish/cantemist-norm/cc_onco984.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco158.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco158.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/6	suelta de globos	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/6	suelta de globos	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco158.ann
8000/1/H	neoplásica de estirpe epitelial	train-set-to-publish/cantemist-norm/cc_onco158.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco416.ann
9180/3	Osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco416.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco416.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco416.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco416.ann
9120/0	hemangioma	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco416.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco416.ann
9451/3	Oligodendroglioma anaplásico de la WHO III	train-set-to-publish/cantemist-norm/cc_onco416.ann
8500/32	Carcinoma ductal infiltrante grado II	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	(LOE) hepática	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	lesión única en región temporo-occipital	train-set-to-publish/cantemist-norm/cc_onco416.ann
8000/6	LOE cerebral	train-set-to-publish/cantemist-norm/cc_onco416.ann
9451/3	oligodendroglioma anaplásico de la WHO III	train-set-to-publish/cantemist-norm/cc_onco416.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco482.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco482.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco482.ann
8936/3	tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco482.ann
8000/3	tumor maligno	train-set-to-publish/cantemist-norm/cc_onco482.ann
8000/6	infiltración de médula ósea	train-set-to-publish/cantemist-norm/cc_onco307.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco307.ann
9500/3	neuroblastoma	train-set-to-publish/cantemist-norm/cc_onco307.ann
9500/3	neuroblastoma	train-set-to-publish/cantemist-norm/cc_onco307.ann
8821/1	tumor desmoide	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/3	Ca	train-set-to-publish/cantemist-norm/cc_onco307.ann
8002/3	Ca. Microcítico	train-set-to-publish/cantemist-norm/cc_onco307.ann
9500/6	metástasis óseas de neuroblastoma	train-set-to-publish/cantemist-norm/cc_onco307.ann
9500/6	Neuroblastoma abdominal intervenido con recidiva metastásica	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/6	afectación sacra	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/6	afectación de médula ósea	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/6	masa de partes blandas prevertebral	train-set-to-publish/cantemist-norm/cc_onco307.ann
8000/6	lesión sacra	train-set-to-publish/cantemist-norm/cc_onco307.ann
8010/9	Carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco216.ann
8140/6	adenocarcinoma (ADC) de pulmón, estadio IV (cT2bN2M1b)	train-set-to-publish/cantemist-norm/cc_onco216.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco216.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco216.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco216.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/6	lesiones blásticas en cuerpos vertebrales	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/6	progresión exclusiva a nivel meníngeo	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/6	nódulos en mama	train-set-to-publish/cantemist-norm/cc_onco216.ann
8010/9	CLM	train-set-to-publish/cantemist-norm/cc_onco216.ann
8010/9	CLM	train-set-to-publish/cantemist-norm/cc_onco216.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/0	neurofibroma	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/1	neurofibromatosis	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/1	neurofibromatosis	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/1	neurofibromas múltiples	train-set-to-publish/cantemist-norm/cc_onco74.ann
8802/34	sarcoma pleomorfico de alto grado	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/3	tumor maligno de la vaina nerviosa periférica	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/3	TMVNP	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/1	neurofibromas múltiples	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/0	neurofibromas	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/3	TMVNP	train-set-to-publish/cantemist-norm/cc_onco74.ann
9561/3	TMVNP con diferenciación rabdomiosarcomatosa	train-set-to-publish/cantemist-norm/cc_onco74.ann
9561/3	tumor de tritón	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/6	metástasis única con tumor	train-set-to-publish/cantemist-norm/cc_onco74.ann
9540/3	TMVNP	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco74.ann
8000/6	extensión local y a distancia	train-set-to-publish/cantemist-norm/cc_onco74.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco914.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco914.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco914.ann
8800/6	sarcoma retroperitoneal primario, con metástasis	train-set-to-publish/cantemist-norm/cc_onco914.ann
8370/1	neoplasia adrenal cortical de rasgos oncocíticos	train-set-to-publish/cantemist-norm/cc_onco914.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco738.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco738.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco738.ann
8441/34	carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco738.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco738.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco738.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco738.ann
9540/0	neurofibroma	train-set-to-publish/cantemist-norm/cc_onco738.ann
9540/0	neurofibroma	train-set-to-publish/cantemist-norm/cc_onco738.ann
9540/1	neurofibromatosis	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/6	implantes subcapsulares hepáticos	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco738.ann
8441/34	carcinoma de ovario (seroso de alto grado)	train-set-to-publish/cantemist-norm/cc_onco738.ann
9560/0	neurinoma	train-set-to-publish/cantemist-norm/cc_onco738.ann
8441/34	carcinoma seroso residual de alto grado	train-set-to-publish/cantemist-norm/cc_onco738.ann
8000/6	YpT2aN0Mx	train-set-to-publish/cantemist-norm/cc_onco738.ann
8452/1	tumoración sólido-quística	train-set-to-publish/cantemist-norm/cc_onco738.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco698.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco698.ann
8246/3	carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco698.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco698.ann
8246/3	carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco698.ann
8240/34	tumor neuroendocrino de alto grado	train-set-to-publish/cantemist-norm/cc_onco698.ann
8240/34	carcinoma neuroendocrino de alto grado	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	pT3pN2aM0	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco698.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco167.ann
9250/33	Tumor óseo de células gigantes grado 3 de Sanerkin	train-set-to-publish/cantemist-norm/cc_onco167.ann
9250/6	Metástasis pulmonares y mediastínicas del tumor de células gigantes óseo	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	infiltración esofágica	train-set-to-publish/cantemist-norm/cc_onco167.ann
8003/3	tumor de células gigantes	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	masa mediastínica	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	Masa medistínica	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/6	enfermedad a nivel mediastínico	train-set-to-publish/cantemist-norm/cc_onco167.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco344.ann
8033/3	sarcomatoide	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/31	OS de bajo grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/31	Osteosarcoma de bajo grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/31/H	osteosarcoma de bajo grado (de 4x3 cm) fusocelular, esclerosante, con formación de matriz ósea, bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco344.ann
8815/11/H	tumor fibroso esclerosante de bajo grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	metastasis	train-set-to-publish/cantemist-norm/cc_onco344.ann
8800/34	sarcoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco344.ann
8802/64	sarcoma pleomorfo indiferenciado de alto grado en estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco344.ann
8802/34	Sarcoma pleomorfo indiferenciado	train-set-to-publish/cantemist-norm/cc_onco344.ann
8800/1	neoformación típica sarcomatoide de partes blandas	train-set-to-publish/cantemist-norm/cc_onco344.ann
8802/34	Sarcoma pleomorfo de alto grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	Metastasis	train-set-to-publish/cantemist-norm/cc_onco344.ann
9180/31	Osteosarcoma bajo grado	train-set-to-publish/cantemist-norm/cc_onco344.ann
8800/64	sarcoma de alto grado en progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8004/3	osteosarcoma de bajo grado (de 4x3 cm) fusocelular	train-set-to-publish/cantemist-norm/cc_onco344.ann
8001/1	celularidad tumoral	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	enfermedad pulmonar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	recaida pulmonar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	nodulo pulmunar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	lesiones a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco344.ann
8000/6	enfermedad a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco344.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco173.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco173.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco173.ann
9530/0	meningioma	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	T4cN3M1	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	lesiones líticas en columna dorsal	train-set-to-publish/cantemist-norm/cc_onco173.ann
8010/6	metástasis dural del carcinoma	train-set-to-publish/cantemist-norm/cc_onco173.ann
8010/6	metástasis dural de carcinoma	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	lesión dural	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	lesión extraaxial occipital	train-set-to-publish/cantemist-norm/cc_onco173.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco939.ann
9185/34	osteosarcoma de células pequeñas de alto grado	train-set-to-publish/cantemist-norm/cc_onco939.ann
9185/6	Osteosarcoma de células pequeñas (de Hutter) estadio IV (afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/6	suelta de globos	train-set-to-publish/cantemist-norm/cc_onco939.ann
8000/6	Nódulo leptomeníngeo	train-set-to-publish/cantemist-norm/cc_onco939.ann
8312/3	carcinoma de células renales	train-set-to-publish/cantemist-norm/cc_onco863.ann
8120/3	carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco863.ann
8312/3	hipernefroma	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco863.ann
8310/3	hipernefroma de células claras	train-set-to-publish/cantemist-norm/cc_onco863.ann
8310/6	Carcinoma renal de células claras estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	lesión lítica en escápula	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	lesión lítica de escápula	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	lesión de apófisis	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco863.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco863.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	afectacion cerebral	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco219.ann
9120/0	hemangiomas	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco219.ann
8140/6	Adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco219.ann
8046/3	CNMP	train-set-to-publish/cantemist-norm/cc_onco219.ann
8046/6	Carcinoma no microcítico de pulmón (CNMP) estadio IV (afectación pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	afectación pulmonar y ósea	train-set-to-publish/cantemist-norm/cc_onco219.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco314.ann
9071/3	tumor del seno endodermico	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco314.ann
9071/3	TCGNS (seno endodérmico)	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/6	pT1cN0cM1bS2	train-set-to-publish/cantemist-norm/cc_onco314.ann
9065/3	TCGNS	train-set-to-publish/cantemist-norm/cc_onco314.ann
9065/3	tumor germinal no seminomatoso	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco314.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco314.ann
8041/3	carcinoma de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco744.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco744.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco744.ann
8041/6	carcinoma microcítico de pulmón, enfermedad extensa (hígado	train-set-to-publish/cantemist-norm/cc_onco744.ann
8041/6	cáncer de pulmón microcítico metastásico	train-set-to-publish/cantemist-norm/cc_onco744.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	neoproliferativo diseminado	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco828.ann
8310/31	carcinoma renal de células claras con grado nuclear I de Führman	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	neoplasia renal estadio IV por afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	diseminación intracraneal	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco828.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco828.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco25.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco25.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco25.ann
8000/6	afectación pulmonar, ósea	train-set-to-publish/cantemist-norm/cc_onco25.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco25.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	adenopático supraclavicular	train-set-to-publish/cantemist-norm/cc_onco759.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco759.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco759.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	lesión en región supraclavicular	train-set-to-publish/cantemist-norm/cc_onco759.ann
8041/3	carcinoma de pulmón neuroendocrino de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco759.ann
8246/3	carcinoma de pulmón neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco759.ann
8041/6	carcinoma microcítico de pulmón, enfermedad extensa por afectación supraclavicular	train-set-to-publish/cantemist-norm/cc_onco759.ann
8000/6	lesión retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco759.ann
8170/3	hepatocarcinoma	train-set-to-publish/cantemist-norm/cc_onco417.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco417.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco417.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco417.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco417.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco417.ann
8160/6	metástasis de colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco417.ann
8160/6	metástasis pulmonares de colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco417.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco218.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco218.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco218.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco363.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco363.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco363.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco363.ann
8046/3	cáncer no microcítico	train-set-to-publish/cantemist-norm/cc_onco363.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco363.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco363.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco837.ann
8041/33	metástasis de carcinoma poco diferenciado de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco837.ann
8041/6	Carcinoma microcítico de pulmón estadio IV por afectación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco837.ann
8041/6	carcinoma microcítico de pulmón estadio IV por afectación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	Adenopatías mediastínicas bilaterales y supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	Nódulo de 31 mm en la suprarrenal	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	implantes leptomeníngeos	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	lesión nodular a nivel del tallo hipofisario	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	lesión nodular en tallo hipofisario	train-set-to-publish/cantemist-norm/cc_onco837.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco837.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco493.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco493.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco493.ann
8046/3	cáncer no microcítico	train-set-to-publish/cantemist-norm/cc_onco493.ann
8000/6	enfermedad pulmonar y hepática	train-set-to-publish/cantemist-norm/cc_onco493.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco493.ann
8140/6	Adenocarcinoma de pulmón E-IVa (c T4N3M1a)	train-set-to-publish/cantemist-norm/cc_onco493.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco278.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco278.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco278.ann
8140/04	adenomatosa con displasia de alto grado	train-set-to-publish/cantemist-norm/cc_onco278.ann
8490/32	Adenocarcinoma de unión rectosigmoidea estenosante (con endoprótesis), moderadamente diferenciado con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco278.ann
8000/6	metástásica	train-set-to-publish/cantemist-norm/cc_onco278.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco352.ann
8825/1	TUMOR MIOFIBROBLASTICO INFLAMATORIO	train-set-to-publish/cantemist-norm/cc_onco352.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco352.ann
8858/3	liposarcoma desdiferenciado	train-set-to-publish/cantemist-norm/cc_onco352.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco352.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco352.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco352.ann
8825/1	tumor miofibroblástico inflamatorio	train-set-to-publish/cantemist-norm/cc_onco352.ann
8936/3	tumor estromal gastro-intestinal	train-set-to-publish/cantemist-norm/cc_onco352.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco326.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco326.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco326.ann
8160/3	colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	cTxNxM0	train-set-to-publish/cantemist-norm/cc_onco326.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	ypT3N0/M0	train-set-to-publish/cantemist-norm/cc_onco326.ann
8144/6	adenocarcinoma de tipo intestinal compatible con afectación metastásica	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	recidiva paracardíaca	train-set-to-publish/cantemist-norm/cc_onco326.ann
8000/6	progresión paracardíaca	train-set-to-publish/cantemist-norm/cc_onco326.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco14.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco14.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco14.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco14.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco14.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco762.ann
8144/32	adenocarcinoma gástrico moderadamente diferenciado de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco762.ann
8140/6	infiltración hepática por adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/6	LOE hepáticas	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/6	lesión a nivel de cúpula hepática	train-set-to-publish/cantemist-norm/cc_onco762.ann
8000/6	lesión hipermetabólica en cúpula hepática	train-set-to-publish/cantemist-norm/cc_onco762.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco922.ann
8220/0	poliposis adenomatosa familiar	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco922.ann
8821/1	fibromatosis mesentérica de tipo desmoide	train-set-to-publish/cantemist-norm/cc_onco922.ann
8821/1	tumores desmoides	train-set-to-publish/cantemist-norm/cc_onco922.ann
8220/0	PAF	train-set-to-publish/cantemist-norm/cc_onco922.ann
8220/0	PAF	train-set-to-publish/cantemist-norm/cc_onco922.ann
9680/3/H	linfoma B difuso de células grandes, inmunofenotipo germinal	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	afectación a nivel abdominal	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	masas intraperitoneales	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	masas a nivel abdominal	train-set-to-publish/cantemist-norm/cc_onco922.ann
9680/3/H	Linfoma difuso de células grandes B (LCGB) tipo centrogerminal	train-set-to-publish/cantemist-norm/cc_onco922.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco496.ann
8041/6	metástasis de carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco496.ann
8140/6	adenocarcinoma de pulmón estadio IV por metástasis	train-set-to-publish/cantemist-norm/cc_onco496.ann
8000/6	lesión subpleural	train-set-to-publish/cantemist-norm/cc_onco496.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco255.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco255.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco255.ann
8000/6	T2N1M0	train-set-to-publish/cantemist-norm/cc_onco255.ann
8050/3	carcinoma papilar	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco57.ann
8260/3	carcinoma papilar	train-set-to-publish/cantemist-norm/cc_onco57.ann
8260/3	Carcinoma papilar	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco57.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	adenopatías mediastínicas, hiliares, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	implantes mesentéricos	train-set-to-publish/cantemist-norm/cc_onco816.ann
8140/6	metástasis de ADK	train-set-to-publish/cantemist-norm/cc_onco816.ann
8140/6	ADK de pulmón en estadio IV (T2N3M1)	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco816.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco318.ann
8936/6	GIST con fenotipo epitelioide con metástasis	train-set-to-publish/cantemist-norm/cc_onco318.ann
8936/61	Tumor del estroma gastrointestina epitelioide, G1	train-set-to-publish/cantemist-norm/cc_onco318.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco318.ann
8936/6	GIST con metástasis	train-set-to-publish/cantemist-norm/cc_onco318.ann
8804/3	GIST con fenotipo epitelioide	train-set-to-publish/cantemist-norm/cc_onco318.ann
8804/3	Tumor del estroma gastrointestina epitelioide	train-set-to-publish/cantemist-norm/cc_onco318.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco54.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco54.ann
8000/6	diseminación hepática	train-set-to-publish/cantemist-norm/cc_onco54.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco993.ann
8140/6	adenocarcinoma de colon estadio IV (hepáticas)	train-set-to-publish/cantemist-norm/cc_onco993.ann
8140/6	Adenocarcinoma de colon estadio IV (hepáticas	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	Progresión hepática	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	recidiva hepática	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	lesiones micronodulares pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	lesiones lumbares	train-set-to-publish/cantemist-norm/cc_onco993.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco506.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco506.ann
8000/6	Nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco379.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco379.ann
8500/6	metástasis de carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco379.ann
8500/6	Carcinoma ductal infiltrante de mama derecha estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesión lítica en húmero	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesión lítica en tercio medio humeral	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	enfermedad a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	enfermedad cerebral	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones supra e infratentoriales	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	infiltración leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco379.ann
8000/6	lesiones similares milimétricas en ilíaco	train-set-to-publish/cantemist-norm/cc_onco379.ann
8010/6	metástasis ósea con masa de partes blandas de Carcinoma	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/1	Tumoral	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco364.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco364.ann
8310/32	Carcinoma (ca.) renal de células claras, estadio pT1b G2	train-set-to-publish/cantemist-norm/cc_onco364.ann
8010/3	ca.	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	recaída a distancia	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	masa prevertebral	train-set-to-publish/cantemist-norm/cc_onco364.ann
8000/6	lesión en L2	train-set-to-publish/cantemist-norm/cc_onco364.ann
8310/6	Recaída a distancia con ILE 5.9 años de Ca. renal de células claras	train-set-to-publish/cantemist-norm/cc_onco364.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco558.ann
8500/32	carcinoma ductal infiltrante grado histológico 2	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco558.ann
8500/6	carcinoma ductal infiltrante bilateral luminal A estadio IV por enfermedad bilateral, ósea	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	nódulos espiculados pulmonares	train-set-to-publish/cantemist-norm/cc_onco558.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco35.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco35.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco35.ann
8020/3	carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco35.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco35.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	lesiones líticas óseas	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	masa ovárica	train-set-to-publish/cantemist-norm/cc_onco35.ann
8010/6	carcinoma metastásico	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	lesión en el párpado	train-set-to-publish/cantemist-norm/cc_onco35.ann
8000/6	enfermedad pélvica	train-set-to-publish/cantemist-norm/cc_onco35.ann
8140/6	Metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco120.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco120.ann
8895/0	mioma	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/6	pT3N1M0	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/6	implante secundario	train-set-to-publish/cantemist-norm/cc_onco120.ann
8480/6	metástasis de adenocarcinoma con diferención mucinosa	train-set-to-publish/cantemist-norm/cc_onco120.ann
8070/34/H	Carcinoma epitelial maligno indiferenciado con componente mucinoso	train-set-to-publish/cantemist-norm/cc_onco120.ann
8070/34/H	tumoración epitelial maligna indiferenciada con componente mucinoso	train-set-to-publish/cantemist-norm/cc_onco120.ann
8070/34/H	carcinoma epitelial maligno indiferenciado con componente mucinoso	train-set-to-publish/cantemist-norm/cc_onco120.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco535.ann
8140/32	adenocarcinoma Gleason 7	train-set-to-publish/cantemist-norm/cc_onco535.ann
8140/32	adenocarcinoma Gleason 7	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	T3bN0 con estudio de extensión negativo	train-set-to-publish/cantemist-norm/cc_onco535.ann
8140/33	adenocarcinoma Gleason 8	train-set-to-publish/cantemist-norm/cc_onco535.ann
8140/33	adenocarcinoma Gleason 8	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	cáncer prostático resistente a castración metastásico	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	CPRCm	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	lesión invasiva en la base del hueso occipital	train-set-to-publish/cantemist-norm/cc_onco535.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco211.ann
8270/34	carcinoma de células cromófobas, grado 4 de Furhman	train-set-to-publish/cantemist-norm/cc_onco211.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco211.ann
8270/6	recidiva retroperitoneal y suprarrenal de carcinoma cromófobo	train-set-to-publish/cantemist-norm/cc_onco211.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco211.ann
8000/6	lesión suprarenal	train-set-to-publish/cantemist-norm/cc_onco211.ann
8000/6	nódulos retroperitoneales	train-set-to-publish/cantemist-norm/cc_onco211.ann
8000/6	nódulos peritonales	train-set-to-publish/cantemist-norm/cc_onco211.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco573.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco573.ann
8140/33	adenocarcinoma mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco573.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco573.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco585.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco585.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco585.ann
8070/6	carcinoma epidermoide de pulmón cT4 N3 M1b	train-set-to-publish/cantemist-norm/cc_onco585.ann
8000/3	neoplásica	train-set-to-publish/cantemist-norm/cc_onco585.ann
8000/3	neoplásica	train-set-to-publish/cantemist-norm/cc_onco585.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco998.ann
8120/34	carcinoma urotelial de alto grado	train-set-to-publish/cantemist-norm/cc_onco998.ann
8120/3	carcinoma urotelial de vejiga de alto grado	train-set-to-publish/cantemist-norm/cc_onco998.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco998.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco998.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco998.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco998.ann
8000/6	nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco998.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco919.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco919.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco919.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/32	ADC de próstata pT3b, Gleason 3 + 4	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8000/6	diseminación a distancia	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/33	metástasis de ADC pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco919.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco947.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco947.ann
8140/6	diseminación linfática única de un adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco947.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco947.ann
8490/33	adenocarcinoma de colon con células en anillo de sello, grado histológico III	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/6	pT3pN2bM0	train-set-to-publish/cantemist-norm/cc_onco947.ann
8000/6	diseminación broncovascular y linfática	train-set-to-publish/cantemist-norm/cc_onco947.ann
8140/6	Progresión pulmonar de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco947.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco721.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco721.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco721.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco721.ann
8140/6	adenocarcinoma de pulmón T4 N2 M1	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	progresión mínima en pulmón y hueso	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	progresión pulmonar y ósea	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco721.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco721.ann
8070/3	carcinoma escamoso	train-set-to-publish/cantemist-norm/cc_onco382.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco382.ann
8050/0	papiloma	train-set-to-publish/cantemist-norm/cc_onco382.ann
8077/2	lesión escamosa intraepitelial de alto grado	train-set-to-publish/cantemist-norm/cc_onco382.ann
8077/2	SHIL	train-set-to-publish/cantemist-norm/cc_onco382.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco382.ann
8000/6	progresión pleural	train-set-to-publish/cantemist-norm/cc_onco382.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco662.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	intratumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8800/3	sarcoma	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/3/H	neoplasia maligna pleomórfica	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/6	cT4cN0cM0	train-set-to-publish/cantemist-norm/cc_onco662.ann
8001/1	celularidad tumoral	train-set-to-publish/cantemist-norm/cc_onco662.ann
8800/1	neoplasia de estirpe mesenquimal	train-set-to-publish/cantemist-norm/cc_onco662.ann
8140/3	adenocarcinomas	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/6	diseminación sistémica	train-set-to-publish/cantemist-norm/cc_onco662.ann
8000/6	progresión sistémica	train-set-to-publish/cantemist-norm/cc_onco662.ann
8800/34	sarcoma (alto grado histológico)	train-set-to-publish/cantemist-norm/cc_onco662.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	neoplasia de pulmón en estadio IV (T4N3M1b)	train-set-to-publish/cantemist-norm/cc_onco788.ann
8140/6	adenocarcinoma de pulmón estadio IV, con afectación hepática	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	enfermedad a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco788.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco788.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco694.ann
8046/3	adenocarcinoma pulmonar de célula no pequeña	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8140/6	Metástasis única hepática de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco694.ann
8140/6	metastásica de la lesión por adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco694.ann
8046/3	Carcinoma de célula no pequeña	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	enfermedad a otros niveles: hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	implante en colon	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	lesión focal hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/6	lesiones esclerosas desde cuerpo vertebral	train-set-to-publish/cantemist-norm/cc_onco694.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco778.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco778.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco778.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco778.ann
9040/3/H	sarcoma sinovial monofásico	train-set-to-publish/cantemist-norm/cc_onco778.ann
9040/3	sarcoma sinovial	train-set-to-publish/cantemist-norm/cc_onco778.ann
9040/3/H	sarcoma sinovial monofásico	train-set-to-publish/cantemist-norm/cc_onco778.ann
9041/3	sarcoma sinovial de patrón fusocelular monofásico	train-set-to-publish/cantemist-norm/cc_onco778.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco411.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco411.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco411.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco411.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco411.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco411.ann
8453/2	neoplasia mucinosa papilar intraductal con displasia de alto grado	train-set-to-publish/cantemist-norm/cc_onco411.ann
8140/6	Adenocarcinoma de páncreas estadio IV, con infiltración del retroperitoneo	train-set-to-publish/cantemist-norm/cc_onco411.ann
8140/6	adenocarcinoma de páncreas metastásico	train-set-to-publish/cantemist-norm/cc_onco411.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco87.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco87.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco87.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco87.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco87.ann
8500/33	CDI, Grado III	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	pT1cN2aM0	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco87.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco87.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco87.ann
9220/3	condrosarcoma	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco973.ann
8800/34	tumor de estirpe sarcomatoide de alto grado	train-set-to-publish/cantemist-norm/cc_onco973.ann
9243/34	condrosarcoma desdiferenciado de alto grado	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/6	recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco973.ann
9220/34	condrosarcoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco973.ann
9220/34	condrosarcoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/6	progresión subcutánea	train-set-to-publish/cantemist-norm/cc_onco973.ann
8000/6	lesión en dedo índice	train-set-to-publish/cantemist-norm/cc_onco973.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco513.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco513.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco513.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco513.ann
8046/3	cáncer de pulmón no microcítico	train-set-to-publish/cantemist-norm/cc_onco513.ann
8001/1/H	células neoplásicas de estirpe epitelial	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	M1b	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	M1b	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	afectación tumoral costal	train-set-to-publish/cantemist-norm/cc_onco513.ann
8000/6	masa de pared costal	train-set-to-publish/cantemist-norm/cc_onco513.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco409.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco409.ann
8140/6	Adenocarcinoma de pulmón cT1NxM1a	train-set-to-publish/cantemist-norm/cc_onco409.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco409.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco409.ann
8000/6	enfermedad a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco409.ann
8000/6	enfermedad radiológica (pleural	train-set-to-publish/cantemist-norm/cc_onco409.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco980.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco980.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco980.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco491.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco491.ann
8211/3/H	ADC tubular infiltrante	train-set-to-publish/cantemist-norm/cc_onco491.ann
8263/3	adenoma tubulovelloso	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/3	neoformativa	train-set-to-publish/cantemist-norm/cc_onco491.ann
8211/32/H	ADC tubular infiltrante moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco491.ann
8140/6	ADC de colon derecho, G2, estadio IV (hepática	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/6	lesión dudosa en el lóbulo hepático	train-set-to-publish/cantemist-norm/cc_onco491.ann
8000/6	nódulos subcentimétricos en todos los lóbulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco491.ann
8901/3	Rabdomiosarcoma pleomórfico	train-set-to-publish/cantemist-norm/cc_onco187.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco187.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco187.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco187.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco187.ann
8901/3	rabdomiosarcoma pleomórfico	train-set-to-publish/cantemist-norm/cc_onco187.ann
8901/3	rabdomiosarcoma pleomórfico	train-set-to-publish/cantemist-norm/cc_onco187.ann
8802/3	sarcoma pleomórfico	train-set-to-publish/cantemist-norm/cc_onco187.ann
8802/3	sarcoma pleomórfico	train-set-to-publish/cantemist-norm/cc_onco187.ann
8900/3	rabdomiosarcomas	train-set-to-publish/cantemist-norm/cc_onco187.ann
9970/1	enfermedad linfoproliferativa	train-set-to-publish/cantemist-norm/cc_onco387.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco387.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco387.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco387.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco387.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco387.ann
9591/34	linfoma difuso de alto grado	train-set-to-publish/cantemist-norm/cc_onco387.ann
9680/3	Linfoma Difuso de Célula Grande B	train-set-to-publish/cantemist-norm/cc_onco387.ann
9651/3	LINFOMA HODGKIN PREDOMINIO LINFOCÍTICO	train-set-to-publish/cantemist-norm/cc_onco387.ann
9651/3	enfermedad de Hodgkin predominio linfocítico	train-set-to-publish/cantemist-norm/cc_onco387.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco517.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco517.ann
8720/3	melanoma cutáneo maligno	train-set-to-publish/cantemist-norm/cc_onco517.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco517.ann
8000/6	lesiones líticas	train-set-to-publish/cantemist-norm/cc_onco517.ann
8720/6	recidiva de melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco517.ann
8310/3	carcinoma renal de celulas claras	train-set-to-publish/cantemist-norm/cc_onco222.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco222.ann
8310/33	Carcinoma renal de células claras grado 3 de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco222.ann
8272/0	macroadenoma hipofisario	train-set-to-publish/cantemist-norm/cc_onco222.ann
8272/0	macroadenoma hipofisario	train-set-to-publish/cantemist-norm/cc_onco222.ann
8272/0	macroadenoma hipofisario	train-set-to-publish/cantemist-norm/cc_onco222.ann
8310/6	Metástasis cerebral de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	realces leptomeníngeos	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/6	masa adrenal	train-set-to-publish/cantemist-norm/cc_onco222.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco820.ann
8010/3/H	carcinoma mixto	train-set-to-publish/cantemist-norm/cc_onco820.ann
8380/31	endometrioide bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco820.ann
8005/3	tumor de células claras	train-set-to-publish/cantemist-norm/cc_onco820.ann
8000/6	diseminación peritoneal	train-set-to-publish/cantemist-norm/cc_onco820.ann
8000/6	progresión tumoral a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco820.ann
8041/3	carcinoma de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco799.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco799.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco799.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco799.ann
8000/6	focos osteoblásticos	train-set-to-publish/cantemist-norm/cc_onco799.ann
8041/6	carcinoma microcítico estadio IV (enfermedad extendida)	train-set-to-publish/cantemist-norm/cc_onco799.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco288.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco288.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco288.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco288.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco288.ann
8000/6	LOEs hepáticas	train-set-to-publish/cantemist-norm/cc_onco288.ann
8000/6	lóbulo hepático	train-set-to-publish/cantemist-norm/cc_onco288.ann
8746/6	melanoma mucoso nasal y progresión masiva metastásica	train-set-to-publish/cantemist-norm/cc_onco288.ann
8746/3	melanoma mucoso	train-set-to-publish/cantemist-norm/cc_onco288.ann
8746/6	melanoma mucoso nasal y progresión masiva metastásica	train-set-to-publish/cantemist-norm/cc_onco288.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco720.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco720.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco720.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco720.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	pT2N2cM0	train-set-to-publish/cantemist-norm/cc_onco720.ann
8140/31	Adenocarcinoma de próstata Gleason 6	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	cT1cN0M0	train-set-to-publish/cantemist-norm/cc_onco720.ann
8500/3	adenocarcinoma de tipo ductal	train-set-to-publish/cantemist-norm/cc_onco720.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco720.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco769.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco769.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco769.ann
8090/3	epitelioma basocelular	train-set-to-publish/cantemist-norm/cc_onco769.ann
8090/3	epitelioma basocelular	train-set-to-publish/cantemist-norm/cc_onco769.ann
9010/0	fibroadenoma	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco769.ann
8140/31	adenocarcinoma colorrectal bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco769.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/6	pT3N1aM0	train-set-to-publish/cantemist-norm/cc_onco769.ann
8574/3	carcinoma con diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco769.ann
8070/3	diferenciación escamosa	train-set-to-publish/cantemist-norm/cc_onco769.ann
8574/3	neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco769.ann
8574/3	diferenciación neuroendocrina del epitelioma basocelular	train-set-to-publish/cantemist-norm/cc_onco769.ann
8090/3	carcinoma con morfología basaloide	train-set-to-publish/cantemist-norm/cc_onco769.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco741.ann
8503/3	Ca papilar infiltrante	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	T2N0M0	train-set-to-publish/cantemist-norm/cc_onco741.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	nódulo de la suprarrenal	train-set-to-publish/cantemist-norm/cc_onco741.ann
8140/6	metástasis de ADC	train-set-to-publish/cantemist-norm/cc_onco741.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco741.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3	linfoma difuso de células grandes B	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3	LDCGB	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3	LDCGB	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3	LDCGB	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3	LDCGB	train-set-to-publish/cantemist-norm/cc_onco1000.ann
9680/3/H	linfoma de células grandes B difuso subtipo ABC	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/6	lesión de pared torácica	train-set-to-publish/cantemist-norm/cc_onco1000.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco646.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco646.ann
8152/6	glucagonoma estadio IV (T3N0M1	train-set-to-publish/cantemist-norm/cc_onco646.ann
8249/3	tumor neuroendocrino con un grado de diferenciación 2	train-set-to-publish/cantemist-norm/cc_onco646.ann
8249/3	tumor neuroendocrino de 4,2 cm, con un grado 2 de diferenciación	train-set-to-publish/cantemist-norm/cc_onco646.ann
8152/1	glucagonoma	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/6	metastásica tumoral	train-set-to-publish/cantemist-norm/cc_onco646.ann
8246/6	metástasis de carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco646.ann
8152/1	glucagonoma	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco646.ann
8000/6	nódulos a nivel de tejido celular subcutáneo	train-set-to-publish/cantemist-norm/cc_onco646.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco726.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/3	malignas	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/6	lesiones pulmonares y en glándulas suprarrenales	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco726.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco103.ann
8120/31	carcinoma urotelial papilar de bajo grado	train-set-to-publish/cantemist-norm/cc_onco103.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco103.ann
9052/3	mesotelioma epitelial	train-set-to-publish/cantemist-norm/cc_onco103.ann
8013/3	carcinoma neuroendocrino de célula grande	train-set-to-publish/cantemist-norm/cc_onco103.ann
8013/6	carcinoma neuroendocrino de células grandes metastásico	train-set-to-publish/cantemist-norm/cc_onco103.ann
9050/3	mesotelioma pleural maligno	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/6	lesiones pleurales	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/3	tumoral	train-set-to-publish/cantemist-norm/cc_onco103.ann
8000/6	progresión a nivel pleural	train-set-to-publish/cantemist-norm/cc_onco103.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco174.ann
8260/3	CPT	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/1	Tumor	train-set-to-publish/cantemist-norm/cc_onco174.ann
8500/31	carcinoma ductal infiltrante (CDI) grado 1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8500/21	carcinoma intraductal (CDIS) 8 mm de bajo grado	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco174.ann
8050/3/H	carcinoma papilar invasivo	train-set-to-publish/cantemist-norm/cc_onco174.ann
8500/2	CDIS	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	adenopatia (ADP) supraclavicular	train-set-to-publish/cantemist-norm/cc_onco174.ann
8010/6	metástasis (M1) de carcinoma	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	ganglios supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	cT0N3M1	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	afectación retropectoral	train-set-to-publish/cantemist-norm/cc_onco174.ann
8260/3	carcinoma papilar tiroidal	train-set-to-publish/cantemist-norm/cc_onco174.ann
8010/6	M1 ganglionar por carcinoma	train-set-to-publish/cantemist-norm/cc_onco174.ann
8290/0	metaplasia de células de Hürthle	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	ADP supraclavicular	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	ADP SPCL	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	Nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	Nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco174.ann
8000/6	ADP SCLD	train-set-to-publish/cantemist-norm/cc_onco174.ann
8041/3	carcinoma neuroendocrino de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco578.ann
8246/34	carcinoma neuroendocrino indiferenciado	train-set-to-publish/cantemist-norm/cc_onco578.ann
8140/34	adenocarcinoma de próstata Gleason 5 + 4	train-set-to-publish/cantemist-norm/cc_onco578.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco351.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco351.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco351.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	lesiones a distancia	train-set-to-publish/cantemist-norm/cc_onco351.ann
9180/34	osteosarcoma osteoide osteoblástico grado IV	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	pT1pN0cM0	train-set-to-publish/cantemist-norm/cc_onco351.ann
9180/6	Osteosarcoma osteoide osteoblástico con recaída local y pulmonar	train-set-to-publish/cantemist-norm/cc_onco351.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco351.ann
9180/6	metástasis de osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco351.ann
8000/6	Lesión ocupante de espacio cerebral	train-set-to-publish/cantemist-norm/cc_onco351.ann
8452/1	Neoplasia sólido-quística	train-set-to-publish/cantemist-norm/cc_onco817.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco817.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco817.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco817.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco817.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco817.ann
9380/3	neoplasia primaria cerebral de estirpe glial	train-set-to-publish/cantemist-norm/cc_onco817.ann
9391/32	ependimoma variante de células claras grado II según la Organización Mundial de la Salud	train-set-to-publish/cantemist-norm/cc_onco817.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco71.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco71.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	cáncer de mama metastásico	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	neoplasia primaria renal sin descartar metástasis	train-set-to-publish/cantemist-norm/cc_onco71.ann
8500/6	metástasis de carcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco71.ann
8270/3	carcinoma de células cromófobas	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	lesión supra-acetabular cadera	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	lesión costal izquierda (partes blandas)	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	masa localizada en polo superior del riñón	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	lesiones blásticas	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	lesión lítica L4-L5	train-set-to-publish/cantemist-norm/cc_onco71.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco541.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco541.ann
9709/3	Linfoma cutáneo primario T	train-set-to-publish/cantemist-norm/cc_onco541.ann
9700/3	micosis fungoide	train-set-to-publish/cantemist-norm/cc_onco541.ann
8000/6	T1N0M0	train-set-to-publish/cantemist-norm/cc_onco541.ann
9718/3	linfoma cutáneo primario T tipo micosis fungoide con nódulos de transformación a células grandes CD30 +	train-set-to-publish/cantemist-norm/cc_onco541.ann
9700/3	micosis fungoide	train-set-to-publish/cantemist-norm/cc_onco541.ann
9718/3	linfoma T de células grandes	train-set-to-publish/cantemist-norm/cc_onco541.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco541.ann
8140/0	Adenoma	train-set-to-publish/cantemist-norm/cc_onco330.ann
8140/0	Adenoma	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco330.ann
8500/6	Metástasis de carcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/3/H	cáncer inflamatorio	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/3/H	tumor neurogénico	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/3/H	tumor neurogénico	train-set-to-publish/cantemist-norm/cc_onco330.ann
8000/3/H	Cáncer inflamatorio	train-set-to-publish/cantemist-norm/cc_onco330.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco587.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco587.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco587.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco587.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco587.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco32.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco32.ann
8140/6	adenocarcinoma de recto-sigma KRAS nativo, con metástasis	train-set-to-publish/cantemist-norm/cc_onco32.ann
8140/6	adenocarcinoma de sigma ypT3 N1b M1	train-set-to-publish/cantemist-norm/cc_onco32.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco32.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco826.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco826.ann
8520/6	Recaída múltiple a nivel de tracto digestivo (esofágica y rectal) de carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco826.ann
8520/6	metástasis de carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/6	adenopatías axilares o supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/6	afectación visceral	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/6	progresión esofágica	train-set-to-publish/cantemist-norm/cc_onco826.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco961.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco961.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco961.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco961.ann
9508/34	Tumor rabdoide-teratoide atípico grado IV de la Organización Mundial de la Salud (OMS)	train-set-to-publish/cantemist-norm/cc_onco961.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco271.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco271.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco271.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco271.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco271.ann
8004/3	tumor de células fusiformes	train-set-to-publish/cantemist-norm/cc_onco271.ann
8936/3	tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco271.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco271.ann
8001/3	celularidad maligna	train-set-to-publish/cantemist-norm/cc_onco271.ann
8000/6	implantes peritoneales múltiples	train-set-to-publish/cantemist-norm/cc_onco271.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco704.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco704.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco704.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco704.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco704.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco20.ann
8170/3	hepatocarcinoma	train-set-to-publish/cantemist-norm/cc_onco20.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco20.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco20.ann
8077/0	Lesión escamosa intraepitelial (SIL) de bajo grado	train-set-to-publish/cantemist-norm/cc_onco20.ann
8077/0	CIN I	train-set-to-publish/cantemist-norm/cc_onco20.ann
8077/0	SIL	train-set-to-publish/cantemist-norm/cc_onco20.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco377.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco377.ann
8481/3	adenocarcinoma mucosecretor	train-set-to-publish/cantemist-norm/cc_onco377.ann
8140/31	Adenocarcinoma pancreático de bajo grado	train-set-to-publish/cantemist-norm/cc_onco377.ann
8000/6	pT2pN1M0	train-set-to-publish/cantemist-norm/cc_onco377.ann
8140/31	Adenocarcinoma de pancreas de bajo grado	train-set-to-publish/cantemist-norm/cc_onco377.ann
8000/6	pT2pN1M0	train-set-to-publish/cantemist-norm/cc_onco377.ann
8720/3	Melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco467.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco467.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco467.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco467.ann
8720/6	recidiva intestinal de melanoma	train-set-to-publish/cantemist-norm/cc_onco467.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco893.ann
9120/33	Angiosarcoma cutáneo convencional de 4,5 cm, grado histológico 3 (según sistema de gradación de la FNCLCC)	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco893.ann
9120/6	metástasis de angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco893.ann
8000/6	nódulo subcutáneo	train-set-to-publish/cantemist-norm/cc_onco893.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco39.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco39.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco39.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco39.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco39.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco39.ann
8000/1	tumoración previsiblemente benigna	train-set-to-publish/cantemist-norm/cc_onco39.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/33	adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco457.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco457.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco457.ann
8490/3	células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/1	neoplásicas	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco457.ann
8144/33	adenocarcinoma gástrico tipo intestinal, grado 3	train-set-to-publish/cantemist-norm/cc_onco457.ann
8140/33	adenocarcinoma gástrico pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco457.ann
8000/6	masa biliopancreática	train-set-to-publish/cantemist-norm/cc_onco457.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco192.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco192.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco192.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/31	tumor neuroendocrino (TNE) G1	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/6	Metástasis retroocular de tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/31	TNE grado I	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/31	TNE G1	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	tumor de características neuroendocrinas	train-set-to-publish/cantemist-norm/cc_onco192.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	nódulo de 1,2 cm de localización retroorbitaria	train-set-to-publish/cantemist-norm/cc_onco192.ann
8000/6	nódulo de localización posterior al globo ocular	train-set-to-publish/cantemist-norm/cc_onco192.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco49.ann
8520/3	carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco49.ann
8520/32	carcinoma lobulillar infiltrante grado II de Nottingham	train-set-to-publish/cantemist-norm/cc_onco49.ann
8520/3	Carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco49.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco49.ann
8520/6	metástasis de carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco49.ann
8000/6	cT2N0M0	train-set-to-publish/cantemist-norm/cc_onco850.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco850.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco850.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco850.ann
8500/3	cáncer de mama ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco850.ann
8000/3	SCHMO	train-set-to-publish/cantemist-norm/cc_onco850.ann
8000/3	SCHMO	train-set-to-publish/cantemist-norm/cc_onco850.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	pT3aN0M0	train-set-to-publish/cantemist-norm/cc_onco157.ann
8720/6	metástasis subcutánea de melanoma	train-set-to-publish/cantemist-norm/cc_onco157.ann
8720/6	melanoma diagnosticado en el año 1992, metastásico	train-set-to-publish/cantemist-norm/cc_onco157.ann
8720/6	melanoma metastásico	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco157.ann
8000/6	nódulo peritoneal	train-set-to-publish/cantemist-norm/cc_onco157.ann
8441/34	Carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco233.ann
8441/64	metástasis de carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco233.ann
8000/6	implantes en omento	train-set-to-publish/cantemist-norm/cc_onco233.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco317.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco317.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco317.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco317.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco317.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco317.ann
8000/3	neoformación pulmonar maligna	train-set-to-publish/cantemist-norm/cc_onco317.ann
8000/6	T4N1MO	train-set-to-publish/cantemist-norm/cc_onco317.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco974.ann
8140/33	adenocarcinoma Gleason 8	train-set-to-publish/cantemist-norm/cc_onco974.ann
8140/33	adenocarcinoma de próstata Gleason 8	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco974.ann
8574/6	infiltración de médula ósea por carcinoma de próstata con diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco974.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco196.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco196.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco196.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco196.ann
8000/3/H	tumor maligno de la vaina nerviosa	train-set-to-publish/cantemist-norm/cc_onco196.ann
8000/3/H	Tumor maligno de la vaina nerviosa	train-set-to-publish/cantemist-norm/cc_onco196.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco327.ann
8550/31	Adenocarcinoma acinar bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco327.ann
8470/31	Cistoadenocarcinoma de ovario mucinosos bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/6	(LOEs) en riñón	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/6	LOEs renales	train-set-to-publish/cantemist-norm/cc_onco327.ann
8010/3/H	carcinoma multifocal	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1/H	neoplasias pancreáticas exocrinas	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/1/H	tumor primario sería de estirpe exocrina	train-set-to-publish/cantemist-norm/cc_onco327.ann
8154/3	neoplasia de páncreas de orígen mixto	train-set-to-publish/cantemist-norm/cc_onco327.ann
8154/3	Adenocarcinoma Acinar Endocrino	train-set-to-publish/cantemist-norm/cc_onco327.ann
8000/6	lesiones renales	train-set-to-publish/cantemist-norm/cc_onco327.ann
8150/1	neoplasias de estirpe endocrinas	train-set-to-publish/cantemist-norm/cc_onco327.ann
8154/3	Adenocarcinoma Acinar Endocrino	train-set-to-publish/cantemist-norm/cc_onco327.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco109.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco109.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco109.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco109.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	tumoral a distancia	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/3	CM	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	pT2N0M0	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	adenopatía (ADP) en la región supraclavicular	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	ADP supraclavicular	train-set-to-publish/cantemist-norm/cc_onco109.ann
8500/6	metástasis de CDI	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	lesión ósea	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	lesión ósea	train-set-to-publish/cantemist-norm/cc_onco109.ann
8500/6	metástasis de CDI	train-set-to-publish/cantemist-norm/cc_onco109.ann
8500/6	oligometastásica de CDI	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco109.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco425.ann
8583/1	timoma tipo B1	train-set-to-publish/cantemist-norm/cc_onco425.ann
8584/3	timoma tipo B2 invasor	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	implantes intraabdominales	train-set-to-publish/cantemist-norm/cc_onco425.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	lesiones pleurales	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	progresión pleural	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	progresión a nivel pleuropulmonar	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	enfermedad locorregional y pleural	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	enfermedad a nivel pleural	train-set-to-publish/cantemist-norm/cc_onco425.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco766.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco766.ann
8000/1	neoplásicas	train-set-to-publish/cantemist-norm/cc_onco766.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco766.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/6	cáncer de colon derecho metastásico	train-set-to-publish/cantemist-norm/cc_onco559.ann
8140/6	adenocarcinoma de sigma con metástasis	train-set-to-publish/cantemist-norm/cc_onco559.ann
8140/31	adenocarcinoma de tipo colorrectal bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/6	progresión tumoral a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco559.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/0	fibromatosis	train-set-to-publish/cantemist-norm/cc_onco988.ann
8000/0	Fibromatosis	train-set-to-publish/cantemist-norm/cc_onco988.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco634.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	implante peritoneal	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco634.ann
8310/6	metástasis de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco634.ann
8936/3	tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco634.ann
8310/34	carcinoma de células claras de 1,4cm pT1pN0M0, grado IV de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	pT1pN0M0	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	masa abdominal	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	recidiva a nivel perihepático	train-set-to-publish/cantemist-norm/cc_onco634.ann
8310/6	carcinoma renal de células claras metastásico	train-set-to-publish/cantemist-norm/cc_onco634.ann
8310/6	CCRm	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	masa en la pared abdominal	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/6	nódulos subcutáneos	train-set-to-publish/cantemist-norm/cc_onco634.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco675.ann
9180/3/H	osteosarcoma esclerosante	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/6	tumoral a distancia	train-set-to-publish/cantemist-norm/cc_onco675.ann
9180/6	Osteosarcoma metastásico	train-set-to-publish/cantemist-norm/cc_onco675.ann
8800/1	neoplasia mesenquimal	train-set-to-publish/cantemist-norm/cc_onco675.ann
9180/6	metástasis de osteosarcoma osteoblástico	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/6	lesiones en pulmón	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/6	masa pulmonar	train-set-to-publish/cantemist-norm/cc_onco675.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco783.ann
8580/1	neoplasia tímica	train-set-to-publish/cantemist-norm/cc_onco783.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco783.ann
8000/6	neoplásica metastásica	train-set-to-publish/cantemist-norm/cc_onco783.ann
8000/6	neoplásico con afectación metastásica	train-set-to-publish/cantemist-norm/cc_onco783.ann
8140/6	Metástasis de Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/6	metastasica	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco302.ann
8140/6	metástasis de Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco302.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/1	neoplasico	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/6	pT1N0M0	train-set-to-publish/cantemist-norm/cc_onco302.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco302.ann
8490/3	adenocarcinoma de células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco302.ann
8140/6	adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco302.ann
8041/3	metástasis de carcinoma neuroendocrino de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco302.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco396.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco396.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco396.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco396.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco396.ann
8140/6	adenocarcinoma de pulmón T4N3M1c	train-set-to-publish/cantemist-norm/cc_onco396.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco64.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco64.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco64.ann
8500/33	carcinoma ductal infiltrante con patrón sólido predominantemente grado histológico 3	train-set-to-publish/cantemist-norm/cc_onco64.ann
8230/3	carcinoma ductal infiltrante con patrón sólido	train-set-to-publish/cantemist-norm/cc_onco64.ann
8500/33	Carcinoma ductal infiltrante de mama izquierda de 2 cm, grado 3	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/6	cT2cN1M0	train-set-to-publish/cantemist-norm/cc_onco64.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco583.ann
8240/6	NET metastásico	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/11	tumor de bajo grado	train-set-to-publish/cantemist-norm/cc_onco583.ann
8240/6	tumor neuroendocrino de intestino delgado metastásico	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco583.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco7.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco7.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco7.ann
8012/34	Carcinoma indiferenciado de célula grande	train-set-to-publish/cantemist-norm/cc_onco7.ann
8140/6	adenocarcinoma estadio IV B (cTx, cN3, cM1b	train-set-to-publish/cantemist-norm/cc_onco7.ann
8041/3	CPCNP	train-set-to-publish/cantemist-norm/cc_onco7.ann
8000/6	afectación pulmonar, adenopática mediastínica, hepática	train-set-to-publish/cantemist-norm/cc_onco7.ann
8000/6	lesiones osteoblásticas	train-set-to-publish/cantemist-norm/cc_onco7.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco370.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco370.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco370.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco370.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/1	neo-formación	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/31	adenocarcinoma bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco370.ann
8500/31	adenocarcinoma ductal bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/6	implantes, 2 de ellos en intestino delgado	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/6	implante subcutáneo	train-set-to-publish/cantemist-norm/cc_onco370.ann
8140/6	metástasis por adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco370.ann
8000/6	enfermedad (PE) pulmonar	train-set-to-publish/cantemist-norm/cc_onco370.ann
8860/0	angiomiolipoma	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	implante tumoral	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco269.ann
8441/63	Adenocarcinoma seroso de ovario G3 estadio IV por afectación pleural	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco269.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco269.ann
8441/33	Adenocarcinoma seroso G3	train-set-to-publish/cantemist-norm/cc_onco269.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco269.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	masa residual retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	masa mesentérica	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	afectación meníngea	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	lesiones intraparenquimatosas	train-set-to-publish/cantemist-norm/cc_onco269.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco34.ann
9080/0	teratoma quístico	train-set-to-publish/cantemist-norm/cc_onco34.ann
9080/6	teratoma con degeneración maligna, con metástasis	train-set-to-publish/cantemist-norm/cc_onco34.ann
9080/6	teratoma maligno mediastínico estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco34.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	neoplasia renal izquierda primaria con metástasis	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco459.ann
8310/31	carcinoma renal de células claras grado de Fuhrman I	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco459.ann
8310/32	carcinoma renal de células claras bifocal grado nuclear II (Fuhrman)	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco459.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco459.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco345.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/34	neoplasia de alto grado de malignidad	train-set-to-publish/cantemist-norm/cc_onco345.ann
9401/3	tumor astrocitario de alto grado	train-set-to-publish/cantemist-norm/cc_onco345.ann
8041/3	Ca microcítico	train-set-to-publish/cantemist-norm/cc_onco345.ann
8041/6	Carcinoma microcítico de pulmón hiliar derecho, con metástasis	train-set-to-publish/cantemist-norm/cc_onco345.ann
8041/6	microcítico de pulmón mestastásico	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/6	(LOE ) frontal	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/6	LOE cerebral	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/6	recidiva tumoral a nivel craneal	train-set-to-publish/cantemist-norm/cc_onco345.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	neoplasia pulmonar metastásica	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	afectación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	adenopático supraclavicular	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	afectación de glándula suprarrenal	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	neoplasia pulmonar metastásica	train-set-to-publish/cantemist-norm/cc_onco758.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco758.ann
9698/3	linfoma folicular, grado 3A	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	malignas	train-set-to-publish/cantemist-norm/cc_onco758.ann
9698/6	linfoma folicular grado 3A estadio IVA (metástasis	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	consolidaciones pulmonares	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco758.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco808.ann
9120/0	hemangiomas	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco808.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco808.ann
9020/1	tumor Phyllodes	train-set-to-publish/cantemist-norm/cc_onco808.ann
8010/3/H	carcinoma infiltrante con grado histológico III	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	(LOE) en el hígado	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	LOE hepáticas	train-set-to-publish/cantemist-norm/cc_onco808.ann
8246/61	metástasis hepática de carcinoma neuroendocrino bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco808.ann
8240/3	tumores neuroendocrinos	train-set-to-publish/cantemist-norm/cc_onco808.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco808.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco284.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco284.ann
8140/6	adenocarcinoma de uraco estadio IV por recaída peritoneal	train-set-to-publish/cantemist-norm/cc_onco284.ann
8480/3	adenocarcinoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco284.ann
8480/3	adenocarcinoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/6	afectación secundaria	train-set-to-publish/cantemist-norm/cc_onco284.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco284.ann
8480/3	adenocarcinoma de patrón mucinoso	train-set-to-publish/cantemist-norm/cc_onco284.ann
8120/31	carcinoma urotelial de bajo grado	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco284.ann
8490/3	adenocarcinoma de patrón mucinoso, con presencia de células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco284.ann
8490/3	"adenocarcinoma mucinoso (coloide) con componente de células ""en anillo de sello"""	train-set-to-publish/cantemist-norm/cc_onco284.ann
8000/6	afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco284.ann
8070/3	carcinoma escamoso	train-set-to-publish/cantemist-norm/cc_onco528.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/6	diseminación neoplásica	train-set-to-publish/cantemist-norm/cc_onco528.ann
8072/33	carcinoma escamoso no queratinizante, mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/6	cT3N0M0	train-set-to-publish/cantemist-norm/cc_onco528.ann
8072/33	carcinoma escamoso no queratinizante, mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco528.ann
8070/2	carcinoma escamoso in situ	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/6	pT4N0M0	train-set-to-publish/cantemist-norm/cc_onco528.ann
8000/1	neoproliferativo	train-set-to-publish/cantemist-norm/cc_onco528.ann
9872/3	Leucemia aguda mieloblástica	train-set-to-publish/cantemist-norm/cc_onco714.ann
9220/3	condrosarcoma	train-set-to-publish/cantemist-norm/cc_onco714.ann
9220/3	condrosarcoma	train-set-to-publish/cantemist-norm/cc_onco714.ann
8800/3	sarcomas	train-set-to-publish/cantemist-norm/cc_onco714.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco714.ann
9866/3	Leucemia aguda mieloblástica (fenotipo sugestivo de M3)	train-set-to-publish/cantemist-norm/cc_onco714.ann
9866/3	leucemia aguda mieloblástica M3	train-set-to-publish/cantemist-norm/cc_onco714.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco516.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco516.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco516.ann
8041/34/H	carcinoma indiferenciado de célula pequeña infiltrante	train-set-to-publish/cantemist-norm/cc_onco516.ann
8041/3	carcinoma neuroendocrino de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco516.ann
8041/3	carcinoma neuroendocrino de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco516.ann
8041/3	Carcinoma neuroendocrino de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco516.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco27.ann
8460/3	adenocarcinoma seroso papilar	train-set-to-publish/cantemist-norm/cc_onco27.ann
8980/3	Carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco27.ann
8950/3	tumor mülleriano mixto maligno	train-set-to-publish/cantemist-norm/cc_onco27.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco27.ann
8805/34	sarcoma indiferenciado de alto grado	train-set-to-publish/cantemist-norm/cc_onco27.ann
8441/34	Carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco27.ann
8010/2	carcinoma intraepitelial	train-set-to-publish/cantemist-norm/cc_onco27.ann
8441/34	Carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco27.ann
8010/2	carcinoma intraepitelial	train-set-to-publish/cantemist-norm/cc_onco27.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco27.ann
8441/64	adenocarcinoma seroso de alto grado, siendo un estadio UICC pT3c pN1 pM1	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/6	implantes miliares a nivel del peritoneo	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/6	implante de epiplón	train-set-to-publish/cantemist-norm/cc_onco27.ann
8000/6	implantes en el peritoneo	train-set-to-publish/cantemist-norm/cc_onco27.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco872.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco872.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco872.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/34	tumor indiferenciado, con grado nuclear (G) alto (G3)	train-set-to-publish/cantemist-norm/cc_onco872.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco707.ann
8140/3/H	adenocarcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco707.ann
8140/31/H	adenocarcinoma infiltrante bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco707.ann
8140/3	adenoma maligno	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/34	maligna de alto grado	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/6	infiltración ósea	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/6	infiltración ósea	train-set-to-publish/cantemist-norm/cc_onco707.ann
8000/6	lesión ósea	train-set-to-publish/cantemist-norm/cc_onco707.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco328.ann
8895/0	mioma	train-set-to-publish/cantemist-norm/cc_onco328.ann
8000/6	pT3N2b(+9/23)M0	train-set-to-publish/cantemist-norm/cc_onco328.ann
8000/6	T1N0M0	train-set-to-publish/cantemist-norm/cc_onco794.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco794.ann
8310/3	carcinoma de células renales tipo células claras	train-set-to-publish/cantemist-norm/cc_onco794.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco794.ann
8312/34	carcinoma de células renales tipo células claras, estadio patológico pT1b, grado nuclear Fuhrman III/IV	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/6	enfermedad radiológica pulmonar	train-set-to-publish/cantemist-norm/cc_onco794.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco971.ann
8310/32	carcinoma renal de células claras con infiltración capsular, grado 2 de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	neoplasia renal metastásica	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	cM1	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/6	progresión local y pulmonar	train-set-to-publish/cantemist-norm/cc_onco971.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco488.ann
8247/3	carcinoma de las células de Merkel	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco488.ann
8041/6	metástasis por carcinoma neuroendocrino de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco488.ann
8247/3	carcinoma de las células de Merkel	train-set-to-publish/cantemist-norm/cc_onco488.ann
8247/6	Carcinoma de células de Merkel estadio IV por implante rectovaginal	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco488.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco488.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/1	Tumoración	train-set-to-publish/cantemist-norm/cc_onco50.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco50.ann
8500/33	carcinoma ductal infiltrante (CDI) grado III	train-set-to-publish/cantemist-norm/cc_onco50.ann
8500/33	carcinoma ductal infiltrante grado 3	train-set-to-publish/cantemist-norm/cc_onco50.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco50.ann
9120/3	Angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco50.ann
8810/3	fibrosarcoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
8830/3	histiocitoma fibroso maligno	train-set-to-publish/cantemist-norm/cc_onco286.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco286.ann
9732/3	mieloma	train-set-to-publish/cantemist-norm/cc_onco286.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
9180/3	osteosarcoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco286.ann
9680/3	Linfoma de Hodgkin difuso centroblástico	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/1/H	tumoración fibroblástica	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/6	pT1-2N0M0	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/6	pT1-2N0M0	train-set-to-publish/cantemist-norm/cc_onco286.ann
8000/1	neoproliferativo	train-set-to-publish/cantemist-norm/cc_onco286.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	T2N2M0	train-set-to-publish/cantemist-norm/cc_onco923.ann
8070/3	Carcinoma de pulmón no microcítico (CPNM) de tipo epidermoide	train-set-to-publish/cantemist-norm/cc_onco923.ann
8046/3	CPNM	train-set-to-publish/cantemist-norm/cc_onco923.ann
8046/3	Carcinoma de pulmón no microcítico	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/1/H	neoplasia mucinosa	train-set-to-publish/cantemist-norm/cc_onco923.ann
8452/1	neoplasia sólido-quística	train-set-to-publish/cantemist-norm/cc_onco923.ann
8452/1	neoplasia sólido-quística	train-set-to-publish/cantemist-norm/cc_onco923.ann
8070/62	metástasis de carcinoma escamoso moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masas nodulares sólidas de situación suprarrenal	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masas suprarrenales	train-set-to-publish/cantemist-norm/cc_onco923.ann
8070/3	CA epidermoide	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco923.ann
8070/3	CA epidermoide	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masa de la suprarrenal	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	lesión sólida en suprarrenal	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	lesión hipodensa en cuerpo de páncreas	train-set-to-publish/cantemist-norm/cc_onco923.ann
8070/6	MTS de CA epidermoide	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masa en la cola del páncreas	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	masa pancreática	train-set-to-publish/cantemist-norm/cc_onco923.ann
8000/6	T1N0M0	train-set-to-publish/cantemist-norm/cc_onco5.ann
8825/1	Tumor Miofibroblástico inflamatorio	train-set-to-publish/cantemist-norm/cc_onco5.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco5.ann
8001/1	celularidad tumoral	train-set-to-publish/cantemist-norm/cc_onco5.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco864.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco864.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	T3N2M1b	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	implante retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	lesiones subcutáneas	train-set-to-publish/cantemist-norm/cc_onco864.ann
8720/6	metástasis solitaria intramedular de melanoma	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	implante mesentérico	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	Nódulo retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	enfermedad a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	lesión medular	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco864.ann
8000/6	T3N1M0	train-set-to-publish/cantemist-norm/cc_onco4.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco4.ann
8070/3	carcinoma de células escamosas	train-set-to-publish/cantemist-norm/cc_onco4.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco4.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/6	lesiones pleurales	train-set-to-publish/cantemist-norm/cc_onco4.ann
8586/3	carcinoma tímico	train-set-to-publish/cantemist-norm/cc_onco4.ann
8586/3	carcinoma tímico	train-set-to-publish/cantemist-norm/cc_onco4.ann
8140/31	adenocarcinoma de colon bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco4.ann
8070/6	carcinoma escamoso pulmonar metastásico	train-set-to-publish/cantemist-norm/cc_onco4.ann
8586/6	carcinoma tímico escamoso con afectación pleural	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco4.ann
8000/6	afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco633.ann
8200/3	carcinoma adenoide quístico	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco633.ann
9960/3	síndrome mieloproliferativo crónico	train-set-to-publish/cantemist-norm/cc_onco633.ann
9962/3	trombocitemia esencial	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco633.ann
8200/32	carcinoma adenoide quístico grado 2	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	pT2N1miM0	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	nódulos diafragmáticos	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	pleura visceral y parietal con lesiones	train-set-to-publish/cantemist-norm/cc_onco633.ann
8200/3	adenoide quístico	train-set-to-publish/cantemist-norm/cc_onco633.ann
8200/6	carcinoma adenoide quístico metastásico	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/6	recaída sistémica	train-set-to-publish/cantemist-norm/cc_onco633.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco940.ann
8140/31	adenocarcinoma de próstata grado combinado Gleason 6	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco940.ann
8010/6	metastásicas vertebrales por carcinoma	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/3	neoplásica	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/6	afectación casi completa de los cuerpos vertebrales	train-set-to-publish/cantemist-norm/cc_onco940.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco940.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco613.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco613.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco613.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco613.ann
8000/6	invasión de 4ª a 6ª vértebras	train-set-to-publish/cantemist-norm/cc_onco613.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco59.ann
8858/32	liposarcoma desdiferenciado de 27 cm, grado 2	train-set-to-publish/cantemist-norm/cc_onco59.ann
8858/32	liposarcoma retroperitoneal desdiferenciado grado 2	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco59.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco79.ann
8310/6	metástasis de carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco79.ann
8310/6	metástasis de carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/6	pT1aN0M0	train-set-to-publish/cantemist-norm/cc_onco79.ann
8310/3/H	carcinoma de células claras de patrón tubuloquístico	train-set-to-publish/cantemist-norm/cc_onco79.ann
8310/3	carcinoma de ovario de células claras	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco79.ann
8010/6	carcinoma concordante con origen ovárico metastásico	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/6	lesión en el seno cardiofrénico	train-set-to-publish/cantemist-norm/cc_onco79.ann
8313/3	carcinoma de células claras de patrón tubuloquístico asociado a áreas de patrón adenofibroso	train-set-to-publish/cantemist-norm/cc_onco79.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco531.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco531.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco531.ann
8000/6	micrometastásica	train-set-to-publish/cantemist-norm/cc_onco531.ann
8720/6	Recaída locorregional, ganglionar y pulmonar de melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco531.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco531.ann
8000/6	Adenopatías patológicashipervasculares supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco531.ann
8000/6	adenopatías laterocervicales bilaterales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco531.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco168.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco168.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco168.ann
9591/3	linfoma difuso de células B	train-set-to-publish/cantemist-norm/cc_onco168.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco168.ann
8140/6	Adenocarcinoma de sigma diseminado	train-set-to-publish/cantemist-norm/cc_onco168.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco605.ann
8000/6	diseminación pulmonar	train-set-to-publish/cantemist-norm/cc_onco605.ann
9064/3	neoplasia de estirpe germinal	train-set-to-publish/cantemist-norm/cc_onco605.ann
9064/6	neoplasia de origen germinal diseminada	train-set-to-publish/cantemist-norm/cc_onco605.ann
9100/6	coriocarcinoma primario mediastínico diseminado	train-set-to-publish/cantemist-norm/cc_onco605.ann
8000/6	nódulos hepáticos	train-set-to-publish/cantemist-norm/cc_onco605.ann
8000/6	nódulos tumorales hemorrágicos pulmonares	train-set-to-publish/cantemist-norm/cc_onco605.ann
8000/6	nódulos únicos en riñón	train-set-to-publish/cantemist-norm/cc_onco605.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco815.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco815.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco815.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/1	cTxcN2cM 1	train-set-to-publish/cantemist-norm/cc_onco815.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco823.ann
8000/3/H	tumor maligno de crecimiento bifásico	train-set-to-publish/cantemist-norm/cc_onco823.ann
9040/6	metástasis de SS	train-set-to-publish/cantemist-norm/cc_onco823.ann
9040/34	Sarcoma sinovial primario cardiaco de alto grado	train-set-to-publish/cantemist-norm/cc_onco823.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco823.ann
8000/6	lesión de 5 cm entre esófago y ventrículo	train-set-to-publish/cantemist-norm/cc_onco823.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco96.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco96.ann
8840/0	mixoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
8900/3	rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
8900/3	rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
8900/3	rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco96.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco96.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco96.ann
8041/1	tumor de células redondas	train-set-to-publish/cantemist-norm/cc_onco96.ann
8000/6	Adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco102.ann
8012/3	Carcinoma de células grandes	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco102.ann
8046/3	cáncer de pulmón no microcítico	train-set-to-publish/cantemist-norm/cc_onco102.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco102.ann
8012/6	metástasis de carcinoma de células grandes	train-set-to-publish/cantemist-norm/cc_onco102.ann
8000/6	T1N3M0	train-set-to-publish/cantemist-norm/cc_onco102.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco194.ann
8090/3	carcinoma basocelular	train-set-to-publish/cantemist-norm/cc_onco194.ann
8246/3	carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/1/H	tumor mixto	train-set-to-publish/cantemist-norm/cc_onco194.ann
8140/34	adenocarcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco194.ann
8140/34	adecarcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco194.ann
8490/33	adenocarcinoma pobremente diferenciado grado 3 difuso con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco194.ann
8240/3	tumor una diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco194.ann
8490/33	adenocarcinoma pobremente diferenciado con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco194.ann
8145/33	adenocarcinoma pobremente diferenciado grado 3 difuso	train-set-to-publish/cantemist-norm/cc_onco194.ann
8244/3	tumor mixto: adenocarcinoma pobremente diferenciado con células en anillo de sello y carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco194.ann
8000/1	Neoplasia	train-set-to-publish/cantemist-norm/cc_onco276.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco276.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco276.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco276.ann
8800/6	sarcoma cardiaco metastásico	train-set-to-publish/cantemist-norm/cc_onco276.ann
8800/3	tumor cardíaco de estirpe mesenquimal	train-set-to-publish/cantemist-norm/cc_onco276.ann
8804/3	angiosarcoma epiteloide	train-set-to-publish/cantemist-norm/cc_onco276.ann
9120/6	angiosarcoma cardíaco estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco276.ann
8000/6	enfermedad pulmonar	train-set-to-publish/cantemist-norm/cc_onco276.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco442.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco442.ann
8140/6	adenocarcinoma de pulmón estadio IV (T1bN3M1b)	train-set-to-publish/cantemist-norm/cc_onco442.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco610.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco610.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco610.ann
8140/6	Adenocarcinoma de pulmón lóbulo superior derecho (cT1acN2pM1b)	train-set-to-publish/cantemist-norm/cc_onco610.ann
8140/6	adenocarcinoma de 1,5 cm y metástasis	train-set-to-publish/cantemist-norm/cc_onco610.ann
8000/6	estadio IV por cerebral	train-set-to-publish/cantemist-norm/cc_onco610.ann
8000/6	lesión temporoparietal	train-set-to-publish/cantemist-norm/cc_onco610.ann
8247/3	Carcinoma de células de Merkel	train-set-to-publish/cantemist-norm/cc_onco111.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco111.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco111.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco111.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco111.ann
8247/3	tumor de células de Merkel	train-set-to-publish/cantemist-norm/cc_onco111.ann
8247/3	tumor de células de Merkel	train-set-to-publish/cantemist-norm/cc_onco111.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco111.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco1.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco1.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco1.ann
8240/3	TNEp	train-set-to-publish/cantemist-norm/cc_onco897.ann
8240/3	TNEp	train-set-to-publish/cantemist-norm/cc_onco897.ann
8240/3	TNEp	train-set-to-publish/cantemist-norm/cc_onco897.ann
8240/3	TNEp	train-set-to-publish/cantemist-norm/cc_onco897.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco897.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco897.ann
8140/0	adenoma	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco897.ann
9161/1	hemangioblastoma	train-set-to-publish/cantemist-norm/cc_onco897.ann
9161/1	hemangioblastoma	train-set-to-publish/cantemist-norm/cc_onco897.ann
9161/1	hemangioblastomas	train-set-to-publish/cantemist-norm/cc_onco897.ann
9161/1	hemangioblastomas	train-set-to-publish/cantemist-norm/cc_onco897.ann
9161/1	hemangioblastomas	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco897.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco897.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco897.ann
8310/3/H	carcinoma renal de células claras multicéntrico	train-set-to-publish/cantemist-norm/cc_onco897.ann
8860/0	angiomiolipomas	train-set-to-publish/cantemist-norm/cc_onco897.ann
8240/3	Tumor neuroendocrino pancreático bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco897.ann
8860/0	angiomiolipomas	train-set-to-publish/cantemist-norm/cc_onco897.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco291.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco291.ann
8900/3	rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco291.ann
9835/36	leucemia linfoblástica aguda L1 de células B	train-set-to-publish/cantemist-norm/cc_onco291.ann
9835/3	leucemia linfobástica aguda	train-set-to-publish/cantemist-norm/cc_onco291.ann
8920/3	rabdomiosarcoma alveolar	train-set-to-publish/cantemist-norm/cc_onco291.ann
8000/6	adenopatías cervicales, supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco291.ann
8920/3	rabdomiosarcoma alveolar	train-set-to-publish/cantemist-norm/cc_onco291.ann
9800/3	leucemia	train-set-to-publish/cantemist-norm/cc_onco291.ann
8920/3	rabdomiosarcoma alveolar	train-set-to-publish/cantemist-norm/cc_onco291.ann
8441/34	carcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco423.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco423.ann
8950/3	tumor endometrial mülleriano mixto	train-set-to-publish/cantemist-norm/cc_onco423.ann
8950/3	tumor mülleriano mixto	train-set-to-publish/cantemist-norm/cc_onco423.ann
8800/34/H	sarcoma de alto grado con diferenciación rabdomioblástica	train-set-to-publish/cantemist-norm/cc_onco423.ann
8000/6	progresión peritoneal	train-set-to-publish/cantemist-norm/cc_onco423.ann
8000/6	recaída a nivel peritoneal	train-set-to-publish/cantemist-norm/cc_onco423.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco350.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	pT3N0M0	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	nódulos hepáticos	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	lesiones blásticas óseas	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	captación ósea	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	lesiones nodulares hepáticas	train-set-to-publish/cantemist-norm/cc_onco350.ann
8000/6	lesiones blásticas en cuerpos vertebrales	train-set-to-publish/cantemist-norm/cc_onco350.ann
9064/3	TCG	train-set-to-publish/cantemist-norm/cc_onco188.ann
9065/3	TCGNS	train-set-to-publish/cantemist-norm/cc_onco188.ann
9070/3	carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	micronódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco188.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco188.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco188.ann
9064/3/H	tumor de células germinales (TCG) mixto	train-set-to-publish/cantemist-norm/cc_onco188.ann
9065/6	tumor de células germinales no seminomatoso (TCGNS) T2 N3 M1a	train-set-to-publish/cantemist-norm/cc_onco188.ann
9071/3	tumor del seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	lesión retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco188.ann
8000/6	masa retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco188.ann
8001/1	celulas neoplasicas	train-set-to-publish/cantemist-norm/cc_onco82.ann
9530/0	meningioma	train-set-to-publish/cantemist-norm/cc_onco82.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco82.ann
9471/34	meduloblastoma desmoplásico nodular grado IV de la OMS	train-set-to-publish/cantemist-norm/cc_onco82.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco301.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco301.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco301.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco301.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco301.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco301.ann
9370/3	cordoma	train-set-to-publish/cantemist-norm/cc_onco301.ann
9370/3	cordoma	train-set-to-publish/cantemist-norm/cc_onco301.ann
9370/3	cordoma	train-set-to-publish/cantemist-norm/cc_onco301.ann
9064/3	TCG	train-set-to-publish/cantemist-norm/cc_onco148.ann
9064/6	Tumor de células germinales testicular estadio III por enfermedad retroperitoneal	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco148.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco148.ann
9071/3	tumor seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco148.ann
9064/3/H	TCG mixto	train-set-to-publish/cantemist-norm/cc_onco148.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco148.ann
9064/3	tumor germinal maligno	train-set-to-publish/cantemist-norm/cc_onco148.ann
9071/3	tumor de seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/6	masa pélvica	train-set-to-publish/cantemist-norm/cc_onco148.ann
8000/6	afectación pélvica	train-set-to-publish/cantemist-norm/cc_onco148.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco485.ann
9800/3	leucemia	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco485.ann
8140/33	metástasis adenocarcinoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco485.ann
8000/6	progresión pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco485.ann
8480/3	Adenocarcinoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco777.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco777.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco777.ann
8480/3	adenocarcinoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco777.ann
8480/31	adenocarcinoma mucinoso bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco777.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco777.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco777.ann
8000/6	pT4NxM1a	train-set-to-publish/cantemist-norm/cc_onco777.ann
8000/6	derrame pleural maligno	train-set-to-publish/cantemist-norm/cc_onco777.ann
8002/3	cáncer de pulmón de células no pequeñas	train-set-to-publish/cantemist-norm/cc_onco777.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco553.ann
8720/3	melanoma maligno	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	progresión cerebral	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco553.ann
8000/6	progresión franca de la enfermedad adenopática, peritoneal	train-set-to-publish/cantemist-norm/cc_onco553.ann
8440/0	cistoadenoma	train-set-to-publish/cantemist-norm/cc_onco870.ann
9120/0	hemangiomas	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco870.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco870.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco870.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco870.ann
8330/1	tumor folicular	train-set-to-publish/cantemist-norm/cc_onco870.ann
9090/3	Struma ovárico maligno	train-set-to-publish/cantemist-norm/cc_onco870.ann
9090/6	Struma ovárico metastatizado	train-set-to-publish/cantemist-norm/cc_onco870.ann
9090/1	Struma ovarii	train-set-to-publish/cantemist-norm/cc_onco870.ann
9090/6	Teratoma maligno con diferenciación folicular (Struma ovarii) con afectación hepática	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	lesión focal hepática	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	foco hipermetabólico a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco870.ann
9090/6	metástasis de estruma ovárico maligno	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	lesiones ocupantes de espacio localizadas en parénquima hepático	train-set-to-publish/cantemist-norm/cc_onco870.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco870.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco916.ann
8046/3	carcinoma no célula pequeña	train-set-to-publish/cantemist-norm/cc_onco916.ann
8033/3	carcinoma sarcomatoide	train-set-to-publish/cantemist-norm/cc_onco916.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco916.ann
8004/3	tumor maligno con presencia de células fusiformes	train-set-to-publish/cantemist-norm/cc_onco916.ann
8033/6	neoplasia de origen pulmonar de características sarcomatoides con metástasis	train-set-to-publish/cantemist-norm/cc_onco916.ann
8033/1	tumores de estirpe sarcomatoide	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8046/3	CPNCP	train-set-to-publish/cantemist-norm/cc_onco916.ann
8046/6	CPNCP en estadio IV por afectación ósea	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	implante tumoral	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	nódulo en espacio pararrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	lesión adrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	nódulo en el espacio pararrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	masa suprarrenal	train-set-to-publish/cantemist-norm/cc_onco916.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco22.ann
8000/6	Lesión focal hepática	train-set-to-publish/cantemist-norm/cc_onco247.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco247.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco247.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco247.ann
8140/6	Adenocarcinoma rectal T3N1M1	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	lesión segmento VI hepática	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	lesión ocupante de espacio en segmento VI hepático	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	lesión en el segmento VI hepático	train-set-to-publish/cantemist-norm/cc_onco247.ann
8000/6	afectación secundaria	train-set-to-publish/cantemist-norm/cc_onco679.ann
8013/3	carcinoma neuroendocrino de célula grande	train-set-to-publish/cantemist-norm/cc_onco679.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco679.ann
8140/0	macroadenoma	train-set-to-publish/cantemist-norm/cc_onco679.ann
8046/33	carcinoma no célula pequeña, pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco679.ann
8013/3	carcinoma neuroendocrino de células grandes	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	diseminación a nivel infradiafragmático	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	implantes a nivel subcutáneo	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	lesiones subcutáneas	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	lesiones parenquimatosas	train-set-to-publish/cantemist-norm/cc_onco679.ann
8000/6	lesión pituitaria	train-set-to-publish/cantemist-norm/cc_onco679.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco795.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco795.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco795.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco795.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco225.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco225.ann
8500/33	CDI grado histológico III	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	pT1N3M0	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco225.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco525.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco525.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco525.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco525.ann
8140/31	adenocarcinoma enteroide bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco525.ann
8481/3	adenocarcinoma enteroide bien diferenciado con 10 % de componente mucosecretor	train-set-to-publish/cantemist-norm/cc_onco525.ann
8140/31	adenocarcinoma enteroide bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco525.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco525.ann
8000/6	diseminación tumoral	train-set-to-publish/cantemist-norm/cc_onco525.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco394.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco394.ann
8480/31	adenocarcinoma mucinoso bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco394.ann
8480/6	Adenocarcinoma mucinoso de uraco estadio IV por afectación peritoneal	train-set-to-publish/cantemist-norm/cc_onco394.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco394.ann
8490/31	adenocarcinoma mucinoso bien diferenciado, con aisladas células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco394.ann
8000/6	progresión peritoneal	train-set-to-publish/cantemist-norm/cc_onco394.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco453.ann
8033/1	sarcomatoide	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/13	tumoral pobremente diferenciada	train-set-to-publish/cantemist-norm/cc_onco453.ann
8004/1	neoplasia fusocelular	train-set-to-publish/cantemist-norm/cc_onco453.ann
8122/64	carcinoma urotelial de alto grado con diferenciación sarcomatoide estadio IV (pT4N2M1)	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco453.ann
8000/6	enfermedad a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco453.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco202.ann
9161/1	hemangioblastoma	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco202.ann
9064/2	neoplasia germinal intratubular	train-set-to-publish/cantemist-norm/cc_onco202.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco202.ann
8720/0/H	nevus melanocítico lentiginoso	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	N0M0	train-set-to-publish/cantemist-norm/cc_onco202.ann
9065/3	Carcinoma germinal de testículo no seminomatoso	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	pT1N0M0	train-set-to-publish/cantemist-norm/cc_onco202.ann
9071/3	yolk-sac	train-set-to-publish/cantemist-norm/cc_onco202.ann
9085/3	tumores de estirpe germinal mixtos	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/6	metástasis del tumor	train-set-to-publish/cantemist-norm/cc_onco202.ann
9064/3	tumor primario de origen germinal	train-set-to-publish/cantemist-norm/cc_onco202.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco202.ann
9081/3	teratoma maligno mixto con áreas de carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco202.ann
8721/3	Melanoma Nodular	train-set-to-publish/cantemist-norm/cc_onco235.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco235.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco235.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco235.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco235.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco235.ann
9440/3	glioblastoma	train-set-to-publish/cantemist-norm/cc_onco181.ann
9440/3	glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco181.ann
9440/3	glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco181.ann
9440/3	glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco181.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco181.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco905.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco905.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco905.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco905.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco371.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco371.ann
8500/31	carcinoma ductal infiltrante de mama grado I	train-set-to-publish/cantemist-norm/cc_onco371.ann
8500/31	carcinoma ductal infiltrante grado I	train-set-to-publish/cantemist-norm/cc_onco371.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/6	Metástasis en trígono retromolar de un adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco647.ann
8000/6	lesión exofítica en trígono retromolar	train-set-to-publish/cantemist-norm/cc_onco647.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco597.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/6	diseminación hepática	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/6	progresión radiológica a nivel peritoneal	train-set-to-publish/cantemist-norm/cc_onco597.ann
8000/6	nódulos hipodensos en ambos lóbulos hepáticos	train-set-to-publish/cantemist-norm/cc_onco597.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco213.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco213.ann
8046/3	carcinoma no de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco213.ann
8140/6	metástasis pulmonar de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco213.ann
8140/6	adenocarcinoma compatible con metástasis	train-set-to-publish/cantemist-norm/cc_onco213.ann
8140/6	Metástasis intratraqueal de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	nódulo de 2,3 cm en el LSD	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	lesión en intratraqueal	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco213.ann
8000/6	lesión traqueal	train-set-to-publish/cantemist-norm/cc_onco213.ann
9080/0	Teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco804.ann
8170/3	hepatocarcinoma	train-set-to-publish/cantemist-norm/cc_onco804.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco804.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco804.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco804.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco804.ann
8574/3	diferenciación neuroendocrina	train-set-to-publish/cantemist-norm/cc_onco804.ann
8576/6	metástasis de carcinoma hepatoide	train-set-to-publish/cantemist-norm/cc_onco804.ann
9071/3	variante hepatoide de tumor germinal tipo seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco804.ann
8576/3	Carcinoma hepatoide	train-set-to-publish/cantemist-norm/cc_onco804.ann
8576/3	carcinoma hepatoide	train-set-to-publish/cantemist-norm/cc_onco804.ann
9071/3	tumor del seno endodérmico hepatoide	train-set-to-publish/cantemist-norm/cc_onco804.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco804.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco804.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	metastásis	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco262.ann
8260/3	adenocarcinoma papilar	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	pM0	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco262.ann
8240/6	metástasis por tumor carcinoide atípico	train-set-to-publish/cantemist-norm/cc_onco262.ann
8240/3	carcinoide pulmonar atipico	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco262.ann
8240/6	metástasis de tumor carcinoide atípico	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco262.ann
8240/3	TNE	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	lesión acetabular sugestiva de implante	train-set-to-publish/cantemist-norm/cc_onco262.ann
8000/6	PE hepática	train-set-to-publish/cantemist-norm/cc_onco262.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco968.ann
8500/6	Carcinoma ductal infiltrante de mama derecha, cT3N1M1	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco968.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco481.ann
8900/3	rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco481.ann
8900/3	Rabdomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco481.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco481.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco481.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco481.ann
8000/6	N1 cervical y supraclavicular	train-set-to-publish/cantemist-norm/cc_onco481.ann
8980/3	Carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8950/3	Tumor mulleriano mixto maligno	train-set-to-publish/cantemist-norm/cc_onco67.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco67.ann
8441/34	adenocarcinoma seroso de alto grado	train-set-to-publish/cantemist-norm/cc_onco67.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8160/3	colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco67.ann
8950/3	tumor mulleriano mixto maligno	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco67.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8802/3	sarcoma pleomorfo	train-set-to-publish/cantemist-norm/cc_onco67.ann
8980/3	carcinosarcoma	train-set-to-publish/cantemist-norm/cc_onco67.ann
8802/3	sarcoma pleomorfo	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/6	enfermedad a nivel peritoneal	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/6	recaída local y peritoneal	train-set-to-publish/cantemist-norm/cc_onco67.ann
8010/3	síndrome de Lynch	train-set-to-publish/cantemist-norm/cc_onco67.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco509.ann
8140/0	adenoma	train-set-to-publish/cantemist-norm/cc_onco509.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco509.ann
8890/3	leiomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco509.ann
8890/3	leiomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco509.ann
8890/3	leiomiosarcoma	train-set-to-publish/cantemist-norm/cc_onco509.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco509.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco509.ann
8004/3	tumor fusocelular maligno	train-set-to-publish/cantemist-norm/cc_onco509.ann
8890/34	leiomiosarcoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco509.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco582.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco582.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco582.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco582.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco582.ann
8720/0	nevus	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/3	NEM	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/3	NEM2	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	LOE hepáticas	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	lesiones sospechosas en mama	train-set-to-publish/cantemist-norm/cc_onco582.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/6	adenocarcinoma de recto inferior, estadio IV (2 metástasis	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	cT3N0M1	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/6	Adenocarcinoma de recto inferior, estadio IV (2 metástasis	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	cT3N0M1	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/6	adenocarcinoma de origen colorrectal ypT3N0 (0/17)M1	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	metastático	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco83.ann
8000/6	progresiones a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco83.ann
8140/6	adenocarcinoma metastásico	train-set-to-publish/cantemist-norm/cc_onco163.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco163.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco163.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco163.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco163.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco163.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco163.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco163.ann
8010/3/H	carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	Ib1N1M0	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	cT2N1M0	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	implante dural	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco163.ann
8140/6	Adenocarcinoma de colon de novo con afectación metastásica	train-set-to-publish/cantemist-norm/cc_onco163.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	lesiones cutáneas	train-set-to-publish/cantemist-norm/cc_onco163.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco81.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco81.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco81.ann
8140/0	adenoma	train-set-to-publish/cantemist-norm/cc_onco81.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco81.ann
9872/3	leucemia mieloblástica aguda	train-set-to-publish/cantemist-norm/cc_onco81.ann
9440/3	glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco957.ann
9440/3	glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco957.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco957.ann
8001/1	células neoplásicas	train-set-to-publish/cantemist-norm/cc_onco957.ann
9380/64	metástasis de tumor glial de alto grado	train-set-to-publish/cantemist-norm/cc_onco957.ann
9380/6	metástasis de tumor glial de alto grado	train-set-to-publish/cantemist-norm/cc_onco957.ann
9440/6	Metástasis ganglionares cervicales bilaterales de un glioblastoma multiforme	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/6	diseminación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/6	diseminación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco957.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco250.ann
8240/3	neoformación maligna, con rasgos neuroendocrinos	train-set-to-publish/cantemist-norm/cc_onco250.ann
8240/32	Tumor neuroendocrino grado 2	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/11	tumor bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco250.ann
8240/3	carcinoide	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco250.ann
8000/3	cancer	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco298.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco298.ann
8409/3	pororcarcinoma ecrino	train-set-to-publish/cantemist-norm/cc_onco298.ann
8409/6	metástasis de porocarcinoma	train-set-to-publish/cantemist-norm/cc_onco298.ann
8409/3	porocarcinoma ecrino	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco298.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco298.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco700.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco700.ann
8500/32	carcinoma ductal infiltrante, grado II	train-set-to-publish/cantemist-norm/cc_onco700.ann
8500/6	Carcinoma ductal infiltrante de mama E IV por afectación ganglionar axilar, hepática	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco700.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco800.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco800.ann
8070/34	carcinoma escamoso de alto grado	train-set-to-publish/cantemist-norm/cc_onco800.ann
8070/32/H	carcinoma escamoso moderadamente diferenciado, infiltrante	train-set-to-publish/cantemist-norm/cc_onco800.ann
8000/6	rpT4NxM0	train-set-to-publish/cantemist-norm/cc_onco800.ann
8001/3	celularidad maligna	train-set-to-publish/cantemist-norm/cc_onco800.ann
8010/33	carcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco800.ann
8000/6	cT1bN0M0	train-set-to-publish/cantemist-norm/cc_onco800.ann
8000/6	pT1N0M0	train-set-to-publish/cantemist-norm/cc_onco800.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco962.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	adenopatías cervicales y supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	adenopatías cervicales y supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco962.ann
8000/6	lesiones focales en los segmentos II y VI hepáticos	train-set-to-publish/cantemist-norm/cc_onco962.ann
8041/3	carcinoma de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco743.ann
8041/3	carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	T4N2M0	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	T2aN2M0	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	T2aN2M0	train-set-to-publish/cantemist-norm/cc_onco743.ann
8041/6	carcinoma metastásico de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco743.ann
8041/6	Metástasis tiroidea de carcinoma microcítico de pulmón	train-set-to-publish/cantemist-norm/cc_onco743.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco743.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco169.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco169.ann
8001/3	células tumorales malignas	train-set-to-publish/cantemist-norm/cc_onco169.ann
8001/3	CTM	train-set-to-publish/cantemist-norm/cc_onco169.ann
8140/6	adenocarcinoma de pulmón derecho metastásico	train-set-to-publish/cantemist-norm/cc_onco169.ann
8001/3	CTM	train-set-to-publish/cantemist-norm/cc_onco169.ann
8010/9	carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco169.ann
8010/9	MC	train-set-to-publish/cantemist-norm/cc_onco169.ann
8010/9	MC	train-set-to-publish/cantemist-norm/cc_onco169.ann
8726/0	Melanocitoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco572.ann
8726/02	melanocitoma de grado intermedio	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	tumorales con afectación ósea	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco572.ann
8726/02	melanocitoma de grado intermedio	train-set-to-publish/cantemist-norm/cc_onco572.ann
9560/3	Schwannoma melanocítico maligno	train-set-to-publish/cantemist-norm/cc_onco572.ann
9560/0	schwannomas	train-set-to-publish/cantemist-norm/cc_onco572.ann
9560/0	schwannomas	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	lesiones cervicales	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	invasión vertebral	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	invasión mediastínica	train-set-to-publish/cantemist-norm/cc_onco572.ann
8000/6	lesión en fosa clavicular	train-set-to-publish/cantemist-norm/cc_onco572.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco91.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco91.ann
8000/6	adenopatías sospechosas a nivel supraclavicular	train-set-to-publish/cantemist-norm/cc_onco91.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco622.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco622.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco622.ann
8000/6	realce meníngeo	train-set-to-publish/cantemist-norm/cc_onco622.ann
8010/9	Carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco654.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco654.ann
9560/0	neurilemoma	train-set-to-publish/cantemist-norm/cc_onco654.ann
9050/3	mesotelioma maligno	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco654.ann
9050/3/H	mesotelioma convencional de patrón túbulo papilar	train-set-to-publish/cantemist-norm/cc_onco654.ann
9050/3/H	mesotelioma monofásico	train-set-to-publish/cantemist-norm/cc_onco654.ann
9050/3	mesotelioma	train-set-to-publish/cantemist-norm/cc_onco654.ann
9050/3/H	Mesotelioma maligno inguinal monofásico	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/6	progresión peritoneal	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/6	infiltración peritoneal	train-set-to-publish/cantemist-norm/cc_onco654.ann
8000/6	infiltración peritoneal	train-set-to-publish/cantemist-norm/cc_onco654.ann
9051/3	sarcomatoides	train-set-to-publish/cantemist-norm/cc_onco654.ann
9120/0	angioma	train-set-to-publish/cantemist-norm/cc_onco755.ann
8312/3	carcinoma de células renales	train-set-to-publish/cantemist-norm/cc_onco755.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	cT3aN0Mx	train-set-to-publish/cantemist-norm/cc_onco755.ann
8310/3	carcinoma de células renales tipo células claras	train-set-to-publish/cantemist-norm/cc_onco755.ann
8310/6	metástasis en parénquima testicular de carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	progresión a nivel testicular	train-set-to-publish/cantemist-norm/cc_onco755.ann
8000/6	lesión de aspecto lítico D11	train-set-to-publish/cantemist-norm/cc_onco755.ann
9064/2	neoplasia intratubular de células germinales	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco55.ann
9064/3	tumor germinal	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco55.ann
9065/3	tumor germinal no seminoma	train-set-to-publish/cantemist-norm/cc_onco55.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1/H	tumor quemado	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/3	sarcoma	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/3	sarcoma	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/3	sarcoma	train-set-to-publish/cantemist-norm/cc_onco55.ann
9070/6	metástasis de carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/34	sarcoma retroperitoneal de alto grado	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/34	sarcoma retroperitoneal de alto grado	train-set-to-publish/cantemist-norm/cc_onco55.ann
9540/33	tumor maligno de la vaina nerviosa periférica), grado histológico 3	train-set-to-publish/cantemist-norm/cc_onco55.ann
8800/3	Sarcoma de partes blandas	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/14	neoplásico de alto grado	train-set-to-publish/cantemist-norm/cc_onco55.ann
9970/1	síndrome linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco55.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco55.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco723.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco723.ann
8800/3	sarcomas	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	realces leptomeníngeos	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	enfermedad periférica	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	enfermedad a nivel periférico	train-set-to-publish/cantemist-norm/cc_onco723.ann
8140/6	adenocarcinoma de pulmón estadio IV por afectación pulmonar bilateral	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	lesiones nodulares supra e infratentoriales	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	Progresión tumoral en el sistema nervioso central	train-set-to-publish/cantemist-norm/cc_onco723.ann
8000/6	progresión en SNC	train-set-to-publish/cantemist-norm/cc_onco723.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco420.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco420.ann
8581/1	timoma tipo A	train-set-to-publish/cantemist-norm/cc_onco420.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco420.ann
8580/1	Timoma	train-set-to-publish/cantemist-norm/cc_onco420.ann
8580/1	timoma	train-set-to-publish/cantemist-norm/cc_onco420.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco537.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco537.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco537.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco537.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco537.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco537.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco537.ann
9500/63	Neuroblastoma poco diferenciado (clasificación INPC/OMS2017) con afectación ganglionar retroperitoneal y hepática	train-set-to-publish/cantemist-norm/cc_onco537.ann
9500/33	neuroblastoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco537.ann
8000/6	peritumorales	train-set-to-publish/cantemist-norm/cc_onco537.ann
8041/3	CARCINOMA MICROCITICO	train-set-to-publish/cantemist-norm/cc_onco366.ann
8046/3	carcinoma no microcítico	train-set-to-publish/cantemist-norm/cc_onco366.ann
8000/6	cTxN3M0	train-set-to-publish/cantemist-norm/cc_onco366.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco366.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco232.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco232.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco232.ann
8510/3	carcinoma medular	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco232.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/3	Cáncer	train-set-to-publish/cantemist-norm/cc_onco232.ann
8000/6	afectación a distancia	train-set-to-publish/cantemist-norm/cc_onco944.ann
9687/3/H	linfoma Burkitt like IIB	train-set-to-publish/cantemist-norm/cc_onco944.ann
8542/3	enfermedad de Paget extramamaria	train-set-to-publish/cantemist-norm/cc_onco944.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco361.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco361.ann
8890/0	fibromiomas	train-set-to-publish/cantemist-norm/cc_onco361.ann
9100/0	MOLA HIDATIFORME	train-set-to-publish/cantemist-norm/cc_onco361.ann
8000/6	enfermedad extrauterina	train-set-to-publish/cantemist-norm/cc_onco361.ann
9100/1	Mola hidatiforme invasiva	train-set-to-publish/cantemist-norm/cc_onco361.ann
9100/1	MOLA HIDATIFORME INVASIVA	train-set-to-publish/cantemist-norm/cc_onco361.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco275.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco275.ann
8140/33	Adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco275.ann
9120/0	Hemangioma	train-set-to-publish/cantemist-norm/cc_onco275.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco275.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco275.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco275.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco275.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco275.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco374.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco374.ann
8140/33	adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco374.ann
8046/3	cáncer de pulmón no microcítico	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	pT2aN0M0	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	cTxcN2pM1	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	progresión tumoral a nivel mediastínico, pleural	train-set-to-publish/cantemist-norm/cc_onco374.ann
8000/6	implantes en pectoral	train-set-to-publish/cantemist-norm/cc_onco374.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco490.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco490.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	implante pleural	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco490.ann
8046/33	carcinoma mal diferenciado de célula no pequeña	train-set-to-publish/cantemist-norm/cc_onco490.ann
8046/33	carcinoma pulmonar mal diferenciado de célula no pequeña	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	cM1c	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	infiltración ósea neoplásica	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	implantes pleurales	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	lesión de partes blandas	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	Lesiones en lóbulo hepático	train-set-to-publish/cantemist-norm/cc_onco490.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco490.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco986.ann
8461/34	Carcinoma papilar seroso de ovario de alto grado	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/6	adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco986.ann
8000/6	recaída mediastínica	train-set-to-publish/cantemist-norm/cc_onco986.ann
8310/3	carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/6	metástasis por carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/6	metástasis por carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco900.ann
8240/3	Carcinoide	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/31	Carcinoma renal de células claras E.II (pT2, G1)	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/6	carcinoma renal de células claras bilateral con metástasis	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	enfermedad a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco900.ann
8310/6	metastásica de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	implante tumoral	train-set-to-publish/cantemist-norm/cc_onco900.ann
8743/3	Melanoma maligno de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesión suprarrenal	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesiones pancreáticas	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesiones en el polo inferior del riñón	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesión en segmento 4 hepático	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesiones en cola de páncreas	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesión milimétrica en hígado	train-set-to-publish/cantemist-norm/cc_onco900.ann
8000/6	lesión milimétrica en páncreas	train-set-to-publish/cantemist-norm/cc_onco900.ann
8160/3	Colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco593.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco593.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco593.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco593.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco593.ann
8160/3	colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco593.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco840.ann
8000/6	pT4N0M0	train-set-to-publish/cantemist-norm/cc_onco840.ann
8720/3	melanoma cutáneo maligno	train-set-to-publish/cantemist-norm/cc_onco840.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco840.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco840.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco677.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco677.ann
8070/3	carcinoma epidermoide	train-set-to-publish/cantemist-norm/cc_onco677.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco677.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco677.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco677.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco677.ann
8010/3/H	carcinoma microinvasivo	train-set-to-publish/cantemist-norm/cc_onco677.ann
8000/6	diseminación a distancia	train-set-to-publish/cantemist-norm/cc_onco677.ann
8070/32	carcinoma epidermoide moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco677.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco859.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco859.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco859.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/6	micrometástasis	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco859.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco859.ann
8500/32	carcinoma ductal infiltrante grado 2	train-set-to-publish/cantemist-norm/cc_onco859.ann
8501/3	comedocarcinoma	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/6	macrometástasis	train-set-to-publish/cantemist-norm/cc_onco859.ann
8500/6	Carcinoma ductal infiltrante de mama subtipo luminal B, estadio IV por afectación ósea	train-set-to-publish/cantemist-norm/cc_onco859.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco859.ann
8540/3	enfermedad de Paget del pezón	train-set-to-publish/cantemist-norm/cc_onco859.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco251.ann
8500/33	Carcinoma ductal infiltrante pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco251.ann
8500/3	carcinoma ductal microinfiltrante	train-set-to-publish/cantemist-norm/cc_onco251.ann
8500/23	carcinoma intraductal residual, ambos pobremente diferenciados	train-set-to-publish/cantemist-norm/cc_onco251.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	Neoplasia pulmonar T4N0M1b	train-set-to-publish/cantemist-norm/cc_onco10.ann
8020/3	Carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco10.ann
8020/6	Carcinoma indiferenciado de pulmón T4N0M1b	train-set-to-publish/cantemist-norm/cc_onco10.ann
8020/6	Carcinoma indiferenciado de pulmón T4N0M1b	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	oligometástasica	train-set-to-publish/cantemist-norm/cc_onco10.ann
8020/3	Carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	implante	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	lesión adrenal	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco10.ann
8000/6	lesión cerebral	train-set-to-publish/cantemist-norm/cc_onco10.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco430.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/6	cT2N2M1a	train-set-to-publish/cantemist-norm/cc_onco430.ann
8000/6	cT2N2M1a	train-set-to-publish/cantemist-norm/cc_onco430.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco885.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco885.ann
9070/3	carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco885.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco885.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco885.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco885.ann
9071/3	tumor del seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco885.ann
9064/3	tumor germinal	train-set-to-publish/cantemist-norm/cc_onco885.ann
9065/3/H	tumor mixto de células germinales no seminomatoso	train-set-to-publish/cantemist-norm/cc_onco885.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco885.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T3N0M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco395.ann
8120/3	carcinoma urotelial	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/3	maligna	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/3	malignas	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T3-4N0-2M1a	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	afectación bipulmonar	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	afectación bipulmonar	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/31/H	adenocarcinoma broncopulmonar bien diferenciado, de patrón lepídico/acinar/papilar	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinomas	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3/H	ADC de pulmón lepídico	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	cT4a cN2M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8046/3	CPNM	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3	adenocarcinomas	train-set-to-publish/cantemist-norm/cc_onco395.ann
8140/3/H	ADC lepídico	train-set-to-publish/cantemist-norm/cc_onco395.ann
8000/6	T4N2M0	train-set-to-publish/cantemist-norm/cc_onco395.ann
8041/3	Carcinoma microcítico	train-set-to-publish/cantemist-norm/cc_onco84.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco84.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco84.ann
8041/34	carcinoma indiferenciado de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco84.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco84.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco84.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco84.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco84.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco84.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco84.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco84.ann
8574/34	carcinoma indiferenciado de células pequeñas, de aspecto neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco84.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco90.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco90.ann
8140/6	Adenocarcinoma de páncreas estadio IV por metástasis	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/6	lesión a nivel de hemisferio cerebeloso	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco90.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco40.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco40.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco40.ann
8500/32	carcinoma ductal infiltrante de mama derecha de 3,7 cm, grado histológico II de Nottingham	train-set-to-publish/cantemist-norm/cc_onco40.ann
8000/6	lesión única de 1 cm en hemisferio	train-set-to-publish/cantemist-norm/cc_onco40.ann
8000/6	lesión cerebelosa	train-set-to-publish/cantemist-norm/cc_onco40.ann
8500/3	Carcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco99.ann
8500/3	carcinoma ductal	train-set-to-publish/cantemist-norm/cc_onco99.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco99.ann
8500/24	carcinoma intraductal de alto grado	train-set-to-publish/cantemist-norm/cc_onco99.ann
9010/0	fibroadenoma	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco99.ann
8500/33	carcinoma ductal pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco99.ann
8530/3	carcinoma inflamatorio	train-set-to-publish/cantemist-norm/cc_onco99.ann
8530/3	carcinoma inflamatorio	train-set-to-publish/cantemist-norm/cc_onco99.ann
8230/24	carcinoma intraductal sólido de alto grado	train-set-to-publish/cantemist-norm/cc_onco99.ann
9020/0	tumor phyllodes, histológicamente benigno	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/6	pT4cN1M0	train-set-to-publish/cantemist-norm/cc_onco99.ann
8530/3	Carcinoma ductal inflamatorio	train-set-to-publish/cantemist-norm/cc_onco99.ann
9020/0	Tumor phyllodes benigno	train-set-to-publish/cantemist-norm/cc_onco99.ann
8230/24	carcinoma intraductal sólido de alto grado	train-set-to-publish/cantemist-norm/cc_onco99.ann
8530/3	carcinoma ductal inflamatorio	train-set-to-publish/cantemist-norm/cc_onco99.ann
8000/6	pT4cN1M0	train-set-to-publish/cantemist-norm/cc_onco99.ann
9020/0	tumor phyllodes benigno	train-set-to-publish/cantemist-norm/cc_onco99.ann
8140/3	ADC	train-set-to-publish/cantemist-norm/cc_onco566.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco566.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco566.ann
8310/3	carcinoma renal de tipo células claras	train-set-to-publish/cantemist-norm/cc_onco566.ann
8000/6	lesiones nodulares pulmonares	train-set-to-publish/cantemist-norm/cc_onco566.ann
8000/6	suelta de globo	train-set-to-publish/cantemist-norm/cc_onco566.ann
8000/6	cáncer renal metastásico	train-set-to-publish/cantemist-norm/cc_onco566.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco705.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco705.ann
8140/32	adenocarcinoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco705.ann
8000/6	adenopatías hipermetabólicas retrocrurales derechas, retroperitoneales y supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco705.ann
8010/6	carcinoma de cérvix estadio IV (adenopatías supraclaviculares	train-set-to-publish/cantemist-norm/cc_onco705.ann
8000/6	infiltración mesorrectal	train-set-to-publish/cantemist-norm/cc_onco705.ann
8000/6	infiltración mesorrectal	train-set-to-publish/cantemist-norm/cc_onco705.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco908.ann
8140/6	adenocarcinoma de pulmón estadio IV por afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/6	lesiones cerebrales	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/6	LOES frontales	train-set-to-publish/cantemist-norm/cc_onco908.ann
8000/6	T1N0M0	train-set-to-publish/cantemist-norm/cc_onco199.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco199.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco199.ann
8050/32/H	carcinoma papilar de células claras multifocal con extensas áreas de necrosis, grado de Fuhrman 2	train-set-to-publish/cantemist-norm/cc_onco199.ann
8010/6	Metástasis mediastínica de carcinoma	train-set-to-publish/cantemist-norm/cc_onco199.ann
8000/6	masa mediastínica	train-set-to-publish/cantemist-norm/cc_onco199.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	implantes pericárdicos	train-set-to-publish/cantemist-norm/cc_onco58.ann
8140/6	adenocarcinoma de pulmón, estadio IV (cT4N2M1b)	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	masa de 35 mm en la glándula suprarrenal	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	enfermedad tanto a nivel cerebral	train-set-to-publish/cantemist-norm/cc_onco58.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco312.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco312.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	lesión intrabronquial	train-set-to-publish/cantemist-norm/cc_onco312.ann
8310/6	carcinoma de células claras metastásico	train-set-to-publish/cantemist-norm/cc_onco312.ann
8310/6	Recaída sistémica (pulmonar e intrabronquial) de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	progresión pleural	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	implantes renales y en glándula suprarrenal	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	progresión radiológica a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/6	enfermedad pleural	train-set-to-publish/cantemist-norm/cc_onco312.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco888.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco888.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco888.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	enfermedad secundaria	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	enfermedad hepática	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco888.ann
8000/6	lesiones focales hipermetabólicas en bazo	train-set-to-publish/cantemist-norm/cc_onco888.ann
8310/3	carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	metastásicos	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco779.ann
8310/6	metástasis de carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco779.ann
8310/61	carcinoma renal de células claras (Fuhrman grado 1) de 9 cm (pT3a pN0 pM1)	train-set-to-publish/cantemist-norm/cc_onco779.ann
8310/6	carcinoma renal de células claras metastásico	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	afectación pulmonar	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	progresión pulmonar	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulo de 1,5 cm en la glándula suprarrenal	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	lesión cutánea	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulo subcutáneo	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulo subcutáneo	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulo subcutáneo	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco779.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco779.ann
9560/0	schwannoma	train-set-to-publish/cantemist-norm/cc_onco189.ann
9560/0	schwannoma	train-set-to-publish/cantemist-norm/cc_onco189.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco189.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco189.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco189.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco189.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco189.ann
9540/3	tumor maligno de la vaina nerviosa periférica	train-set-to-publish/cantemist-norm/cc_onco189.ann
9540/3	neurofibrosarcoma	train-set-to-publish/cantemist-norm/cc_onco189.ann
9364/3	Tumor neuroectodérmico primitivo periférico	train-set-to-publish/cantemist-norm/cc_onco189.ann
9260/3	Ewing	train-set-to-publish/cantemist-norm/cc_onco189.ann
9364/3	PNET	train-set-to-publish/cantemist-norm/cc_onco189.ann
9120/0	angioma	train-set-to-publish/cantemist-norm/cc_onco732.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco732.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco732.ann
8500/3	CDI de mama izquierda multifocal, grado 1	train-set-to-publish/cantemist-norm/cc_onco732.ann
8500/3/H	CDI de mama izquierda multifocal	train-set-to-publish/cantemist-norm/cc_onco732.ann
8211/0/H	adenoma tubular con displasia de bajo grado	train-set-to-publish/cantemist-norm/cc_onco732.ann
8490/33	"adenocarcinoma difuso, pobremente diferenciado, con células ""en anillo de sello"""	train-set-to-publish/cantemist-norm/cc_onco732.ann
8145/3	adenocarcinoma difuso	train-set-to-publish/cantemist-norm/cc_onco732.ann
8500/6	metástasis colónicas de CDI	train-set-to-publish/cantemist-norm/cc_onco732.ann
8500/6	metastásica colónica y ganglionar de CDI	train-set-to-publish/cantemist-norm/cc_onco732.ann
8000/6	lesiones líticas en sacro	train-set-to-publish/cantemist-norm/cc_onco732.ann
8000/6	pT2pN1aM0	train-set-to-publish/cantemist-norm/cc_onco732.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/3	neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco869.ann
8140/6	metástasis hepáticas de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8140/6	metástasis hepáticas de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco869.ann
8140/32	adenocarcinoma colorrectal moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	implantes tumorales	train-set-to-publish/cantemist-norm/cc_onco869.ann
8000/6	implantes de menor tamaño en fascia	train-set-to-publish/cantemist-norm/cc_onco869.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco544.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco544.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco544.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco544.ann
8041/3	carcinoma de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco544.ann
8041/3	carcinoma de células pequeñas	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco544.ann
8140/6	adenocarcinoma de pulmón cT2b N3 M1b	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	progresión a nivel local, así como, sistémica	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	progresión a nivel del SNC	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	afectación cerebral	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	afectación del sistema nervioso central	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	lesión cerebelosa	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	afectación del SNC	train-set-to-publish/cantemist-norm/cc_onco544.ann
8000/6	afectación en glándula suprarrenal	train-set-to-publish/cantemist-norm/cc_onco544.ann
8144/3	adenocarcinoma de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco324.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco324.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco324.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco324.ann
9120/0	hemangiomas	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco324.ann
8144/3	adenocarcinoma de cuerpo gástrico de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	lesión hipodensa del segmento VI hepático	train-set-to-publish/cantemist-norm/cc_onco324.ann
8144/33	adenocarcinoma mal diferenciado (4 cm) de tipo intestinal	train-set-to-publish/cantemist-norm/cc_onco324.ann
8000/6	lesión del segmento VI hepático	train-set-to-publish/cantemist-norm/cc_onco324.ann
8010/63	metástasis de carcinoma mal diferenciado	train-set-to-publish/cantemist-norm/cc_onco324.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	Tumor	train-set-to-publish/cantemist-norm/cc_onco185.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco185.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco185.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco185.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco185.ann
8500/33	carcinoma ductal infiltrante Grado II-III	train-set-to-publish/cantemist-norm/cc_onco185.ann
8142/3	linitis plástica	train-set-to-publish/cantemist-norm/cc_onco185.ann
8142/3	linitis plástica	train-set-to-publish/cantemist-norm/cc_onco185.ann
8520/64/H	carcinoma lobulillar de alto grado (pleomórfico) metastásico	train-set-to-publish/cantemist-norm/cc_onco185.ann
8522/32	Carcinoma infiltrante mixto (lobulillar con áreas de ductal) grado 2	train-set-to-publish/cantemist-norm/cc_onco185.ann
8001/1	celularidad tumoral	train-set-to-publish/cantemist-norm/cc_onco185.ann
8522/6	carcinoma de mama infiltrante mixto (lobulillar clásico con áreas de ductal) estadio ypT2ypN2pM1	train-set-to-publish/cantemist-norm/cc_onco185.ann
8142/3	linitis plástica	train-set-to-publish/cantemist-norm/cc_onco185.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco143.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco143.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco143.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco143.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco143.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco143.ann
8000/6	pT1N2M0	train-set-to-publish/cantemist-norm/cc_onco143.ann
9895/3	leucemia aguda mieloide con displasia trilineal de la clasificación de la OMS	train-set-to-publish/cantemist-norm/cc_onco143.ann
9861/3	LAM	train-set-to-publish/cantemist-norm/cc_onco143.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco936.ann
8010/32/H	carcinoma infiltrante NOS, grado II	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/6	implantes meníngeos	train-set-to-publish/cantemist-norm/cc_onco936.ann
8010/3/H	Carcinoma infiltrante	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/6	diseminación pulmonar	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco936.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco936.ann
8140/0	adenoma	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco736.ann
8240/3	tumor carcinoide	train-set-to-publish/cantemist-norm/cc_onco736.ann
8040/1	tumorlet	train-set-to-publish/cantemist-norm/cc_onco736.ann
8240/3	tumor carcinoide	train-set-to-publish/cantemist-norm/cc_onco736.ann
8040/1	tumorlet	train-set-to-publish/cantemist-norm/cc_onco736.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	neoplasia de páncreas con metástasis	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	nódulos pulmonares bilaterales	train-set-to-publish/cantemist-norm/cc_onco736.ann
8000/6	nódulo hepático	train-set-to-publish/cantemist-norm/cc_onco736.ann
8936/3	GIST	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco31.ann
8936/3	tumor del estroma gastrointestinal	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco31.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco31.ann
9050/3	mesotelioma	train-set-to-publish/cantemist-norm/cc_onco706.ann
8000/6	T4N0M0	train-set-to-publish/cantemist-norm/cc_onco706.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco706.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco38.ann
8480/3	adenocarcinoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco38.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco38.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco38.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco38.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco38.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco38.ann
8470/0	cistoadenoma mucinoso	train-set-to-publish/cantemist-norm/cc_onco38.ann
8480/6	pseudomixoma peritonei	train-set-to-publish/cantemist-norm/cc_onco38.ann
8480/6	pseudomixoma peritoneal	train-set-to-publish/cantemist-norm/cc_onco38.ann
9080/0	teratoma maduro quístico	train-set-to-publish/cantemist-norm/cc_onco38.ann
8000/6	enfermedad diseminada	train-set-to-publish/cantemist-norm/cc_onco38.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco38.ann
8000/6	progresión pélvica	train-set-to-publish/cantemist-norm/cc_onco38.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco435.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco435.ann
8000/6	PE a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco435.ann
8010/3	Carcinoma	train-set-to-publish/cantemist-norm/cc_onco160.ann
8070/3	carcinoma de células escamosas	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco160.ann
8070/31/H	carcinoma de células escamosas bien diferenciado infiltrante	train-set-to-publish/cantemist-norm/cc_onco160.ann
8070/6	metástasis de carcinoma de células escamosas	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	Nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	nódulo del LSD	train-set-to-publish/cantemist-norm/cc_onco160.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco160.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco37.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco37.ann
8804/3	angiosarcoma epitelioide	train-set-to-publish/cantemist-norm/cc_onco37.ann
8804/3	angiosarcoma epitelioide	train-set-to-publish/cantemist-norm/cc_onco37.ann
8804/3	Angiosarcoma epitelioide	train-set-to-publish/cantemist-norm/cc_onco37.ann
9120/3	Angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/6	nodulares subpleurales	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/6	lesiones pleurales	train-set-to-publish/cantemist-norm/cc_onco37.ann
8000/6	lesión subpleural	train-set-to-publish/cantemist-norm/cc_onco37.ann
8310/3	carcinoma de células claras	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	implante tumoral	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco562.ann
8895/0	miomatoso	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/31	carcinoma renal de células claras (CCRc), estadio II (pT2) G1 de Fuhrman	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/3	CCRc	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/6	metástasis tiroidea por CCRc	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/62	Carcinoma renal de células claras, Fuhrman 2, estadio IV (metástasis	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/6	metástasis procedentes de CCRc	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/3	CCRc	train-set-to-publish/cantemist-norm/cc_onco562.ann
8310/62	metástasis por carcinoma de células claras, Fuhrman 2	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulo hipoecoico en lóbulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	(LOE) de 15 mm hepática	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	LOE en segmento hepático	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulo hipoecoico en lóbulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	LOE de 15 mm hepática	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulos heterogéneos en cuerpo y cola de páncreas	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulo mamario	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulos heterogéneos en cuerpo y cola de páncreas	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	recaída local y a distancia	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco562.ann
8000/6	nódulo mamario	train-set-to-publish/cantemist-norm/cc_onco562.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco985.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco985.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco985.ann
8140/33	adenocarcinoma endometrioide pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/33	neoplasia de endometrio tipo I estadio IB grado 3	train-set-to-publish/cantemist-norm/cc_onco985.ann
8140/33	adenocarcinoma pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco985.ann
8000/6	nódulos peritoneales	train-set-to-publish/cantemist-norm/cc_onco985.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco208.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	pT1N0M0	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco208.ann
8140/31	adenocarcinoma de sigma bien diferenciado	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	neoformativa	train-set-to-publish/cantemist-norm/cc_onco208.ann
8140/6	Adenocarcinoma de sigma ,estadio IV, por afectación oligometastásica	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	recaída pulmonar	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	recaída precoz pulmonar	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	nódulo tiroideo	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	RP pulmonar	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	enfermedad estable tiroidea	train-set-to-publish/cantemist-norm/cc_onco208.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco208.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco983.ann
8260/3	CPT	train-set-to-publish/cantemist-norm/cc_onco983.ann
8260/6	CPT estadio IV por afectación ósea	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	enfermedad ósea	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	progresión ósea	train-set-to-publish/cantemist-norm/cc_onco983.ann
9989/3	síndrome mielodisplásico	train-set-to-publish/cantemist-norm/cc_onco983.ann
9989/3	síndrome mielodisplásico	train-set-to-publish/cantemist-norm/cc_onco983.ann
9989/3	síndrome mielodisplásico	train-set-to-publish/cantemist-norm/cc_onco983.ann
9989/3	síndrome mielodisplásico	train-set-to-publish/cantemist-norm/cc_onco983.ann
9989/3	síndrome mielodisplásico	train-set-to-publish/cantemist-norm/cc_onco983.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco676.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco676.ann
9732/3	mieloma	train-set-to-publish/cantemist-norm/cc_onco676.ann
9733/3	mieloma leucemizante	train-set-to-publish/cantemist-norm/cc_onco676.ann
9732/3	mieloma múltiple	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/3	carcinoma de tiroides de células de Hürthle	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/3	CCH	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/6	CCH estadio IVc (pT3NxM1	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/3	CCH	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/3	Carcinoma de tiroides de células de Hürthle	train-set-to-publish/cantemist-norm/cc_onco676.ann
8290/3	CCH	train-set-to-publish/cantemist-norm/cc_onco676.ann
9731/3	neoplasia de células plasmáticas	train-set-to-publish/cantemist-norm/cc_onco676.ann
9733/3	leucemia de células plasmáticas	train-set-to-publish/cantemist-norm/cc_onco676.ann
8000/6	METÁSTASIS	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	METÁSTASIS	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	Melanoma	train-set-to-publish/cantemist-norm/cc_onco265.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	pT3aN0M0	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco265.ann
8743/3	Melanoma maligno de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	extensión de enfermedad a otras localizaciones	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	MELANOMA MALIGNO	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	T3aN1bM0	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	MELANOMA MALIGNO	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	T3aN1bM0	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	MELANOMA MALIGNO	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	MELANOMA MALIGNO	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	masa de partes blandas a nível de región dorsal	train-set-to-publish/cantemist-norm/cc_onco265.ann
8000/6	lesión nodular a nivel de extremidad	train-set-to-publish/cantemist-norm/cc_onco265.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco918.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco918.ann
8720/6	melanoma avanzado con afectación hepática	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	recidiva hepática	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	(LOE) hepática	train-set-to-publish/cantemist-norm/cc_onco918.ann
8000/6	LOE de nueva aparición en segmento VIII	train-set-to-publish/cantemist-norm/cc_onco918.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/3	linfangitis carcinomatosa	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco925.ann
8140/6	adenocarcinoma de pulmón T2 N1 M1	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/6	afectación pleural	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco925.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco925.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco924.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco924.ann
9120/3	angiosarcoma	train-set-to-publish/cantemist-norm/cc_onco924.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco924.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco924.ann
8000/1	neoplasias	train-set-to-publish/cantemist-norm/cc_onco924.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco924.ann
9120/3	angiosarcomas	train-set-to-publish/cantemist-norm/cc_onco924.ann
8000/6	pT2aN0M0	train-set-to-publish/cantemist-norm/cc_onco924.ann
9120/32	angiosarcoma moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco924.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco230.ann
8500/31	carcinoma ductal infiltrante, grado I	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco230.ann
8140/32	adenocarcinoma infiltrante de bajo grado histológico (grado II)	train-set-to-publish/cantemist-norm/cc_onco230.ann
8140/6	adenocarcinoma de colon estadío IV (pTxNxM1)	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	N0M0	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	lesión lítica	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco230.ann
8000/6	Implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco761.ann
9071/3	tumor del seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	diseminación intraperitoneal	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/3	teratoma inmaduro	train-set-to-publish/cantemist-norm/cc_onco761.ann
9071/3	variantes hepatoide	train-set-to-publish/cantemist-norm/cc_onco761.ann
8380/0	glandular de tipo endometrioide	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	Implantes en cúpulas diafragmáticas	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	implantes subcentimétricos	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/0	teratoma de características histológicas maduras	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/0	teratoma de características maduras	train-set-to-publish/cantemist-norm/cc_onco761.ann
9080/0	teratoma de características maduras	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/3	neoplásico maligno	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	implantes subcentimétricos	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	omental cake	train-set-to-publish/cantemist-norm/cc_onco761.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	implante pleural	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco982.ann
8490/3	adenocarcinoma de colón-recto con células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	T3dN2M1	train-set-to-publish/cantemist-norm/cc_onco982.ann
8490/3	Adenocarcinoma de recto de células en anillo de sello	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	afectación ganglionar, ósea	train-set-to-publish/cantemist-norm/cc_onco982.ann
8140/6	adenocarcinoma de recto metastásico	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	enfermedad en médula ósea	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	infiltración generalizada de la médula ósea	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	afectación en esqueleto	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/6	masa de partes blandas	train-set-to-publish/cantemist-norm/cc_onco982.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco909.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco909.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco909.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco909.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco909.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco909.ann
9680/3	linfoma B difuso de células grandes	train-set-to-publish/cantemist-norm/cc_onco909.ann
9680/3	Linfoma difuso de células grandes B	train-set-to-publish/cantemist-norm/cc_onco909.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco909.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco408.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco408.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco408.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco408.ann
8441/34	adenocarcinoma seroso de ovario de alto grado	train-set-to-publish/cantemist-norm/cc_onco408.ann
8000/6	letálides	train-set-to-publish/cantemist-norm/cc_onco408.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco128.ann
8850/0	lipoma	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco128.ann
8895/0	miomas	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco128.ann
8240/33	tumor neuroendocrino de páncreas (TNEP) grado 3	train-set-to-publish/cantemist-norm/cc_onco128.ann
8240/3	TNEP	train-set-to-publish/cantemist-norm/cc_onco128.ann
8240/3	TNEP	train-set-to-publish/cantemist-norm/cc_onco128.ann
8240/3	TNEP	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco128.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco128.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco119.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/32	carcinoma grado nuclear 2	train-set-to-publish/cantemist-norm/cc_onco119.ann
8500/31	CDI grado 1	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	T4bN1M1	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	progresión hepática	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	enfermedad sistémica	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco119.ann
8000/6	progresión pleural	train-set-to-publish/cantemist-norm/cc_onco119.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
8310/3/H	carcinoma renal de células claras multicéntrico	train-set-to-publish/cantemist-norm/cc_onco200.ann
8310/3/H	carcinoma renal de células claras multicéntrico	train-set-to-publish/cantemist-norm/cc_onco200.ann
8310/3	carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco200.ann
8700/0	feocromocitoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
9161/1	hemangioblastoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
9161/1	hemangioblastoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
9161/1	hemangioblastomas	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco200.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/1	tumoraciones	train-set-to-publish/cantemist-norm/cc_onco200.ann
9560/0	neurinoma	train-set-to-publish/cantemist-norm/cc_onco200.ann
8310/6	metástasis múltiples de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco200.ann
8310/6	metástasis de carcinoma renal de células claras	train-set-to-publish/cantemist-norm/cc_onco200.ann
8450/0	cistoadenoma papilar	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/12	tumor de mayor tamaño de 5 cm, grado nuclear de Fuhrman II	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/6	masa palpable en el testículo	train-set-to-publish/cantemist-norm/cc_onco200.ann
8000/6	afectación de epidídimo	train-set-to-publish/cantemist-norm/cc_onco200.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco446.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco446.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco446.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco446.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	pT4N0M0	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	implantes mesentéricos	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	lesión subcutánea	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	lesión subcutánea	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/6	lesiones ocupantes de espacio supratentoriales	train-set-to-publish/cantemist-norm/cc_onco446.ann
8000/1	Tumor	train-set-to-publish/cantemist-norm/cc_onco164.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco164.ann
8500/24	carcinoma intraductal de alto grado	train-set-to-publish/cantemist-norm/cc_onco164.ann
8140/6	metástasis de acenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco164.ann
8500/2	Carcinoma intraductal	train-set-to-publish/cantemist-norm/cc_onco164.ann
8000/6	cT4dNxM0	train-set-to-publish/cantemist-norm/cc_onco164.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco164.ann
8000/6	metastásicas	train-set-to-publish/cantemist-norm/cc_onco164.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco16.ann
9590/3	linfoma	train-set-to-publish/cantemist-norm/cc_onco16.ann
9702/3	linfoma cerebral primario de célula T	train-set-to-publish/cantemist-norm/cc_onco16.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco745.ann
8500/3	carcinoma de mama ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco745.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco745.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco745.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco745.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco745.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco745.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco671.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	M1	train-set-to-publish/cantemist-norm/cc_onco671.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco671.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco671.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco671.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	enfermedad pulmonar	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	lesiones pulmonares	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	nódulo pulmonar	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco671.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco671.ann
8240/3	tumor neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco671.ann
8240/6	tumor neuroendocrino de bajo grado de origen desconocido, metastásico	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	cáncer de mama triple negativo metastásico	train-set-to-publish/cantemist-norm/cc_onco671.ann
8246/6	metástasis por carcinoma neuroendocrino de bajo grado	train-set-to-publish/cantemist-norm/cc_onco671.ann
8000/6	T3N2M0	train-set-to-publish/cantemist-norm/cc_onco671.ann
8240/6	Tumor neuroendocrino de bajo grado con metástasis	train-set-to-publish/cantemist-norm/cc_onco671.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco463.ann
8520/3	carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco463.ann
8010/33	carcinoma poco diferenciado	train-set-to-publish/cantemist-norm/cc_onco463.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco463.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco463.ann
8010/9	carcinomatosis	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/6	pT2pN2M0	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/6	implantes de aspecto neoplásico	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/6	cáncer de mama estadio IV con metástasis	train-set-to-publish/cantemist-norm/cc_onco463.ann
8000/6	enfermedad a nivel peritoneal	train-set-to-publish/cantemist-norm/cc_onco463.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco175.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco175.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	nódulos hipodensos hepáticos	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	nódulos hipodensos en ambos lóbulos hepáticos	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco175.ann
8000/6	lesiones focales hepáticas	train-set-to-publish/cantemist-norm/cc_onco175.ann
9650/3	Enfermedad de Hodgkin	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/3	Neoplasia maligna	train-set-to-publish/cantemist-norm/cc_onco280.ann
9591/3	linfoma no Hodgkin	train-set-to-publish/cantemist-norm/cc_onco280.ann
9961/3	mielofibrosis	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco280.ann
9970/1	síndrome linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco280.ann
9758/3	sarcoma de células dendríticas foliculares	train-set-to-publish/cantemist-norm/cc_onco280.ann
9758/6	Sarcoma de células dendríticas foliculares estadio IV (por infiltración de MO y lesiones óseas)	train-set-to-publish/cantemist-norm/cc_onco280.ann
9663/3	Linfoma de Hodgkin clásico tipo esclerosis nodular	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/6	lesiones líticas óseas	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/6	adenopatías a nivel lateterocervical, supraclavicular	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/6	adenopática supra e infradiafragmática de predominio supraclavicular	train-set-to-publish/cantemist-norm/cc_onco280.ann
8000/6	cT4N1M0	train-set-to-publish/cantemist-norm/cc_onco895.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco895.ann
8500/3	carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco895.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco895.ann
8000/6	enfermedad a distancia	train-set-to-publish/cantemist-norm/cc_onco895.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco895.ann
8010/6	metástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco895.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco895.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco895.ann
8010/6	micrometástasis de carcinoma	train-set-to-publish/cantemist-norm/cc_onco895.ann
8246/3	carcinoma neuroendocrino	train-set-to-publish/cantemist-norm/cc_onco948.ann
8041/3	carcinoma neuroendocrino de célula pequeña	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco948.ann
8020/3	carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco948.ann
8020/3	carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco948.ann
8020/3	carcinoma indiferenciado	train-set-to-publish/cantemist-norm/cc_onco948.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco890.ann
8000/6	cT3N0M0	train-set-to-publish/cantemist-norm/cc_onco890.ann
8000/3	maligno	train-set-to-publish/cantemist-norm/cc_onco890.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco890.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco890.ann
8140/02	adenoma prostático grado 2	train-set-to-publish/cantemist-norm/cc_onco890.ann
8140/31	adenocarcinoma prostático Gleason 5	train-set-to-publish/cantemist-norm/cc_onco890.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco890.ann
9120/34	angiosarcoma de alto grado	train-set-to-publish/cantemist-norm/cc_onco890.ann
8000/6	cM0	train-set-to-publish/cantemist-norm/cc_onco193.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco193.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco193.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco193.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco193.ann
8720/6	metástasis de melanoma	train-set-to-publish/cantemist-norm/cc_onco193.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco193.ann
8743/3	melanoma de extensión superficial	train-set-to-publish/cantemist-norm/cc_onco193.ann
9010/0	fibroadenomas	train-set-to-publish/cantemist-norm/cc_onco193.ann
8000/6	enfermedad pulmonar	train-set-to-publish/cantemist-norm/cc_onco193.ann
8720/6	melanoma avanzado por metástasis	train-set-to-publish/cantemist-norm/cc_onco193.ann
8000/6	nódulos en pulmón	train-set-to-publish/cantemist-norm/cc_onco193.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco193.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/6	metastásico	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/1	neoplásico	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/1	tumores	train-set-to-publish/cantemist-norm/cc_onco588.ann
8210/0	pólipos adenomatosos	train-set-to-publish/cantemist-norm/cc_onco588.ann
8211/0/H	adenoma tubular de intestino grueso con displasia moderada-severa	train-set-to-publish/cantemist-norm/cc_onco588.ann
8490/3	carcinoma de células de anillo de sello	train-set-to-publish/cantemist-norm/cc_onco588.ann
8160/3	tumor de Klastkin	train-set-to-publish/cantemist-norm/cc_onco588.ann
8160/32	Colangiocarcinoma extrahepático moderadamente diferenciado	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/6	implantes peritoneales	train-set-to-publish/cantemist-norm/cc_onco588.ann
8160/6	recaída peritoneal de colangiocarcinoma	train-set-to-publish/cantemist-norm/cc_onco588.ann
8000/6	lesiones nodulares en epiplón	train-set-to-publish/cantemist-norm/cc_onco588.ann
8500/3	CDI	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/6	M0	train-set-to-publish/cantemist-norm/cc_onco989.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco989.ann
8010/6	metástasis por carcinoma	train-set-to-publish/cantemist-norm/cc_onco989.ann
8010/6	metástasis por carcinoma	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/1	neoplasia	train-set-to-publish/cantemist-norm/cc_onco989.ann
8500/33	CDI de mama izquierda grado 3	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/6	metastásica	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/6	lesión hepática	train-set-to-publish/cantemist-norm/cc_onco989.ann
8010/6	recaída única hepática por carcinoma	train-set-to-publish/cantemist-norm/cc_onco989.ann
8000/6	recaída pectoral	train-set-to-publish/cantemist-norm/cc_onco989.ann
8500/6	CDI de mama perfil luminal B en recaída sistémica	train-set-to-publish/cantemist-norm/cc_onco989.ann
8010/6	recaída de partes blandas por carcinoma	train-set-to-publish/cantemist-norm/cc_onco989.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	afectación ósea	train-set-to-publish/cantemist-norm/cc_onco907.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/1	neoplásica	train-set-to-publish/cantemist-norm/cc_onco907.ann
9970/1	proceso linfoproliferativo	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco907.ann
8140/31	adenocarcinoma de próstata Gleason 2 + 2	train-set-to-publish/cantemist-norm/cc_onco907.ann
8263/0	adenomas tubulovellosos	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/1/H	neoplasia gástrica infiltrante	train-set-to-publish/cantemist-norm/cc_onco907.ann
8490/3	"carcinoma difuso de ""células en anillo de sello"""	train-set-to-publish/cantemist-norm/cc_onco907.ann
8145/3	carcinoma difuso	train-set-to-publish/cantemist-norm/cc_onco907.ann
8001/6	celularidad metastásica	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	lesiones blásticas	train-set-to-publish/cantemist-norm/cc_onco907.ann
8142/3	linitis plástica	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/6	lesión lítica	train-set-to-publish/cantemist-norm/cc_onco907.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/1	neoformativo	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco814.ann
9470/34	meduloblastoma clásico de localización vermiana, grado IV de la OMS	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/6	diseminación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco814.ann
9470/34	meduloblastoma clásico de localización vermiana grado IV de la OMS	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/6	afectación leptomeníngea	train-set-to-publish/cantemist-norm/cc_onco814.ann
8000/6	realces leptomeníngeos	train-set-to-publish/cantemist-norm/cc_onco814.ann
8520/3	Carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco663.ann
8520/3	carcinoma lobulillar	train-set-to-publish/cantemist-norm/cc_onco663.ann
8520/3	carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco663.ann
8001/1	células tumorales	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco663.ann
8520/32	carcinoma lobulillar de mama izquierda grado 2	train-set-to-publish/cantemist-norm/cc_onco663.ann
8000/1	neoplásicos	train-set-to-publish/cantemist-norm/cc_onco663.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco849.ann
8720/3	melanoma	train-set-to-publish/cantemist-norm/cc_onco849.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco849.ann
8000/6	recaída hepática	train-set-to-publish/cantemist-norm/cc_onco849.ann
8000/6	diseminación	train-set-to-publish/cantemist-norm/cc_onco849.ann
8000/6	lesiones hepáticas	train-set-to-publish/cantemist-norm/cc_onco849.ann
8000/6	afectación hepática	train-set-to-publish/cantemist-norm/cc_onco44.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco44.ann
8010/3	carcinoma	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	lesiones oseas	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	lesiones óseas	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco44.ann
9732/3	mieloma	train-set-to-publish/cantemist-norm/cc_onco44.ann
9732/3	mieloma múltiple	train-set-to-publish/cantemist-norm/cc_onco44.ann
9732/3	mieloma múltiple	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	recaída hepática	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/1	tumorales	train-set-to-publish/cantemist-norm/cc_onco44.ann
8500/33	carcinoma ductal infiltrante de mama izquierda grado III	train-set-to-publish/cantemist-norm/cc_onco44.ann
8500/33	carcinoma ductal infiltrante de mama izquierda grado III	train-set-to-publish/cantemist-norm/cc_onco44.ann
8500/33	carcinoma ductal infiltrante grado III	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	pT3ypN2M0	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	lesiones hipodensas a nivel hepático	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	micronódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	LOE hepática	train-set-to-publish/cantemist-norm/cc_onco44.ann
9731/6	infiltración hepática por plasmocitoma	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	cT3N1M0	train-set-to-publish/cantemist-norm/cc_onco44.ann
8000/6	afectación iliaca	train-set-to-publish/cantemist-norm/cc_onco44.ann
8140/3	adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco110.ann
8001/3	células malignas	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco110.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco110.ann
8140/6	metástasis de adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/1	tumoral	train-set-to-publish/cantemist-norm/cc_onco110.ann
8140/3	Adenocarcinoma	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	Mx	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	lesión pulmonar	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	progresión a nivel pulmonar	train-set-to-publish/cantemist-norm/cc_onco110.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco110.ann
9065/3	TGNS	train-set-to-publish/cantemist-norm/cc_onco768.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco768.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco768.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco768.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco768.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco768.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco768.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco768.ann
8000/6	suelta de globos	train-set-to-publish/cantemist-norm/cc_onco768.ann
8000/1/H	tumor primitivo	train-set-to-publish/cantemist-norm/cc_onco768.ann
8070/33	carcinoma escamoso pobremente diferenciado	train-set-to-publish/cantemist-norm/cc_onco768.ann
9064/6/H	metástasis de tumor con diferenciación germinal de tipo trofoblástico	train-set-to-publish/cantemist-norm/cc_onco768.ann
9065/3/H	tumor germinal no seminomatoso mixto	train-set-to-publish/cantemist-norm/cc_onco768.ann
9071/3	tumor de seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco768.ann
9065/3/H	Tumor germinal no seminomatoso (TGNS) mixto	train-set-to-publish/cantemist-norm/cc_onco768.ann
9071/3	tumor de seno endodérmico	train-set-to-publish/cantemist-norm/cc_onco768.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco768.ann
9070/3	carcinoma embrionario	train-set-to-publish/cantemist-norm/cc_onco845.ann
9100/3	coriocarcinoma	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/1	neoformación	train-set-to-publish/cantemist-norm/cc_onco845.ann
9061/3	seminoma	train-set-to-publish/cantemist-norm/cc_onco845.ann
9080/1	teratoma	train-set-to-publish/cantemist-norm/cc_onco845.ann
9080/0	teratoma maduro	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/1	tumor	train-set-to-publish/cantemist-norm/cc_onco845.ann
9071/3	tumor del saco vitelino	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/1	tumoración	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	adenopatía supraclavicular	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	adenopatía necrótica supraclavicular	train-set-to-publish/cantemist-norm/cc_onco845.ann
9085/3	TCG mixto	train-set-to-publish/cantemist-norm/cc_onco845.ann
9085/6	TCG mixto de teste derecho estadio pT3cN3cM1a	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	enfermedad ganglionar (supraclavicular	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	adenopático supraclavicular	train-set-to-publish/cantemist-norm/cc_onco845.ann
8000/6	nódulos pulmonares	train-set-to-publish/cantemist-norm/cc_onco845.ann
8500/3	Carcinoma ductal infiltrante	train-set-to-publish/cantemist-norm/cc_onco644.ann
8520/3	Carcinoma lobulillar infiltrante	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/6	Metástasis	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/3	cáncer	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/3	malignidad	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/6	metástasis	train-set-to-publish/cantemist-norm/cc_onco644.ann
8523/33	carcinoma ductal infiltrante, grado 2-3 con focos de diferenciación mucinosa	train-set-to-publish/cantemist-norm/cc_onco644.ann
8520/34	carcinoma lobulillar invasivo de alto grado	train-set-to-publish/cantemist-norm/cc_onco644.ann
8010/3/H	carcinoma invasivo	train-set-to-publish/cantemist-norm/cc_onco644.ann
8500/3	carcinoma de tipo lobulillar	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/6	metástasis de su neoplasia	train-set-to-publish/cantemist-norm/cc_onco644.ann
8500/3	carcinoma de tipo lobulillar	train-set-to-publish/cantemist-norm/cc_onco644.ann
8000/6	lesiones conocidas en ambas mamas y a nivel óseo	train-set-to-publish/cantemist-norm/cc_onco644.ann
